AU4807190A - Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones - Google Patents

Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Info

Publication number
AU4807190A
AU4807190A AU48071/90A AU4807190A AU4807190A AU 4807190 A AU4807190 A AU 4807190A AU 48071/90 A AU48071/90 A AU 48071/90A AU 4807190 A AU4807190 A AU 4807190A AU 4807190 A AU4807190 A AU 4807190A
Authority
AU
Australia
Prior art keywords
benzopyran
cpd
morpholinyl
methyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU48071/90A
Other versions
AU634994B2 (en
Inventor
Ronald B. Gammill
Thomas M. Judge
Joel Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AU4807190A publication Critical patent/AU4807190A/en
Application granted granted Critical
Publication of AU634994B2 publication Critical patent/AU634994B2/en
Assigned to PHARMACIA & UPJOHN COMPANY reassignment PHARMACIA & UPJOHN COMPANY Request to Amend Deed and Register Assignors: UPJOHN COMPANY, THE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/201,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Description

ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ONES AND 2-AMINO-1,3-BENZOXAZINE-4-ONES
BACKGROUND OF THE INVENTION
The present specification provides methods for use of pharmacologically active substances. Further the present specification provides novel compositions of matter and novel methods of their preparation.
Atherosclerosis in mammals is a disease characterized by the deposition of atherosclerotic plaque on arterial walls. While atherosclerosis exhibits many varied forms and consequences, typical consequences of atherosclerotic diseases include angina pectoris, myocardial infarction, stroke and transient cerebral ischemic attacks. Other forms of atherosclerotic diseases include certain peripheral vascular diseases and other ischemias (e.g., bowel and renal).
Medical science now recognizes that certain forms of atherosclerosis may be preventable or reversible. Agents capable of preventing or reversing atherosclerosis are characterized as exhibiting antiatherosclerotic activity. Since serum lipids have a recognized association with atherogenesis, an important class of antiatherosclerotic agents are those with serum lipid-modifying effects. Serum lipids implicated in atherogenesis include serum cholesterol, serum triglycerides, and serum lipoproteins.
With respect to serum lipoproteins, at least three different classes of these substances have been characterized; high density lipoproteins (HDL's), low density lipoproteins (LDL's), and very low density lipoproteins (VLDL's). HDL's are often referred to as alphalipoproteins, while LDL's and VLDL's are referred to as betalipoproteins. The enhancement of HDL levels (hyperalphalipoproteinemic activity) is postulated to have direct antiatherosclerotic effects. See Eaton, R.P., J. Chron. Dis .31:131-135 (1978). In contrast, agents which reduce serum LDL's and serum VLDL's (hypobetalipoproteinemic agents) are also associated with antiatherogenic effects. See Haust, M.D., "Reaction Patterns of Intimal Mesenchyme to Injury and Repair in Atherosclerosis", Adv. Exp. Med. Biol. 43:3557 (1974), which postulates that serum LDL is a factor in atherosclerotic lesion formation.
Numerous animal models have been developed for assessing antiatherosclerotic activity. Principal among these are models for assessing hypolipoproteinemic activity in the rat and antiatherosclerotic activity in the Japanese quail. For a description of the operation of the hypobetalipoproteinemic rat model, refer to the known methods of Schurr, P.E., et al., "High
Volume Screening Procedure for Lypobetalipoproteinemia Activity in
Rats", Adv. Exp. Med. Biol. 67: Atherosclerotic Drug Discovery, pp.
215-229, Plenum Press (1975). For a description of the Japanese quail model, see Day, C.E. et al., "Utility of a Selected Line (SEA) of the Japanese Quail (Corturnic Cortumix japonica) for the
Discovery of New Anti-Atherosclerosis Drugs", Laboratory Animal
Science 27:817-821 (1977).
2-Aminochromones (4H-1-benzopyran-4-ones) are known in the literature. For example, the antiallergic activity of 2- aminochromones has been described in the literature by Mazzei, Balbi,
Ermili, Sottofattori and Roma (Mazzei, M., Ballbi, A., Ernili, A.,
Sottofattori, E., Roma, G., Farmaco. Ed. Sci., (1985) 40, 895 and
Mazzei, M., Ermili, A., Balbi, A., Di Braccio, M., Farmaco. Ed. Sci.,
(1986), 41, 611; CA 106:18313w). The CNS activity of 2-aminochromones has also been described (Balbi, A., Roma, G., Ermili, A.,
Farmaco. Ed. Sci., (1982) 37, 582; Ermili, A., Mazzei, M., Roma, G.,
Cacciatore, C, Farmaco. Ed. Sci., (1977), 32, 375 and 713). The nitro derivatives of various 2-aminochromones have recently been described (Balbi, A., Roma, G., Mazzei, M., Ermili, A., Farmaco. Ed. Sci., (1983) 38, 784) and Farmaco. Ed. Sci., 41(7), 548-57. 2-Amino¬
3-hydroxychromones are described in DE 2205913 and GB 1389186.
U.S. Patent 4,092,416 (see also DE 2555290 and CA 87:102383r) discloses various benzopyrone derivatives exhibiting anti-allergic activity, including 2- {2- [4-(2-methoxyphenyl) -piperazinyl-1] -ethyl)- 5-methoxy-4-oxo-4H-1-benzopyran and 2-{2-[4-(2-methoxyphenyl)- piperazinyl-1]-ethyl)-5-(2-hydroxypropoxy)-4-oxo-4H-1-benzopyran.
JA-O25657 and JP-259603 descrive various 2-amino-3-carboxamide derivatives and 3-phenyl (optionally substituted)-2-aminochromone derivatives as useful as oncostatic and immunosuppressive agents.
The pharmacomodulation of α-adrenergic blocking agents by a series of benzopyrans, including 2- (1-piperidinylmethylene)-4H-1- benzopyran-4-one, is described in Eur. J. Med. Chem., 1987, 22(6), 539-44; CA 109:92718k. Structurally, the closest compounds in the literature to 2-(4-morpholinyl)-4H-1-benzopyran-4-one (Cpd 2) is believed to be the 3-hydroxy, 3-methoxy and 3-acetyloxy analogues (i.e., 2-(4-morpholinyl)-3-hydroxychromone, 2-(4-morpholinyl)-3-methoxychromone and 3-(acetyloxy)-2-(4-morpholinyl)chromone) reported by Eiden and Docher (Eiden, F., Dolcher, D., Arch. Pharm. (Weinheim Ger.) (1975) 308, 385) and DE 2205913; CA 83(11) :96942w and CA79 (19) :115440s. 6,7-dimethoxy-2-(4-morpholinyl)chromone is disclosed in J. Chem. Soc, Perkins Trans. 1, (2), 173-4; CA78(9); 58275v. 3-Acetyl-2-(4-morpholinyl)chromone is disclosed in Arch. Pharm. 316(1), 34-42; CA98(15):12915g.
3-hydroxy-2-[4-(2-hydroxyethyl)-1-piperazinylj-4H-1-benzopyran4-one and 3-hydroxy-2-(4-methyl-1-piperazinyl)-4H-1-benzopyran-4-one are disclosed in Arch. Pharm 308(5), 385-8; CA83(11) :96942w. 5,8-dimethoxy-2-(4-methyl-1-piperazinyl)-4H-1-benzopyran-4-one is disclosed in J. Heterocycl. Chem., 18(4), 679-84; CA95(17): 150348v.
The synthesis of 2-aminochromones from the corresponding 2-sulphonyl and 2-sulphinyl analogues has been reported by Bantick and Suschitzky (Bantick, J.R., Suschitzky, J.L., J. Heterocyclic Chem., (1981) 18, 679). Also described in this report is the preparation of the HCL and H2SO4 salts of several 2-aminochromones.
The anti-platelet activity of some 2-(dialkylamino)chromones, namely: 2-(diethylamino)-5,6-dimethyl-4H-1-benzopyran-4-one,
2-(diethylamino)-6,7-dimethyl-4H-1-benzopyran-4-one, 2-(diethy1- amino)-7-hydroxy-5-methyl-4H-1-benzopyran-4-one, 2-(diethylamino)-5-hydroxy-7-methyl-4H-1-benzopyran-4-one, 2-(diethylamino)-6-chloro-8-isopropyl-4H-1-benzopyran-4-one, 2-(diethylamino)-5,7-methoxy-4H-1-benzopyran-4-one, 2-(ethylamino)-5-hydroxy-4H-1-benzopyran-4-one, 2-(ethylamino)-7-hydroxy-4H-1-benzopyran-4-one, 2-(diethylamino)-7-hydroxy-6-nitro-4H-1-benzopyran-4-one, 2-(diethylamino)-4H-1-benzopyran-4-one, 2-(dimethylamino)-7-methoxy-4H-1-benzopyran-4-one, 2-(diethylamino)-7-methoxy-4H-1-benzopyran-4-one, 2-(1-pyrrolidinyl)-7-methoxy-4H-1-benzopyran-4-one, 2-(1-piperidinyl)-7-methoxy-4H-1-benzopyran-4-one, 2-(diethylamino)-7-hydroxy-4H-1-benzopyran-4-one, 2-(1-piperdinyl)-7-hydroxy-4H-1-benzopyran-4-one, 2-(ethylamino)-7-methoxy-4H-1-benzopyran-4-one, 2-(diethylamino)-5-hydroxy-4H-1-benzopyran-4-one, 2-(diethylamino)-5-methyl-8-isopropyl-4H-1-benzopyran-4-one, and 2-(diethylamino)-3-(4-morpohoinomethyl)-7-methoxy- 4H-1-benzopyran-4-one, was reported by Mazzei et al. in Eur. J. Med. Chem. 23, 237-242 (May-June 1988); CA 110:75246h.
The literature on the use of an ynamine in the synthesis of a 2-aminochromones has been reported by Tronchet, Bachler and Bonenfant (Tronchet, J.M. J., Bachler, B., Bonenfant, A., Helv. Chim. Acta.
(1976), 59, 941). In this report, a 2-amino-3-glycosylchromone was prepared.
2-Amino-1,3-benzoxazin-4-ones are also known in the literature. Specifically, 2-morpholinyl-4H-1,3-benzoxazin-4-one (Cpd 98) and 8-methyl-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one (Cpd 84) are described in Netherlands patent application 6,412,966 (see also U.S. 3,491,092), and in the literature (Grigat, E., Putter, R., Schneider, K., Wedemeyer, K., Chem. Ber., (1964) 97, 3036).
The fungicide and analgesic activity of 2-amino-1,3-benzoxazin-4-ones are also claimed by Sankyo in Japn. Tokkyo Koho 79 20,504 (CA 91:157755b) and in Japan (Kokai 72, 17,781 (CA 77:140107e). These patents appear to cover 2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one (Cpd 98) and 6,7-substituted-2-(4-morpholinyl) analogues for the above indications.
The synthesis of 2-dialkylamino-1,3-benzoxazin-4-ones has been described by Kokel et al (see Tet. Letters (1984) 3837).
2-N-Alkyl and 2-N-aryl-1,3-benzoxazin-4-ones have been described by Palazzo and Giannola (Palazzo, S., Giannola, L.I., Atti. Accad. Sci. Lett. Arti Palermo, Parte 1, (1976) 34(2), 83-7).
2-Benzamidino-1,3-benzoxazin-4-one have been described by Brunetti, H., and Luthi, C.E. (in Helv. Chim. Acta., (1972) 55, 1566).
BRIEF DESCRIPTION OF THE INVENTION
This invention relates to compounds of the Formula I which are useful in association with a pharmaceutical carrier as antiatherosclerotic agents. In addition, various compounds of the
Formula I are useful inhibitors of cell proliferation and/or platelet aggregation.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of this invention are represented by Formula I wherein
X is N, or CZ where Z is H, C1-C5 alkyl, amino (-NH2) or a halogen atom; when X is CZ, Y is selected from the group consisting of
"(CH2)nNR9R10 wherein R9 and R10, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that R9 and R10 are not both hydrogen; (b) C1-C12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4 alkyl); (d)
-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], (e) -(CH2)npyridinyl or (f) wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted
with one or two members selected from
the group consisting of C1-C4 alkyl,
C1-C4 alkoxy, halo or trifluoromethyl
(bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
(cc) 3-amino-1-pyrrolidine,
(dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
(ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl),
(ff) 1-piperazine, 4-methyl-1-piperazine, 4-(cycloC3¬
C6alkyl)-1-piperazine, 4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1¬
C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4- pyridinyl-1-piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl, -CH2OH, -CO2H, -CO2CH3 or -CO2CH2CH3, and (gg) thiazolidine, thiazolidine-4-carboxylic
acid, pipecolinic acid, p-piperazinacetophenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetrahydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole;
and R5, R6, R7 and R8, being the same or different, are selected from the group consisting of hydrogen, C1-C8 alkyl,
-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)nnaphthyl, -(CH2)npyridinyl,
-(CH2)qNR9R10, -CH-CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -CH2-CH=CH2, -CH=CH-CH3, -O-CH2-CH=CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O(CH2)p(N-methylpiperdin-3-yl), -O-(CH2)pNR9R10, -O-CH2CH(OCH3)2, -O-(CH2)pOR15 [wherein R15 is selected from C1-C5 alkyl, -(CH2)nphenyl [phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)],
-(CH2)npyridin-1-yl or -(CH2)ppiperidin-1-yl], -(CH2)nC(O)- (CH2)nR9, -(CH2)nC(O)O-(CH2)pR9, -(CH)nC(O)O-(CH2)pNR9R10, -(CH2)nC(O)(CH2)nNR9R10, NO2, -O-(CH2)nC(O) -(CH2)pR9,
-O-(CH2)nC(O)O-(CH2)pR9, -O-(CH2)nC(O)- (CH2)nNR9R10, -NR9R10, -N(R9)(CH2)nC(O)-(CH2)nR10, -N(R9)-(CH2)nC(O)O-(CH2)nR10. N(R9)(CH2)nC(O)-(CH2)nNR9R10, -O-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)],
-O-(CH2)npyridine, -O(CH2)nC(O)-(CH2)npyridine, -O-(CH2)nC(O)O- (CH2)npyridine, -O(CH2)nC(O)-N(R9) (CH2)npyridine,
-O-(CH2)nquinoxalinyl, -O-(CH2)nquinolinyl, -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O-(CH2)nC(O)-(CH2)nnaphthyl,
-O-(CH2)nC(O)O-(CH2)nnaphthyl, -O-(CH2)nC(O)NR9-(CH2)nnaphthyl, halo (fluoro, chloro, bromo, iodo), OH, -(CH2)q-OH, (CH2)q0C(O)R9, -(CH2)qOC(O)-NR9R10, -(1-cyclohexyl-1H-tetrazol- 5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, - [1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or
-CO2(C1-C4alkyl)], -[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(1-phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -C1-C4 alkoxyl, or a group of Formula II (see Formula Sheet) wherein R' is methyl or carboxy, R'' is hydrogen and R''' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], C1-C5 alkyl, -(CH2)nCO2H, -CH2SH, -CH2SCH3, imidazolinylmethylene, indolinylmethylene, CH3CH(OH), CH2OH, H2N(CH2)4- (optionally in protected form) or H2NC(NH)NH(CH2)3 (optionally in protected form); with the overall proviso that when Y is other than -(CH2)nmorpholinyl, at least one member of R5, R6, R7 or R8 is other than hydrogen, C1C8 alkyl, NO2, OH, C1-C4 alkoxy, a halogen atom, phenyl, benzyl, 4-morpholinylmethyl, NH2, or dimethyamino; with the further proviso that when Y is 4-morpholinyl, the compound is other than:
6,7-dimethoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one, 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one,
N-cyclohexyl-2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7-yl]oxy]-acetamide,
2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7-yl]oxy]-N-phenyl-acetamide,
6-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one,
2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7-yl]oxy]-N-(1-phenylethyl)-acetamide;
with the further provisio that when Y is dimethylamino, the compound is other than:
2-(Dimethylamino)-8-methyl-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester,
(Dimethylamino)-4-oxo-4H-1-benzopyran-6-yl carbamic acid dimethyl ester, 2-(Dimethylamino)-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester;
when X is N, Y is selected from the group consisting of
-NR9R10 wherein R9 and R10, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that R9 and R10 are not both hydrogen;
(b) C1-C12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl); (d) -(CH2)nphenyl
[wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or- CO2(C1-C4alkyl)], (e) -(CH2)npyridinyl or (f) wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of
(aa) 4-morpholine optionally substituted
with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
(bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
(cc) 3-amino-1-pyrrolidine,
(dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
(ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH,
-CO2H, -CO2CH3, -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3
C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-1-piperazine,
4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl,
-CH2OH, -CO2H, -CO2CH3 or -CO2CH2CH3, and
(gg) thiazolidine, thiazolidine-4-carboxylic
acid, pipecolinic acid, p-piperazinacetophenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-1 ,2-3,6tetrahydropyridine, proline, tetrahydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole;
and R5, R6 , R7 and R8, being the same or different, are selected from the group consisting of hydrogen, C1-C8 alkyl,
-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)nnaphthyl, -(CH2)npyridinyl,
-(CH2)qNR9R10, -CH=CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -CH2-CH-CH2, -CH-CH-CH3, -O-CH2-CH-CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 allsyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O(CH2)p(N-methylpiperdin-3-yl), -O-(CH2)pNR9R10, -O-CH2CH(OCH3)2, -O-(CH2)pOR15 [wherein R15 is selected from C1-C5 alkyl, -(CH2)nphenyl [phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)],
-(CH2)npyridin-1-yl or -(CH2)ppiperidin-1-yl], -(CH2)nC(O)-(CH2)nR9, -(CH2)nC(O)O-(CH2)pR9, - (CH)nC(O)O-(CH2)pNR9R10, - (CH2)nC(O) (CH2)nNR9R10, N02 , -O- (CH2)nC(O) - (CH2)pR9,
-O-(CH2)nC(O)O-(CH2)pR9, -O-(CH2)nC(O) - (CH2)nNR9R10, -NR9R10,
-N(R9)(CH2)nC(O)-(CH2)nR10, -N(R9) - (CH2)nC(O)O-(CH2)nR10, N(R9)(CH2)nC(O)-(CH2)nNR9R10, -O- (CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl),
-O-(CH2)npyridine, -O(CH2)nC(O)- (CH2)npyridine, -O-(CH2)nC(O)O-(CH2)npyridine, -O(CH2)nC(O) -N(R9) (CH2)npyridine,
-O-(CH2)nquinoxalinyl, -O-(CH2)nquinolinyl, -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O-(CH2)nC(O)-(CH2)nnaphthyl, -O-(CH2)nC(O)O-(CH2)nnaphthyl. -O-(CH2)nC(O)NR9-(CH2)nnaphthyl, halo (fluoro, chloro, bromo, iodo), OH, -(CH2)q-OH, (CH2)qOC(O)R9, -(CH2)qOC(O)-NR9R10, -(1-cyclohexyl-1H-tetrazol- 5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -[1-(pyridinyl)-1H-tetrazol-5-yl] C1-C4 alkoxy, -[1-(1- phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, or -C1-C4 alkoxyl, or a group of Formula II (see Formula Sheet) wherein R' is methyl or carboxy, R'' is hydrogen and R''' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], C1-C5 alkyl, -(CH2)nCO2H, -CH2SH,
-CH2SCH3, imidazolinylmethylene, indolinylmethylene, CH3CH(OH), CH2OH, H2N(CH2)4- (optionally in protected form) or H2NC(NH)NH(CH2)3 (optionally in protected form);
n is 0-5, preferably 0 or one;
p is 2-5, preferably 2 or 3;
q is 1-5, preferably 1 or 2;
and pharmaceutically acceptable salts thereof.
X is preferably CZ where Z is H or C1-C5 alkyl, more preferably H or methyl, most preferably H.
When X is CZ, Y is preferably selected from the group consiting of -(CH2)nNR9R10 wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of:
(aa) 4-morpholine optionally substituted
with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
(bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
(cc) 3-amino-1-pyrrolidine,
(dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
(ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH,
-CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3
C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), and
(ff) 1-piperazine, 4-methyl-1-piperazine,
4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH2OH,- CO2H, -CO2CH3 or -CO2CH2CH3.
When X is CZ wherein Z is H or C1-C5 alkyl (most preferably H), Y is more preferably selected from the group consisting of
- (CH2)nNR9R10 wherein n is 0 or 1 (most preferably 1) and R9 and R10, taken together with N, form:
(aa) morpholine (preferably 4-morpholine) optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl or phenyl (wherein phenyl is optionally substituted with one or 2 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl);
and preferably, at least one member selected from R5, R6, R7 or R8 is selected from:
the group consisting of - (CH2)pphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)],
-(CH2)nnaphthyl, -(CH2)npyridinyl, -(CH2)qNR9R10, -CH=CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1C4alkyl)], -CH2-CH=CH2, -CH=CH-CH3, -O-CH2-CH=CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1C4alkyl)], -O(CH2)p(N-methylpiperdin-3-yl), -O-(CH2)pNR9R10,
-O-CH2CH(OCH3)2, -O-(CH2)pOR15 [wherein R15 is selected from C1C5 alkyl, -(CH2)nphenyl [phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)npyridin-1-yl or -(CH2)ppiperidin-1- yl], -(CH2)nC(O)-(CH2)nR9, -(CH2)nC(O)O-(CH2)pR9, -(CH)nC(O)O- (CH2)pNR9R10, -(CH2)nC(O)(CH2)nNR9R10, -O-(CH2)nC(O) - (CH2)pR9, -O-(CH2)nC(O)O-(CH2)pR9, -O-(CH2)nC(O)-(CH2)nNR9R10,
-NR9R10, -N(R9)(CH2)nC(O)-(CH2)nR10, -N(R9)-(CH2)nC(O)O- (CH2)nR10, N(R9)(CH2)nC(O)-(CH2)nNR9R10, -O-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1C4alkyl)], -O-(CH2)npyridine, -O(CH2)nC(O)-(CH2)npyridine, -O-(CH2)nC(O)O-(CH2)npyridine, -O(CH2)nC(O)-N(R9) (CH2)npyridine, -O-(CH2)nquinoxalinyl, -O-(CH2)nquinolinyl, -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O-(CH2)nC(O) - (CH2)nnaphthyl,
-O-(CH2)nC(O)O- (CH2)nnaphthyl, -O-(CH2)nC(O)NR9- (CH2)nnaphthyl, -(CH2)q-OH, (CH2)qOC(O)R9, - (CH2)qOC(O)-NR9R10, -(1-cyclohexyl- 1H-tetrazol-5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5- yl]C1-C4 alkoxy, -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1C4alkyl)], -[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy,
-[1-(1-phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, or -C1-C4 alkoxyl;
more preferably,
(i) R5, R6, R7 and R8 are each hydrogen; or
(ii) R5, R6, and R8 are each hydrogen, and R7 is selected from:
-O-(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -C≡C-phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), or -(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1C4 alkoxy, halo or trifluoromethyl); or
(iii) R5 and R6 are hydrogen, R8 is hydrogen, halo or C1-C5 alkyl, and R7 is selected from: -O-(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl),
-O-(CH2)npyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -O-(CH2)nnaphthyl, -(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl),
-(CH2)ppyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -(CH2)p(1-piperidinyl), -(CH2)p(1-pyrrolidinyl) or -[(1-cyclohexyl-1H-tetrazol-5- yl)C1-C4 alkoxy; or
(iv) R5, R7 and R8 are each hydrogen, and R6 is
-NH-C(O)-O-CH2phenyl.
X is most preferably CH.
Y is most preferably 4-morpholinyl.
R8 is preferably hydrogen or C1-C5 alkyl, more preferably hydrogen or methyl.
Accordingly the present invention includes the novel 2-amino(4H)-1-benzopyran-4-ones and 2-aminoalky1(4H)-1-benzopyran-4-ones of Formula I when X is CZ and the antiatherosclerotic utility of said compounds as well as the antiatherosclerotic utility of the known compounds of Formula I, including the 2-amino-1,3-benzoxazine-4-ones of Formula IB.
The carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Ci-Cj indicates a carbon atoms content of the integer "i" to the integer "j" carbon atoms, inclusive. Thus, C1-C3 alkyl refers to alkyl of 1-3 carbon atoms, inclucive, or methyl, ethyl, propyl, and isopropyl.
With respect to the above, C1-C4 alkyl is methyl, ethyl, propyl, or butyl, including isomeric forms thereof.. Similarly, C1-C6 alkyl is methyl, ethyl, propyl, butyl, pentyl, hexyl, and isomeric forms thereof.
The term "halo" includes fluoro, chloro, bromo and iodo.
Examples of C1-C8 alkylthiomethyl are methylthiomethyl, ethylthiomethyl, propylthiomethyl, butylthiomethyl, pentylthiomethyl, hexylthiomethyl, and heptylthiomethyl, and isomeric forms thereof.
Examples of C1-C8 alkoxymethyl are methoxymethyl, ethoxymethyl, propoxymethyl, butoxymethyl, pentoxymethyl, butoxymethyl, pentoxymethyl, hexoxymethyl, and heptoxymethyl, and isomeric forms thereof.
Examples of heterocylic amines corresponding to heterocyclic amine rings according to -NR9N10 are:
4-morpholine,
4-phenyl-1-piperazine,
4-(2-pyridinyl)-1-piperazine,
2,6-dimethyl-4-morpholine,
1-pyrrolidine,
4-methyl-1-piperazine,
1-piperidine,
4-phenyl-1-piperidine
thiazolidine,
3-piperidine methanol,
2-piperidine methanol,
pipecolic acid,
3-piperidine ethanol,
2-piperidine ethanol,
1-piperazine propanol,
p-piperazinoacetophenone,
4-phenyl-1,2,3,6-tetrahydropyridine,
4-phenylpiperidine,
proline,
1-(3-hydroxy)pyrrolidine,
tetrahydrofurylamine,
pyrrolidimethanol,
3-pyrroline,
thiazolidine-4-carboxylic acid,
thiomorpholine,
nipecotamide,
2-methylpiperidine,
3-methylpiperidine,
4-methylpiperidine,
N-methylpiperazine,
1-methylhomopiperazine,
1-acetylpiperazine,
N-carboethoxypiperazine, 3-methylpiperazine-2-carboxylic acid,
2-methylpiperazine,
2,3,5,6,-tetramethylpiperazine,
1,4-dimethylpiperazine,
2,6-dimethylpiperazine,
2-methyl-1-phenylpiperazine,
1-(1-phenylethyl)piperazine,
1-(2-pyrazinyl)piperazine,
1-cyclopropylpiperazine,
1-cyclobutylpiperazine,
1,2,3,4-tetrahydroisoquinoline,
imidazole,
homopiperdine, and pharmaceutically acceptable salts and hydrates thereof.
Examples of -O(CH2)p(N-methylpiperdin-3-yl) include (2-(N-methylpiperdin-3-yl)ethyl)oxy, (3-(N-methylpiperdin-3-yl)propy)loxy, (4-(N-methylpiperdin-3-yl)butyl)oxy.
Examples of -O-(CH2)pNR9R10 include (2-(1-piperidinyl)ethyl)oxy, (2-(4-morpholinyl)ethyl)oxy, (2-(1-pyrrolidinyl)ethyl)oxy, (3-(N-methylpiperazinyl)propyl)oxy, (4-(N-ethyl-N-phenylamino)butyl)oxy, (5-(diethylamino)pentyl)oxy, (2-(4-benzylpiperazinyl)ethyl)oxy, and (3-(N,N-diisopropyl)propyl)oxy.
Examples of O-(CH2)pOR15 include (2-methoxyethyl)oxy, (3- butoxypropyl)oxy, (4-phenoxybutyl)oxy, (2-benzyloxyethyl)oxy, (2-(2-(1-piperidinyl)ethoxy)ethyl)oxy and (3-(3-picolylmethoxy)propyl)oxy.
Examples of -(CH2)npyridinyl include 2-pyridyl, 3-pyridylmethyl and 4-pyridylethyl.
Examples of -(CH2)npiperdinyl include 1-piperidinyl, 1-peiperidinylmethyl, 2-(1-piperidinyl)ethyl and 3-(1-piperidinyl)propyl.
Examples of -(CH2)qNR9R10 include (1-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 3-(1-pyrrolindinyl)propyl and 4-(1-piperazinyl)butyl.
Examples of -(CH2)nC(O)-(CH2)nR9 include acetyl, acetylmethyl, methylacetylmethyl, methylacetylethyl, phenylacetyl, phenylacetylmethyl, 2-(phenylacetyl)ethyl, 2-pyridylacetyl, 3-pyridylacetylmethyl, 3-(t-butylacetyl)propyl and 4- (ethylacetyl)butyl. Examples of τ(CH2)nC(O)O- (CH2)pRg include carbomethoxy, carbomethoxymethyl, 2 -(carbomethoxy) ethyl, carbophenylmethoxy, carbophenylmethoxymethyl, 2-(carbo(3-pyridyl)methoxy)ethyl, carboethoxymethyl and 3-(carbopropoxy)propoxy.
Examples of - (CH2)nC(O)Q-(CH2)pNR9R10 include -G(O)O- (CH2)2N(ethyl)2, -(CH2)C(O)O=(CH2)2N(CH3) (phenyl), - (CH2)3C(O)O- (CH2)3(l-pyrrolidine), -(CH2)3C(O)O-(CH2)2(l-piperidinyl),
and -(CH2)C(O)O-(CH2)2(4-morpholinyl).
Examples of -(CH2)nC(O) (CH2)nNR9R10 include
- (CH2)C(O) (CH2)N(ethyl)2, -(CH2)2C(O) (CH2)2N (methyl) (phenyl),
-C(O) (1-pyrrolidine), -(CH2)2C(O) (CH2)3(1-piperidine), and
-(CH2)3C(O) (CH2) (4-morpholine).
Examples of -O-(CH2)nC(O)-(CH2)pR9 include -O-(CH2)C(O)- (CH2)(CH3), -O-C(O)-(CH2)2(CH3), -O-(CH2)3C(O)-(CH2)phenyl,
-O-(CH2)2C(O)-(CH2)3(2-pyridyl), -O-(CH2)C(O)-(CH2)2(3-pyridyl) and -O-(CH2)4C(O)-(CH2)4(t-butyl).
Examples of -O-(CH2)nC(O)O- (CH2)pR9 include -O-(CH2)C(O)O- (CH2)(CH3), -O-C(O)O-(CH2)2(CH3), -O-(CH2)2C(O)O-(CH2)3(phenyl) and -O-(CH2)3C(O)O-(CH2)2(3-pyridyl).
Examples of -O-(CH2)nC(O)-(CH2)nNR9R10 include -O-(CH2)C(O)- (CH2)N(CH3)2, -O-C(O)-(CH2)(1-pyrrolidine), -O-(CH2)C(O)-(1- piperidine), -O-(CH2)2C(O)-(CH2) (1-N-methylpiperazine),
-O-(CH2)2C(O)-(CH2)2(4-morpholine), -O-(CH2)C(O)- (CH2) 3 (cyclohexylamine), -O-(CH2)2C(O)-(CH2)3(t-butylamine),
-O-(CH2)C(O)-(CH2)2(1-phenylethylamine). -O-(CH2)C(O)- (CH2)2(aniline), -O-(CH2)C(O)-(CH2) (L-phenylalanine ethyl ester) and -O-(CH2)2nC(O)-(CH2)3(3-pyridylamine).
Examples of -N(R9) (CH2)nC(O)-(CH2)nR10 include -N(CH3)C(O)- (CH3), -N(H)(CH2)2C(O)-(CH2) (phenyl), -N(H) (CH2)C(O) -(CH2)2(3- pyridyl) and -N(CH3) (CH2)3C(O)-(CH2) (CH3).
Examples of -N(R9)- (CH2)nC(O)O-(CH2)nR10 include
-N(H)-(CH2)C(O)O-(CH3), -N(H)-(CH2)2C(O)O-(CH2) (benzyl), -N(H)- (CH2)2C(O)O-(CH2)(3-pyridyl) and -N(CH3)-(CH2)C(O)O-(CH2)2(t-butyl).
Examples of -N(R9) (CH2)nC(O)-(CH2)nNR9R10 include
-N(H)(CH2)C(O)-(CH2)N(CH3)2, -N(H)C(O) -(CH2) (1-pyrrolidine),
-N(H)(CH2)2C(O)-(CH2)2(1-piperidine), and -N(CH3) (CH2)C(O) - (CH2)2(4- morpholine).
Examples of -O-(CH2)nphenyl include 2-(4- trifluoromethylphenyl)ethoxy, 4-chlorophenoxy, 4-fluorophenylmethoxy, 3-(4-methoxyphenyl)propoxy, 4-(2-methyl-4-fluorophenyl)butoxy, 2-(2-methoxyphenyl)ethoxy, 3-methoxyphenylmethoxy, 4-carbomethoxyphenylmethoxy, 2-(3,4-dichlorophenyl)ethoxy, 4-ethoxyphenylmethoxy, 3-(4-nitrophenyl)propoxy, 4-t-butylphenylmethoxy, 4-benzyloxyphenylmethoxy and 2-(3-triflouromethylphenyl)ethoxy.
Examples of -O-(CH2)npyridine include 2-pyridyloxy, 3-pyridylmethoxy and 2- (4-pyridyl)ethoxy.
Examples of -O(CH2)nC(O)-(CH2)npyridine include -O(CH2)C(O)-(CH2)(2-pyridine), -O(CH2)3C(O) - (CH2) (3-pyridine) and -O(CH2)2C(O) -(CH2)3(4-pyridine).
Examples of -O-(CH2)nC(O)O-(CH2)npyridine include
-O(CH2)C(O)O-(CH2)(2-pyridine), -O(CH2)3C(O)O-(CH2) (3-pyridine) and -O(CH2)2C(O)O-(CH2)3(4-pyridine).
Examples of -O(CH2)nC(O) -N(R9) (CH2)npyridine include
-O(CH2)C(O)-N(CH3) (CH2) (2-pyridine), -O(CH2)2C(O) -N(CH3) (CH2) (3-pyridine) and -O(CH2)C(O)-N(benzyl) (CH2)2(4-pyridine).
Examples of -O-(CH2)nquinoxalinyl include 2-quinoxalinyloxy, 2-quinoxalinylmethoxy and 2-(2-quinoxalinyl)ethoxy.
Examples of -O-(CH2)nquinolinyl include 2-quinolinyloxy, 2-quinolinylmethoxy and 2- (2-quinolinyl)ethoxy.
Examples of -O-(CH2)npyrazinyl include 2-pyrazinyloxy, 2-pyrazinyImethoxy and 2-(2-pyraziny1)ethoxy.
Examples of -O-(CH2)nnaphthyl include 1-naphthyloxy, 2-naphthylmethoxy and 2- (1-naphthyl)ethoxy.
Examples of -O-(CH2)nC(O)- (CH2)nnaphthyl include -O-(CH2)C(O)-(CH2)(1-naphthyl), -O-(CH2)2C(O)-(CH2) (2-naphthyl), -O-C(O)-(CH2)(1-naphthyl) and -O-(CH2)2C(O)-(CH2)2(2-naphthyl).
Examples of -O-(CH2)nC(O)O-(CH2)nnaphthyl include
-O-(CH2)C(O)O-(CH2)(1-naphthyl), -O- (CH2)2C(O)O- (CH2) (2-naphthyl), -O-C(O)O-(CH2)(1-naphthyl) and -O-(CH2)2C(O)O- (CH2)2(2-naphthyl).
Examples of -O- (CH2)nC(O)NR9- (CH2)nnaphthyl include
-O- (CH2)C(O)N(H) (CH2) (1-naphthyl) , -O- (CH2)C(O)N((H3) (CH2) 2 (2 -naphthyl) and -O- (CH2) C(O)N(benzyl) (CH2) 3 (1-naphthyl) .
Examples of - (CH2) q-OH include hydroxymethyl , hydroxyethyl and hydroxybutyl .
Examples of (CH2) qOC(O)R9 include (CH2)OC(O)methyl , (CH2)2OC(O) ethyl, (CH2)3OC(O)phenyl, (CH2)4OC(O) (3-pyridyl) and (CH2)OC(O)thiophene.
Examples of -(CH2)qOC(O)-NR9R10 include -(CH2)OC(O)-N(CH2)2, -(CH2)2OC(O)-N(ethyl)2, -(CH2)3OC(O)-(1-pyrrolidine), -(CH2)4OC(O)-(1-piperidine) and -(CH2)OC(O)-N-benzylamine.
Examples of -(1-cyclohexyl-1H-tetrazol-5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy include -(1-cyclohexyl-1H-tetrazol-5-yl)methoxy, -(1-cyclohexyl-1H-tetrazol-5-yl)ethoxy, -[1-(methyl)-1H-tetrazol-5-yl]methoxy, -[1-(cyclopropyl)-1H-tetrazol-5-yl]ethoxy, -[1-(1-tert-butyl)-1H-tetrazol-5-yl]propoxy and -[1-(cyclopenyl)-1H-tetrazol-5-yl]methoxy.
Examples of -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) include -[1-(phenyl)-1H-tetrazol-5-yl]methoxy, -[1-(phenyl)-1H-tetrazol-5-yl]ethoxy, -[1-(4-methoxyphenyl)-1H-tetrazol-5-yl]methoxy, -[1-(4-fluorophenyl)-1H-tetrazol-5-yl]propoxy.
Examples of -[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy or -[1-(1-phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy include -[1-(2-pyridinyl)-1H-tetrazol-5-yl]methoxy, -[1-(3-pyridinyl)-1H-tetrazol-5-yl]ethoxy, -[1-(4-pyridinyl)-1H-tetrazol-5-yl]propoxy, -[1-(1-phenylethyl)-1H-tetrazol-5-yl]methoxy, -[1-(1-phenylethyl)-1H- tetrazol-5-yl]ethoxy.
The tertiary amines and aromatic heterocyclic amines of the subject specification and claims include the N-oxides thereof.
Pharmaceutically acceptable salts means salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, maleate malate, succinate, tartrate, and the like. These salts may be in hydrated form.
The compounds of Formula I are all characterized by pronounced antiatherogenic activity, rendering these compounds useful in the treatment and prophylaxis of atherosclerosis.
Various compounds including 2-(4-morpholinyl)-4H-benzopyran-4- one (Cpd #2), 2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one (Cpd #98), 8- methyl-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one (Cpd #84), 2-(1-(4- thiomorpholinyl) ) -4H-1, 3-benzoxazin-4-one (Cpd #95) and 2- (4-methyl- 1-piperazinyl)-4H-1,3-benzoxazin-4-one (Cpd #96) reduced arterral cholesterol accumulation in the SEA Japanese quail model. The reduction in arterial cholesterol was accompanied with reduced serum cholesterol levels with Compounds 84 and 95, but not with Compounds 2, 98 and 96. In normal cholesterolemic SEA Japanese quail, Compound 84 also lowered serum cholesterol. For a description of the Japanese quail model, see Day, CE. et al., "Utility of a Selected Line (SEA) of the Japanese Quail (Coturnic Coturnix japonica) for the Discovery of New Anti-Atherosclerosis Drugs", Laboratory Animal Science 27:817821 (1977).
Preferred antiatherosclerotic compounds include Compounds 2, 3, 19, 51, 72, 76, 84, 95, 96, 98, 112, 139, 163, 164, 171 and 204.
In addition, various compounds of Formula I are also potent inhibitors of cell proliferation and are contemplated as useful in the treatment of proliferative diseases such as cancer, rheumatoid arthritis, psoriasis, pulmonary fibrosis, scleroderma, cirrhosis of the liver and for the improved utilization of artificial prosthetic devices such as arterial grafts. These agents may also be useful in the prevention or treatment of obstruction or restenosis of arteries by subsequent administration of drug in cases such as by-pass surgery, coronary by-pass surgery, balloon angioplasty (and other procedures directed at re-establishing patency in occluded or partly occluded vessels, i.e atherectomy, laser or ultrasonic procedures), transplants, and post-thrombotic re-stenosis.
Compounds of Formula I which are inhibitors of cell proliferation are those active in the test procedure described in Pledger W.J., Stiles CD., Antniades H.N., Scher CD., [Proc. Natl. Acad. Sci (USA) (1977). Examples of inhibitors of cell proliferation include Compounds 1-14; 16-17; 19-23; 25 and 26; 28; 30-34; 36-39; 42; 46-48; 51, 52; 54-56; 58-76; 81, 100-103; 105-112; 120-122; 125133; 135-145; 149; 155 and 156; 158-160; 163; 165 and 166; 171; 173180, 183-190, 193, 204, 206 and 207.
In addition, various compounds of Formula I are also inhibitors of ADP induced platelet aggregation and are useful in the prevention or treatment of thrombotic diseases and related complications by, for example, inhibition or reversal of platelet aggregation, or platelet adhesion or blood coagulation.
Compounds of Formula I which are inhibitors of platelet aggregation are those active in the test procedure described in Born, G.R., Cross M.J., J. Physiol., 168, p. 178 (1963). Examples of inhibitiors of ADP induced platelet aggreation include: Compounds 23, 5-6, 9-11, 13, 20-22, 25-26, 28, 31-32, 34, 36-39, 31, 36-38, 5153, 56, 58-59, 63, 65, 69, 72-76, 80, 100, 102, 104, 106-107, 109113, 115, 116, 118, 120-123, 125-131, 133, 136-140, 147, 149, 154160, 162-167, 169, 171, 172, 178, 181-188, 192-198, and 207.
Accordingly, in using compounds of Formula I for the prevention or treatment of atherosclerotic disease or thrombotic diseases, an oral route of administration, either by conventional oral dosage forms or by mixture with food, represents the preferred method of their systemic administration. Alternatively, however, these compounds may be administered by other convenient routes of administration whereby systemic activity is obtained. These other routes of administration would include rectal, vaginal, subcutaneous, intramuscular, intravenous, and like routes.
In using compounds of Formula I for use in angioplasty, an oral route of administration represents the preferred method of their systemic adminstration. Alternatively, however, these compounds may be administered by other convenient routes of administration whereby systemic activity is obtained.
The patient or animal being treated must be given periodic doses of the drug in amounts effective to reduce serum and/or arterial cholesterol, and reduce arterial atherosclerotic lesion size (as determined by angiogram, ultrasound, NMR, etc.); or, by the irihibition or reversal of platelet aggregation, platelet adhesion or blood coagulation; or, by preventing arterial occlusion in vascular trauma associated with procedures such as by-pass grafts, coronary bypasses, angioplasty, post-thrombotic re-stenosis and transplants.
Such effective dosages are readily determined by methods known in the art. For example, small daily doses of the drug
( e.g., 0.01-200 mg/kg) may be administered initially with higher succeeding doses until levels of serum and/or arterial cholesterol are favorably affected. By this regimen, a compound of Formula I is administered initially at doses as low as about 0.01 mg/kg per patient per day, with increasing doses up to about 200 mg/kg per patient per day. In the event the antiatherogenic response in a patient being treated at a dose of 200 mg/kg per day is insufficient, higher doses are also utilized to the extent patient tolerance permits further increases in dose.
While the preferred dosage regimen is with single daily dosing of patients, also preferred for obtaining more uniform serum levels of drug are multiple dosages per day (e.g., up to 4-6 times daily). Accordingly, when 4 daily doses of drug are to be administered, each such dose may be about 50 mg/kg per patient per dose, or higher depending on tolerance.
Similar doses are employed in hon-human mammals, e.g. 0.01-200 mg/kg/day.
Charts A-I herein describe various methods by which the compounds of Formula I are prepared. With respect to these Charts, X, Y, R5, R6, R7, R8, R9 and R10 are as defined above.
With respect to Chart A, the compounds of Formula I are prepared by mixing the salicylic acid ester with the morpholine ynamine neat, or in an organic solvent, with stirring. After several minutes, a tertiary amine base, e.g. TEA (triethylamine), is added and the reaction stirred for a period of time. The product can be isolated by recrystallization or column chromatography.
With respect to Chart B, the compounds of Formula I are prepared by reaction of a ortho-hydroxyacetophenone with an amideacetal, e.g., N,N-dimethylformamide dimethylacetal, to yield a vinylogous amide. Treatment of that amide with a halogen (Br, Cl, I or F) in an organic solvent such as CHCI3 or CHCN then affords a 3-halochromone. Treatment of that halochromone with amines, either neat or in the presence of organic solvents, then yields the desired 2-aminochromone.
With respect to Chart C, the compounds of Formula I are prepared by treating a ortho-hydroxyacetophenone with carbon disulfide in the presence of base followed by treatment with acid which yields the 2-mercaptochromone. Treatment of the resulting mercaptan with the appropriate amine then affords the desired 2-aminochromone.
With respect to Chart D, the compounds of Formula I are prepared by hydrogenation of the corresponding benzylmethoxy analogues which are prepared by the methods described in Charts A,B and C, followed by alkylation of the resulting phenol.
With respect to Chart E, these compounds can be prepared by treatment of a o-hydroxy acetophenone with an iminium salt such as morpholine-4-phosgene iminium chloride, in the presence of boron trifluoride etherate. Subsequent hydrolysis and alkylation yields the desired compounds.
With respect to Chart F, these compounds can be prepared by the treatment of an o-hydroxy acetophenone containing a trifluoromethyl sulfonate group with an iminium salt such as 4-morpholine dichloromethyleniminium chloride, in the presence of boron trifluoride etherate. Subsequent hydrolysis and alkylation yields the 2-aminochromone. Treatment of the 2-aminochromone with an acetylene in the presence of a palladium catalyst such as (bis)triphenylphosphine palladium dichloride and copper iodide yields a 2-aminochromone with a substituted acetylene. Hydrogenation of the acetylene yields the desired derivative.
With respect to Chart G, the treatment of an o-hydroxy acetophenone containing a halogen group with an iminium salt such as 4-morpholine dichloromethyleniminium chloride, in the presence of boron trifluoride etherate. Subsequent hydrolysis and alkylation yields the 2-aminochromone. Treatment of the 2-aminochromone with a tetraalkyl tin reagent in the presence of a
palladium catalyst such as (bis)triphenylphosphine palladium dichloride and a salt such as lithium chloride affords a 2- aminochromone substituted with an alkyl sύbstituent.
With respect to Chart H, the compounds of formula I are prepared by treating 4-benzyloxy-2-hydroxy-3-methylacetophenone with sodium hydride, then ethyl α-methylthioacetate and finally acid to yield 7- benzyloxy-8-methyl-2-methylthiomethyl-4H-[1]-benzopyran-4-one. Treatment of that compound with methyl iodide affords the corresponding 7-benzyloxy-8-methyl-2-iodomethyl-4H-[1]-benzopyran-4- one. Treatment of that compound with the appropiate amine then afforded the compounds of formula I. Compounds of formula I were also prepared by treating a formula I compound such as 7-benzyloxy-8- methyl-2-(4-morpholiniylmethyl)-4H-[1]-benzopyran-4-one with a transition metal catalyst in an atmosphere of hydrogen to yield 7- hydroxy-8-methyl-2-(4-morpholiniylmethyl)-4H-[1]-benzopyran-4-one. Alkylation of that phenol with the appropiate group also afforded compounds of formula I.
Alternatively, compounds of formula I can also be prepared by hydrogenation of a R5-8 benzyloxy 2-amino-4H-1-benzopyran-4-one followed by alkylation of the resulting phenol as illustrated in chart I .
The synthesis of the compounds of the present invention is more completely understood by the following examples :
Procedure 1: Preparation of 1-ethynyl morpholine.
Part A: Preparation of trichloroacetylmorpholine.
Morpholine (4.0 mL, 45 mmol) is dissolved in EtOAc (50 mL) and saturated K2CO3 (40 mL) added. The mixture is cooled in an ice bath and trichloroacetyl chloride (5.0 mL, 45 mmol) added drop-wise. The reaction is stirred for 20 min then diluted with EtOAc (200 mL) and washed with aq. K2CO3 (20 mL), water (2 X 50 mL) and brine (30 mL). The organic layer is dried over MgSO4. Rotary evaporation gives trichloroacetylmorpholine.
Mp - 80-1ºC
1H NMR (300 MHz, CDC13) 3.81-3.76 (m)
UV (EtOH) 224 (4.520)
IR (mull) 2955, 2926, 2859, 1657, 1431, 1270, 1239, 1116,
962, 852, 848, 842, 810, 777
MS m/e (relative intensity) 233 (12), 231 (12), 115 (8),
114 (100), 86 (10), 70 (67), 56 (26), 42 (20), 28 (18), 27 (8)
HRMS calc'd. for C6H8NO2C13: 230.9621; found: 230.9629; anal, calc'd. for C6H8NO2C13: C, 31.00, H, 3.47, N, 6.02, Cl, 45.75;
FOUND: C, 31.15, H, 3.43, N, 6.07, Cl, 45.88.
Part B: Preparation of tricholorvinylmorpholine.
Trichloroacetylmorpholine (8.3 g, 36 mmol) is dissolved in toluene and triphenylphosphine (9.44 g, 36 mmol) added. The mixture is brought to reflux for 1.5 h, then cooled and solvent removed in vacuo. The residue is fractionally distilled at reduced pressure to give trichlorovinylmorpholine. BP - 85-7 ºC, 20 mm Hg.
Part C: Preparation of the morpholine ynamine.
Trichlorovinylmorpholine (5.50 g, 24.5 mmol) is dissolved in anhydrous ether (30 mL) under a nitrogen atmosphere. The mixture is cooled to -30ºC and butyllithium (50 mL, 1.5 M, 75 mmol) added slowly, then the mixture is allowed to warm to 23 ºC for 2 h. The mixture is cooled to -30 ºC again and poured into cold 20 % ammonium hydroxide (20 mL), ether (50 mL) added and the solutions quickly separated. The organic layer is filtered through anhydrous K2CO3 (5 cm) and concentrated in vacuo to a yellow orange oil that is fractionally distilled (0.9 mm Hg, BP - 53ºC) to give the ynamine, 1-ethynyl morpholine, as a colorless oil (1.1 g, 40%).
IR (film) 2970, 2940, 2870, 2137, 1647, 1458, 1382, 1272,
1123cm-1. 1H-NMR (CDCl3, δ) 3.81, 3.12, 2.36.
Example 1: Preparation of 6-chloro-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Compound 1
The methyl ester of 5-chlorosalicylic acid (2.00 g, 10.7 mmol) is mixed with ethynyl morpholine (neat, 1.00 g, 9.00 mmol) dropwise. The reaction is exothermic. When the mixture cools, triethylamine (TEA, 1 drop) is added and the liquid mixture immediately crystall- ized. The mixture is chromatographed (flash, SiO2, CH2Cl2/EtOH, 95:5) to yield 6-chloro-2-(4-morpholinyl)-4H-1benzopyran-4-one (1.07 g, 45%). Mp 194-5°C; IR (mull) 2949, 2946, 2869, 2855, 1640, 1615, 1566, 1464, 1450, 1437, 1345, 1246, 1118, 822, 787 cm-1; 1H-NMR (CDCI3, 200 MHz, δ) 8.11 (d, J - 2.5 Hz, 1 H), 7.49 (dd, J - 8.7, 2.5 Hz, 1 H), 7.23 (d, J - 8.7 Hz, 1 H), 5.49 (s, 1 H), 3.85-3.82 (m, 4 H), 3.53-3.50 (m, 4 H); UV (EtOH) λ max (ε) 217 (31,360), 230 (24,900), 245sh (12,100), 290sh (11,170), 301 (15,810), 315 (16,070); Mass Spectrum: ions at m/e (relative intensity) 267 (35), 265 (100), 210 (24) 209 (22), 208 (74), 207 (31), 180 (47), 154 (27), 126 (19), 52 (21); High resolution MS calc'd. for C13H12NO3Cl: 265.0506. Found: 265.0512. Anal, calc'd. for C13H14NO3Cl: C, 58.77; H, 4.55; N, 5.27; Cl, 13.34. Found: C, 58.52; H, 4.66; N, 5.11; Cl, 13.58.
Following the general procedure of Example 1, but employing the appropriate o-hydroxy salicylic methyl ester in place of the methyl ester of 5-chlorosalicylic acid and, depending upon the reactivity of the methyl ester, carried out either neat, in methylene chloride, toluene or triethylamine, .there are prepared the following products:
Cpd 2 2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp 160-61ºC; Cpd 4 7-Chloro-2-(4-morpholinyl)-4H-1-benzopyran-4-one,
Mp 160-1ºC (from CH2Cl2/EtOH);
Cpd 5 8-Chloro-2-(4-morpholinyl)-4H-1-benzopyran-4-one,
Mp 190-1°C (from CH2Cl2/Et2O);
Cpd 6 6-Bromo-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp
164-5°C (from CH2Cl2/Et2O);
Cpd 7 6-Fluoro-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp
198-9°C (from CH2Cl2/Et2O);
Cpd 8 6-Methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp 166-7ºC (from CH2Cl2/Et2O);
Cpd 9 7-Methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp
163-4°C (from CH2Cl2/Et2O);
Cpd 10 8-Methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp
169-70ºC (from EtOAc/hexane);
Cpd 11 6-Methoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp
148-9ºC (from EtOH/CH2Cl2);
Cpd 12 7-Methoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp
173-4ºC (from EtOH/hexane);
Cpd 13 6-(Phenylmethoxy)-2-(4-morpholinyl)-4H-1-benzopyran-4- one, Mp 210-12°C;
Cpd 14 8-(Phenylmethoxy)-2-(4-morpholinyl)-4H-1-benzopyran-4- one, Mp 192 -4°C;
Cpd 15 [2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-6-yl]-1,1- dimethylethyl carbamic acid ester;
Cpd 16 6-(3-pyridinecarboxamide)-2-(4-morpholinyl)-4H-1- benzopyran-4-one.
Example 17 Preparation of 2-(Morpholinyl)-6-nitro-4H-1-benzopyran-4-one, Compound #17
The ethyl ester of 5-nitro salicylic acid (634 mg, 3.0 mmol) is dissolved in TEA (2.0 mL) and the morpholine ynamine added. The mixture is then stirred for 48 h. The reaction is diluted with EtOAc
(200 mL) and washed with water (5 X 25 mL), brine (30 mL) and dried
(MgSO4). Evaporation of the solvent yields product which is chromatographed (silica gel [50 g]; 4% EtOH/CH2Cl2) to afford 182 mg (22%) of the desired product. MP - 258-9ºC; 1H NMR (CDCl3, 300 MHz) 9.05
(d, J = 2.9 Hz, 1 H), 8.44 (dd, J = 8.7, 2.9 Hz, 1 H), 7.46 (d, J = 9.3 Hz, 1 H), 5.69 (s, 1 H), 3.91-3.86 (m, 4 H), 3.61-3.56 (m, 4 H);
UV (EtOH) 226 (23,700), 234sh (19,000), 282 (17,600), 316 (15,000); LRMS m/e (rel. intensity) 277 (28), 276 (100), 261 (38), 219 (80),
218 (53), 191 (38), 172 (19), 55 (30), 53 (35), 41 (31); IR (mull)
2954, 2924, 2856, 1637, 1627, 1604, 1565, 1447, 1422, 1347, 1253,
1126, 740, 638; HRMS calc'd. for C13H12N205 : 276.0746; found:
276.0742; anal calc'd. for C13H12N205: C, 56.52, H, 4.38, N, 10.14; found: C, 56.32, H, 4.52, N, 10.16.
Example 18 : Preparation of 2-(4-Morpholinyl)-4H-pyrano[2,3b] pyridin-4-one, Compound 18
The methyl ester of 2-hydroxy-3-carboxypyridine (300 mg, 1.9 mmol) is dissolved in toluene (2.0 mL) and a solution of the morpholine ynamine (250 mg, 2.2 mmol) in toluene (2.0 mL) added dropwise at 23°C The reaction is then warmed to 100°C for 24 h.
The mixture is cooled and purified by flash chromatography (CH2CI2/ EtOH, 95:5) to give the chromone as pale yellow crystals (270 mg, 63
%). Mp 190-1ºC; IR (mull) 2924, 2868, 2855, 1652, 1639, 1611, 1590,
1557, 1463, 1405, 1250, 1120, 788, 602 cm-1; 1H NMR (CDCI3, 200 MHz, δ) 8.60 (s, 1 H), 8.57 (dd, J - 3.2, 2.4 Hz, 1 H), 7.45 (m, 1 H),
5.56 (s, 1 H), 3.92-3.87 (m, 4 H), 3.68-3.63 (m, 4 H); UV (EtOH) λ max (ε) 215 (16,740), 243 (10,250), 281sh (8,330), 289 (10,500), 320
(15,320); Mass spectrum: ions at m/e (relative intensity) 233 (14),
232 (100), 217 (17), 175 (37), 174 (39), 146 (15), 122 (17), 79 (34),
53 (15), 42 (14); Anal, calc'd. for C12H12N2O3: C, 62.06; H, 5.21; N,
12.06. Found: C, 61.85; H, 5.15; N, 11.88.
Example 19 Preparation of 6-([[phenylmethoxy]carbonyl]amino)-2- (4-morpholinyl)-4H-1-benzopyran-4-one, Compound 19 2-Hydroxy-5-([[phenylmethoxy]carbonyl]amino)benzoic acid methyl ester (1.0 g, 3.3 mmol) is added to CH2Cl2 (1 ml) and cooled to 0ºC To that solution is added the ynamine (366 mg) neat and dropwise followed by several drops of TEA. The reaction solution turns yellow and after stirring at room temperature for 18 hr is heated at 80ºC (oil bath) for 6 hr. A solid fills the flask. The reaction is diluted with CH2Cl2 and the solid collected on a filter to yield 350 mg (19.4%) of the desired product. An analytical sample was prepared by recrystallization from CH3CN. Mp 245-50ºC; IR (mull) 3263, 2947, 2925, 2921, 2867, 2854, 1716, 1638, 1623, 1577, 1564, 1558, 1464, 1456, 1453, 1404, 1246, 1231, 1121, 731 cm-1; 1H-NMR (CDCI3, δ) 8.15 (d, 1H, J-2 Hz), 7.95 (s, 1H), 7.87 (s, 1H), 7.3 (m, 7H), 5.42 (s, 1H, vinyl), 5.2 (s, 2H), 3.7 (m, 4H), 3.4 (m, 4H); UV (EtOH λ max (ε) 231 (27,520), 246 (34,960), 300 sh (16,300), 307 (17,830), 320 sl sh (12,800); Mass spectrum: ions at m/e (relative intensity) 380 (17), 335 (12), 272 (100), 215 (69), 187 (44), 161 (32), 108 (79), 91 (87), 79 (99), 53 (32), 44 (50);
Anal. Calc'd. for: C21H20N2O5: C, 66.31; H, 5.26; N, 7.36.
Found: C, 66.40; H, 5.28; N, 7.30.
Example 20: Preparation of 8-Methoxy-2-(4-morpholinyl)-4H-1- benzopyran-4-one, Compound 20
Method A: 3-Methoxy salicyl chloride (750 mg, 4 mmol) is dissolved in THF (4mL) and cooled to 0ºC The morpholine ynamine (445 mg, 4.0 mmol) is dissolved in THF (4 mL) and then added dropwise to the cooled solution of the acid chloride. A white precipitate forms immediately and after stirring for 20 minutes, TEA (0.60 mL), 4.5 mmol) is added and the reaction temperature raised to 23°C After refluxing for 20 minutes the reaction is cooled to room temperature and the THF removed in vacuo. The crude reaction mixture is filtered and the filtrate chromatographed over silica gel (5% EtOH/CH2Cl2) to afford, after recrystallization, 115 mg (12%) of the desired product. Mp 184-6°C; IR 2952, 2925, 2870, 2855, 1642, 1625, 1618, 1581, 1575, 1463, 1455, 1410, 1350, 1250, 1244, 1116, 773 cm-1; UV (EtOH) λ max (ε) 212 sh (20,710), 236 (25,000), 250 sh (12,000), 301 (17,800); 1H-NMR (CDCl3) 7.74 (dd, 1H, J = 2 and 8 Hz), 7.27 (t, 1H, J = 8 Hz), 7.10 (dd, 1H, J = 2 and 8 Hz), 5.52 (s, 1H), 3.96 (s, 3H), 3.88 (m, 4H), 3.55 (m, 4H); Mass spectrum: ions at m/e (relative intensity) 261 (100), 204 (63), 203 (19), 176 (27), 122 (33), 77 (26), 55 (26), 57 (32), 43 (37); Anal, calc'd. for C14H15NO4; C, 64.35; H, 5.76; N, 5.36. Found: C, 64.39; H, 5.83; N, 5.74.
Method B: 3-Methoxy methyl salicylate (547 mg, 3.0 mmol) is dissolved in TEA (4.0 mL) and the morpholine ynamine (400 mg, 3.7 mmol) is added. The mixture is stirred for 48 h, then diluted with EtOAc (200 mL) and washed with water (5 X 20 mL), brine (30 mL) and dried (MgSO4). Evaporation in vacuo affords 690 mg of crude product. Chromatography (silica gel [50 g]; 4% EtOH/CH2Cl2) affords the desired product (160 mg; 20%).
Example 21: Preparation of 3-Amino-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Compound 21
Part A: 2-(4-morpholinyl)-4H-benzopyran-4-one (2.00g, 8.00 mmol) is dissolved in CH2Cl2 (12 mL) and nitric acid (5.00 mL, 24 mmol) added dropwise with stirring at 23°C. After 2H, the mixture is warmed to 60ºC and three drops of sulfuric acid added. The reaction gradually turns red and a brown gas is evolved. After about 4 hrs the starting material is consumed as evidenced by TLC (EtOAc/CH3OH, 9/1). The reaction mixture is poured onto ice (30 mL) and yellow crystals precipitated almost immediately. The crystals are filtered and washed with cold water. The crude product is dissolved in ethyl acetate (200 mL) and the remaining precipitate is removed by filtration. The EtOAc layer is washed with saturated NaHCO3 (2 x 30 mL) and brine (50 mL) then dried (MgS04) . Rotary evaporation yields
1.44g (60%) of 2-(4-morpholinyl)-3-nitro-4H-1benzopryan-4-one. The
2-(4-morpholinyl)-3-nitro-4H-1-benzopyran-4-one is further purified by column chromatography over silica gel (EtOAc) to give analytical material. Mp 206-8°C; IR (mull) 2954, 2925, 2869, 2856, 1646, 1620,
1599, 1575,1487, 1467, 1445, 1435\ 1422, 1379, 1341, 1325, 1116 cm-1; 1H NMR (CDCl3, δ) 8.23 (dd, J = 1.9, 8.9 Hz, 1H), 7.65 (ddd, J = 2.1,
7.3, 10.2, 1H), 7.39 (m, 2H), 3.90 (m, 4H), 3.62 (m, 4H); MS m/e (rel intensity) 276 (78), 201 (36), 187 (38), 121 (100), 120 (56), 92 (30), 79 (23), 77 (21), 73 (22), 42 (25); UV (EtOH) λ max (ε) 230
(15,730), 286 (17,000), 295sh (14,760), 360sh (1,840); Anal, calc'd. for C13H12N2O5: C, 56.52; H 4.38; N, 10.14. Found: C, 56.53; H,
4.56; N, 9.79.
Part B: 2-(4-Morpholinyl)-3-nitro-4H-1-benzopyran-4-one (500 mg) is dissolved in EtOAc (30 mL). Palladium on carbon (10 %, 100 mg) is added under a nitrogen atmosphere. The mixture is fixed to a Parr hydrogenator at 30 psi for 4 hr, then filtered (Celite, 1 cm) and solvent removed in vacuo. The product is purified by flash chromatography (EtOAc) to give 3-Amino-2-(morpholinyl)-4H-1-benzopyran-4-one (419 mg, 94%). Mp 140-1ºC; IR (mull) 2954, 2925, 2856,
1621, 1607, 1551, 1466, 1423, 1382, 1277, 1271, 1240, 1115, 952, 762 cm-1; % NMR (CDCI3, δ) 8.24 (dd, J = 7.8, 2.0 Hz, 1 H), 7.60 (ddd, J
= 6.8, 6.7, 1.8 Hz, 1 H), 7.38 (br.d, J = 7.8 Hz, 2 H), 3.91-3.76 (m,
4 H), 3.52-3.47 (m, 4 H), 3.43 (br.s, 2 H); UV (EtOH) λ max (ε) 212 (19,150), 233 (15,180), 255sh (9,900), 300 (3,000), 356 (12,100);
Mass spectrum: ions at m/e (relative intensity) 262 (21), 246 (100),
201 (21), 188 (18), 187 (40), 148 (88), 121 (52), 114 (21), 70 (36),
42 (17); Anal, calc'd. for C13H14N2O3: C, 63.40, H, 5.73, N, 11.38; found: C, 63.48; H, 5.84; N, 11.46.
Example 22: Preparation of 3-Chloro-2-(4-morpholinyl)-4H-1- benzopyran-4-one, Compound 22
2-(4-Morpholinyl)-4H-benzopyran-4-one (2.0 g, 8.0 mmol) is dissolved in CH2Cl2 (20 mL). t-Butyl hypochlorite (1.0 mL, 8.5 mmol) is added dropwise at 23°C The reaction mixture is warmed slightly and is finished almost instantaneously. The solvent is removed in vacuo and the residue is taken up in EtOAc (200 mL). The organic layer is washed with water (2 X 50 mL) and brine (80 mL), then dried (MgSO4). The solution is concentrated in vacuo giving colorless crystals which are recrystallized from EtOAc to give the desired product (1.86 g, 91%) Mp 127-8°C; IR (mull) 2962, 2923, 2856, 1635, 1612, 1597, 1562, 1555, 1466, 1457, 1325, 1233, 1119, 872, 762 cm-1; 1H NMR (200 Mhz, CDCl3, δ) 8.20 (br d, J = 7.5 Hz, 1H), 7.60 (ddd, J = 9.1, 6.7, 1.7 Hz, 1H), 7.36 (m, 2 H), 3.88 (m, 4H), 3.74 (m, 4H); MS m/e (rel intensity) 267 (33), 266 (15), 265 (100), 231 (15), 230 (98), 209 (16), 207 (45), 120 (27), 110 (19), 41 (16); UV (EtOH) λ max (ε) 214 (18,900), 238 (18,160), 300 sh (11,530); Anal, calc'd. for C13H12NO3Cl: C, 58.76; H, 4.55; N, 5.27. Found: C, 58.82; H, 4.58; N, 5.37.
Example 23: Preparation of 3-Bromo-2-(4-morpholinyl)-4H-1
benzopyran-4-one, Compound 23
2-(4-morpholinyl)-4H-benzopyran-4-one (2.0 g, 8.0 mmol) is dissolved in CH2Cl2 (20 mL). N-Bromosuccinimide (1.6 g, 8.2 mmol) is added and the reaction mixture warmed slightly and the starting material disappears immediately as evidenced by TLC. The solvent is removed in vacuo and the colorless residue is taken up in EtOAc (200 mL) and washed with water (4 X 30 mL), brine (50 mL) and dried (MgSO4). Rotary evaporation gives the desired product (2.27 g, 92%) as colorless crystals, mp: 145-6ºC; IR (mull) 3337, 3016, 2922, 2871, 2855, 1698, 1609, 1585, 1502, 1462, 1378, 1367, 1341, 1303, 1295, 1260, 1234, 996, 812 cm-1; 1H NMR (CDCI3, 5) 8.22 (dd, J = 7.9, 1.8 Hz, 1H), 7.63 (ddd, J = 8.2, 7.4, 1.4 Hz, 1H), 7.44-7.28 (m, 2H), 3.90-3.84 (m, 4H), 3.76-3.69 (m, 4H) ; LRMS m/e (rel intensity) 311 (55), 309 (55), 253 (14), 231 (17), 230 (100), 172 (21), 121 (20), 120 (15), 110 (61), 41 (16); UV (EtOH) λ max (ε) 216 (18,400), 238 (18,600), 317 (17,040); High resolution MS calc'd. for C13H12NO3Br: 309.0001. Found: 308.9990. Anal, calc'd. for C13H12NO3Br: C, 50.34; H, 3.90; N.4.52. Found: C, 50.40; H.4.05; N, 4.46.
Relating to Chart B:
Example 24 Preparation of 8-methyl-2-(4-morpholinyl)-7-(phenyl- methoxy)-4H-1-benzopyran-4-one (Cpd 24).
Part A: 3-(Dimethylamino)-1-(2-hydroxy-3-methyl-4-benzyloxyphenyl)-Propen-1-one.
2-Hydroxy-3-methyl-4-(phenylmethoxy)-acetophenone (25 g, 98 mmol) and DMF-DMA (17.9 g, 150 mmol) is heated at 95-100°C for 2.75 h. The reaction is cooled to room temperature and excess reagent and CH3OH removed in vacuo to leave a dark solid. That solid is tritura ted with ether at 0°C and filtered to yield 19.64 g (64.4 %) of the product as a yellow solid. The mother liquors (9.91 g) also contained product but is not isolated. An analytical sample is prepared by recrystallization from EtOAc/ Skelly-B.
Part B: 3-Bromo-8-methyl-7-(phenylmethoxy)-[4H]-1-benzopyran-4-one.
The vinylogous amide of Part A (19.0 g, 61 mmol) is dissolved in CHC13 and cooled to 0°C. Br2 (9.75 g, 61 mmol), in CHCI3 (50 mL), is added dropwise over a 5 minute period. After complete addition, the reaction is diluted with H2O (200 mL) and vigorously stirred for 5 minutes. The CHCI3 layer is separated, dried (MgSO4) and solvent evaporated in vacuo to yield 23.1 g of crude product. Recrystallization from EtOAc afforded 15.2 g (66%) of analytically pure product. Part C: 8-Methyl-2-(4-morpholinyl)-7-(phenylmethoxy)-4H-1-benzopyran-4-one.
The 3-bromochromone of Part B (1.0 g, 2.9 mmol) is dissolved in acetonitrile (35 mL). Anhydrous potassium carbonate is added (371 mg, 2.9 mmol). Then morpholine (0.252 mg, 2.9 mmol) is added dropwise. Stirring is begun and the reaction warmed to reflux for 36 h. The acetonitrile is removed in vacuo and the organic material is taken up in ethyl acetate. The organic phase is washed with water and brine then dried (MgSO4). The solvent is removed in vacuo and the residue is chromatographed over silica gel ( CH2Cl2/Et2O; 2/1) to give two main fractions. The first contained a 3-amino substituted product.
The second fraction is a mixture of a ring contracted product and the desired 2-morpholinyl chromone. That mixture is rechromatographed (EtOAc/CH3OH; 95/5) giving two fractions, the faster moving containing the ring-contracted product (211 mg, 21%), Mp 171-2ºC; IR (mull) 2954, 2924, 2867, 2855, 1693, 1632, 1613, 1597, 1260, 1166, 1140, 1108, 1099, 749 cm-1; 1H-NMR (200 MHz, CDCI3, δ) 7.64 (dd, J = 8.57 Hz, 1.27, 1 H), 7.49-7.41 (m, 5 H), 6.89 (s, vinyl, 1 H), 8.84 (d, J = 8.57 Hz, 1H), 5.22 (s, 2 H), 3.89-3.84 (m, 4 H), 3.79-3.76 (m, 4 H), 2.30 (s, 3 H); UV (EtOH) λ max (ε) 204 (25,300), 205sh (24,500), 252 (8,550), 258 (8,670), 321 (18,900), 377 (33,100), 391 (29,300); High resolution MS calc'd. for C21H21NO4: 351.1470. Found: 351.1470. Anal, calc'd. for C21H21NO4: C, 71.78; H, 6.02; N, 3.99. Found: C, 71.60; H, 6.15; N, 3.96.
On further elution, the desired 2-morpholinyl chromone (Cpd #24) is isolated (127 mg, 12%). Mp 181.5-182.5°C; IR (mull) 2953, 2925, 2864, 2857, 1637, 1612, 1592, 1575, 1413, 1274, 1272, 1251, 1240, 1119, 782 cm-1; 1H-NMR (200 MHz, CDCl3, δ) 8.00 (d, J = 9.1 Hz, 1 H), 7.47-7.38 (m, 5 H) 6.98 (d, J = 9.1 Hz, 1 H), 5.44 (s, 1 H), 5.19 (s, 2 H), 3.89-3.84 (m, 4 H), 3.54-3.49 (m, 4 H), 2.33 (s, 3 H); UV (EtOH) λ max (ε) 111 (33,610) 239 (23,660), 291sh (13,980), 312 (26,160), 376 (509); High resolution MS calc'd. for C21H21NO4: 351.1470. Found: 351.1464. Anal, calc'd. for C21H21NO4: C, 71.78; H, 6.02; N, 3.99. Found: C, 71.79; H, 5.99; N, 3.98.
Example 25 Preparation of 2-(4-morpholinyl)-5-(phenylmethoxy)-4H- 1-benzopyran-4-one Compound 25
Part A: 6-Benzyloxy-2-hydroxyacetophenone
2,6-Dihydroxyacetophenone (84.48 g, 0.55 M), benzyl bromide (95 g, 0.55 M), and K2CO3 (120 g) is added to acetone (750 mL). That mixture is heated at reflux under nitrogen with vigorous stirring (overhead stirrer) for 18 h. The reaction is then cooled to room temperature and filtered. The filtrate is evaporated in vacuo to yield an oily semi-solid. That material is dissolved in CH2C12 and washed with 1 N HCL. The CH2CI2 solution is dried (MgSO4) and solvent removed in vacuo to yield a pale oil. That material is chromatographed over silica gel (400 g) eluting with CH2Cl2 to afford 72.8 g (54.5%) of the product. An analytical sample is prepared by recrystallization from EtOAc/Skelly-B.
Part B: 3-(Dimethylamino)-1-(2-hydroxy-6-benzyloxyphenyl)-Propen-1-one
A mixture of 6-benzyloxy-2-hydroxyacetophenone (15.0 g, 62 mmol) and N,N-dimethylformamide dimethylacetal (DMF-DMA; 10.71 g, 90 mmol) is heated under nitrogen at 100-10°C for 2 h. Within several minutes of placing the reaction vessel in the oil bath (already at 100°C) the initial heterogeneous mixture became homogeneous and very dark in color. After several additional minutes a solid began to separate from this solution and at the end of the reaction time the flask is filled with a yellow solid. The reaction is cooled to room temperature and excess DMF-DMA and methanol is removed in vacuo. The resulting solid is filtered with the aid of ether and air dried to yield 15.41 g (83.7%) of pure product. An analytical sample is prepared by recrystallization from EtOAc.
Part C: 5-Benzyloxy-3-bromo-[4H]-1-benzopyran-4-one The vinylogous amide of Part B (10.0 g, 33.6 mmol) is dissolved in CHCl3 (150 mL) and cooled to 0°C Br2 (5.38 g, 33.6 mmol) is added to the aforementioned solution in CHCI3 (50 mL) dropwise over 10 minutes. After complete addition the reaction is diluted with H2O and vigorously stirred for 5 minutes. The organic layer is separated and washed with brine, dried (MgSO4), and evaporated to give a dark red oil. Chromatography over silica gel (400 g) eluting with 1% CH3OH/CH2Cl2 afforded, after recrystallization from EtOAc/Skelly-B, 4.76 g (42.8%) of the product.
The 5-benzyloxy-3-bromochromone of Part B (3.31g, 10.0 mmol) is dissolved in acetonitrile (50 mL). Anhydrous potassium carbonate (1.38g, 10.0 mmol) is added, then morpholine (1.02 mL, 11.0 mmol) is added. The mixture is heated to reflux for 72 h. The solvent is removed under vacuo and the residue is taken up in EtOAc (400 mL) and washed with water (3 X 50 mL) and brine (100 mL), then dried (MgSO*4). The solvent is removed in vacuo and the residue purified by flash chromatography (CHCI3/CH3OH, 99/1) giving three main fractions. The first fraction contained a 3-morpholinyl chromone (0.92g, 51%). Mp 122.5-124°C; IR (mull) 2956, 2924, 2856, 1641, 1604, 1464, 1459, 1269, 1235, 1180, 1115, 1070, 1064, 772, 699 cm-1; 1H-NMR (200 MHz, CDCI3, δ) 7.61 (dd, J = 6.7, 1.5 Hz, 1 H), 7.59-7.29 (m, 5 H), 6.98 (dd, J = 8.2, 1.5 Hz, 1 H), 6.77 (dd, J = 8.2, 1.5 Hz, 1 H), 5.31 (s, 2 H), 3.94-3.90 (m, 4 H), 3.08-3.04 (m, 4 H); UV (EtOH) λ max (ε) 244 (22,700), 249 (21,500), 336 (6,270); Anal. calc'd. for C20H19NO4: C, 71.20, H, 5.68, N, 4.15; found: C, 70.84, H, 5.75, N, 4.05.
The second fraction contained a ring contracted product (0.60g, 33%). Mp 179-181ºC
The last fraction contains the desired 2-morpholinyl chromone (Cpd #25) (0.29g, 16%). Mp 139-40°C; IR (mull) 2954, 2926, 2870, 2855, 1640, 1623, 1615, 1600, 1470, 1449, 1407, 1239, 1122, 745, 740 cm-1; 1H-NMR (CDCI3, 200 MHz, δ) 7.65 (broad doublet, J = 7.2 Hz, 2 H), 7.47-7.30 (m, 4 H), 6.92 (dd, J = 8.1, 0.9 Hz, 1 H), 6.85 (br.d, J = 8.1 Hz, 1 H) 5.45 (s, 1 H), 5.32 (s, 2 H), 3.89-3.85 (m, 4 H), 3.52-3.47 (m, 4 H); UV (EtOH) λ max (ε) 210 (32,900), 238 (23,500), 252sh (8,040), 260sh (5,650), 313 (18,460); Mass Spectrum: ions at m/e (rel intensity) 91 (100), 337 (66), 231 (36), 174 (33), 173 (16), 338 (16) 336 (15), 218 (15), 65 (14), 146 (12); High resolution MS calc'd. for C20H19NO4: 337.1314. Found: 337.1312. Anal, calc'd. for C20H19NO4: C, 71-20, H, 5.58, N, 4.16. Found: C, 71.05, H, 5.56, N, 4.17.
Example 26: Preparation of 7,8-dimethoxy-2(4-morpholinyl)-4H-1- benzopyran-4-one, Compound 26
Part A: The 7,8-dimethoxy-3-bromochromone, R.B. Gammill, Synthesis (1979), p. 901, (3.42g, 12.0 mmol) is dissolved in acetonitrile (100 mL) and anhydrous potassium carbonate (1.66g, 12.0 mmol) is added. Morpholine (1.10 mL, 12.5 mL) is added dropwise and the reaction is warmed to reflux (82 C bath temperature) for 24 h. The acetonitrile is removed in vacuo, and the mixture is taken up in ethyl acetate (400 mL). The solution is washed with water (2 x 50 mL) and brine (100 mL), then dried (MgSO4) and concentrated in vacuo to give a yellow solid. Flash chromatography over silica gel (EtOAc/MeOH, 95/5) gave the 3-morpholinyl adduct (2.77g, 79%), the ring contracted product (0.24 g, 6.9 %) and 0.23 g of a mixture of the ring contracted and the 2-substituted product (79%) Mp 168-9°C; IR (mull) 2952, 2924, 2866, 2854, 1639, 1619, 1509, 1456, 1441, 1433, 1322, 1291, 1200, 1171 cm-1; 1H-NMR (200 MHz, CDCl3, δ) 8.0 (d,1H, 7.56 (s,1H,-C(H)OAr), 7.02 (d,1H,J-8 .9Hz), 4.0 (s,3 H, OCH3), 3.98 (s, 3 H, OCH3), 3.91 (m, 4 H), 3.08 (m, 4 H), UV (EtOH) λ max (ε) 247 (30,060), 303 (7,490), 326 (3,990); High resolution MS calc'd. for C15H17NO5: 291.1107. Found: 291.1110. Anal, calc'd. for C15H17NO5: C, 61.85; H, 5.88; N, 4.81. Found: C, 61.79; H, 5.86; N, 4.74.
Part B: The mixture of ring contracted and 2-morpholinyl chromone are rechromatographed (SiO2, CH2CI2/CH3OH, 98/2). The ring-contracted product is recrystallized from EtOH to give pale yellow crystals, Mp 180-181°C
The 2-morpholinyl chromone is recrystallized from EtOH to give the desired product (Cpd #26) (colorless crystals); Mp 194.5-5.5°C; 1H-NMR (CDCI3, δ) 7.88 (d, J = 8.8 Hz, 1 H), 6.97 (d, J = 8.8 Hz, 1 H), 5.43 (s, 1 H), 3.98 (s, 3 H), 3.94 (s, 3 H), 3.86 (m, 4 H), 3.55 (m, 4 H). UV (EtOH) λ max (ε) 217 (27,140), 239 (23,530), 270 (6,700), 311 (23,530); High resolution MS calc'd. for C15H17NO5: 291.1107. Found: 291.1093. Anal, calc'd. for C15H17NO5 : C, 61.85; H, 5.88; N, 4.81. Found: C, 61.85; H, 5.83; N, 4.78.
Example 27: Preparation of 2-(4-methyl-1-piperazinyl)-4H-1- benzopyran-4-one, Compound 27 Following the general procedure outlined in Chart B, the title compound is prepared.
Relating to Chart C:
Example 28: Preparation of 8-methyl-7-(phenylmethoxy)-2-[4-(2- pyridinyl)-1-piperazinylJ-4H-benzopyran-4-one,
Compound 28
Part A: Preparation of 8-Methyl-7-(Phenylmethoxy)-2-mercapto-4H-1-benzopyran-4-one.
Potassium t-butoxide (65.5 g) is covered with 500 mL of benzene under nitrogen and that solution is placed in a water bath. 4'- Benzyloxy-2'hydroxy-3'-methylacetophenone (50.0 g) and carbon disulfide (14.82 g) are dissolved in 500 mL of benzene and added dropwise to the potassium t-butoxide solution over a one hour period.
After complete addition the dark red paste is stirred at room temperature over night and then diluted with one liter of water.
That mixture is poured into a separatory funnel and the organic layer discarded. The aqueous is diluted with 300 mL of 20% H2SO4 and the solid that separated is collected on a filter and air dried to yield
31.0g of a yellow powder. MP 245ºC [D]; 2954, 2916, 2869, 2855, 1619, 1602, 1542, 1499, 1462, 1455, 1377, 1305, 1280, 1113, 1076, 822 cm-1; UV (EtOH) λ max (ε) 208 (34260), 231 (24940), 252 (15070), 263 sl sh (9470), 285 sl sh (5030), 299 (4930), 353 (18200), 392 (6840);
1H-NMR (DMSO-d6) δ 7.73 (d, 1H, J = 8.9 Hz), 7.45 (m, 5H, aromatic),
7.24 (d, 1H, J = 8.9 Hz), 6.58 (s, 1H, vinyl at C-3), 5.29 (s, 2H), 2.29 (s, 3H, -CH3); Mass spectrum: ions at m/e (relative intensity)
298 (12), 207 (1), 179 (1), 149 (1), 121 (1), 91 (100), 65 (6), 43
(1). See Bantick, J.R. and Suschitzky, J.L., J. Heterocyclic Chem.
18, 679 (1981).
Part B: 8-Methyl-7-(phenylmethoxy)-2-mercapto-4H-1-benzopyran-4-one (2.0 g, 6.7 mmol), 1-(2-pyridyl)piperazine (1.19 g, 7.3 mmol) and TsOH (25 mg) is added to toluene and heated at reflux for 20 hours. The reaction temperature is lowered to room temperature and the toluene removed in vacuo. The resulting dark oil is diluted with EtOAc and the resulting crystals collected on a filter to afford 2.42 g of product. MP 148-9ºC
Following the general procedure of Example 28, but employing the appropriate amine in place of 1-(2-pyridyl)piperazine there are prepared the following products: Cpd 29 8-Methyl-7-(phenylmethoxy)-2-(1-piperazinyl)-4H- benzopyran-4-one, Mp 165-70°C;
Cpd 30 8-Methyl-7-(phenylmethoxy)-2-(1-pyrrolidinyl)-4H- benzopyran-4-one, Mp 190-3°C;
Cpd 31 8-Methyl-7-(phenylmethoxy)-2-(1-piperidinyl)-4H- benzopyran-4-one, Mp 172-4ºC;
Cpd 32 8-Methyl-2-(4-methyl-1-piperazinyl)-7-(phenylmethoxy)- 4H-benzopyran-4-one, Mp 180-1ºC;
Cpd 33 8-Methyl-7-(phenylmethoxy)-2-(2,6-dimethyl-4- morpholinyl)-4H-benzopyran-4-one, Mp 166-8ºC;
Cpd 34 2-[4-(Hydroxyethyl)-1-piperazinyl]-8-methyl-7-(phenyl- methoxy)-4H-benzopyran-4-one monohydrochloride, M p 253-5ºC;
Cpd 35 2-[4-(Diphenylmethyl)-1-piperazinyl]-8-methyl-7- (phenylmethoxy)-4H-benzopyran-4-one, Mp 90-5°C;
Cpd 36 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-1-piperidinyl)- 4H-benzopyran-4-one, Mp 193-4ºC;
Cpd 37 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-1-piperazinyl)- 4H-benzopyran-4-one, Mp 153-4°C; and
Cpd 38 2-(4-Hydroxy-1-piperdinyl)-8-methyl-7-(phenylmethoxy)- 4H-benzopyran-4-one.
Relating to Chart D and E:
Example 39: Preparation of 7-hydroxy-2-(4-morpholinyl)-8-methyl- 4H-1-benzopyran-4-one, Compound 39 (according to Chart D).
Part A: 8-Methyl-2-(4-morpholinyl)-7-(phenylmethoxy)-4H-1-benzopyran-4-one (8.59g, 24.4 mmol.) is suspended in 250ml of ethyl acetate. 9.9 ml of cyclohexene is added followed by 0.85g of 10% Palladium on carbon. The mixture is heated at reflux for 18 hours. The reaction is allowed to cool and filtered, the solid is taken up in methanol, decanted and filtered. The methanol is evaporated to give 4.71g (74%) of the phenol (mp > 250 C).
Alternate Part A: 2',4',-Dihydroxy-3'-methyl-acetophenone (90% purity, 1.108g, 6 mmole) is suspended in 25ml 1,2-dichloroethane and the mixture is treated with boron trifluoride etherate (1.48ml, 12 mmole) while stirring in a 50ml one neck round bottom flask under nitrogen. The mixture is stirred for 30 min at room temperature and is subsequently treated with morpholine-4-phosgene iminium chloride (2.70g, 13.2 mmole). The reaction mixture is warmed to 70 C for 3h. The reaction is cooled to room temperature and the insoluble orange solid is collected by filtration and the filter cake is washed well with diethylether. The solid is taken up in 25ml acetonitrile in a 50ml one neck round bottom flask under nitrogen and the solution is cooled to 0 C. The mixture is treated with 2.5ml water and the reaction is stirred for 48h as the cooling bath expired. The acetonitrile is removed in vacuo and the residue is carefully diluted with 75ml 2:1 saturated sodium bicarbonate/sodium chloride. The mixture is extracted with 4 X 35ml dichloromethane. The combined organics are dried over magnesium sulfate and are concentrated in vacuo to an amber solid. The solid is washed successively with ethylacetate and diethylether to afford 980mg (44%) of [8-methyl-2-(4-morpholinyl)-4oxo-4H-1-benzopyran-7-yl]4-morpholinyl carboxylic acid ester (Cpd 100) M.P. 232-234ºC The carbamate (945mg, 2.51 mmole) is suspended in 9ml 2/1 methanol/water in a 25ml on neck round bottom flask under nitrogen. The suspension is treated with lithium hydroxide (236mg, 5.62 mmole) and the reaction mixture is stirred for 48h at room temperature. The methanol is removed in vacuo and the pH of the aqueous residue is adjusted to pH = 4.9 by the addition of 5% hydrochloric acid. The precipitated material is collected by filtration and is dried in vacuo at 25 C to afford 569mg (87%) of phenol 39 (M.P. > 250 C) as a chalky grayish solid.
Second Alternate Part A: 2',4'-Dihydroxy-3'-methyl-acetophenone (90% purity, 18.46g, 100 mmole) is suspended in 50ml diethylether in a 100ml one neck round bottom flask under nitrogen. The mixture is treated with boron trifluoride etherate (18.45ml, 150 mmole) and the reaction is stirred overnight at room temperature. The precipitated material is collected by filtration and the filter cake is washed well with fresh diethylether. The filtered material is air dried to afford 10.45g (47%) of difluoroboronate salt as a yellow solid.
The difluoroboronate salt (10.45g, 47 mmole) is combined with morpholine-4-phosgene iminium chloride (21.2g, 104 mmole) in 125ml 1,2-dichloroethane in a 250ml one neck round bottom flask under argon. The reaction mixture is warmed to 70 C for 3h and is cooled to room temperature. The orange-yellow precipitate is collected by filtration and is washed successively with 1,2-dichloroethane and diethylether to provide 25.3g of an orange solid. The solid is suspended in 200ml acetonitrile in a 500ml one neck round bottom flask and the mixture is cooled to 0 C The cooled mixture is treated with 20ml water and after stirring 20 min at 0 C, the reaction mixture is stirred overnight at room temperature. The mixture is subsequently cooled to -33 C for 2h and the precipitated hydro chloride salt is collected by filtration and is washed with 125ml ice cold acetonitrile. The filter cake is dried to provide 13.25g (69%) of the carbamate-chromone hydrochloride as a white solid. The filtrate is concentrated in vacuo to an amber syrup. The syrup is diluted with 100ml saturated sodium bicarbonate and the mixture is extracted with 4 X 50ml dichloromethane. The combined organics are dried over magnesium sulfate and are concentrated in vacuo to a reddish oil which upon crystallization with ethylacetate yielded 875mg (5%) of carbamate-chromone as a yellow solid. Hydrolysis of the carbamate-chromone as described in method B affords the desired phenol.
Part B: 7-Hydroxy-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one (0.50g, 1.91mmol) is suspended in 15ml of acetonitrile. 1.3g of potassium carbonate is added followed by 0.39g (2.1mmol) of alphabromo-p-xylene. The mixture is refluxed for 5 hours. 0.04 g of additional alkylating agent is added and the mixture is refluxed for 2 hours. The cooled mixture is diluted with 5ml of water and filtered. The white solid is washed with water and dried. The solid is recrystallized from ethyl acetate to afford 0.59g (84%) of the product 48 (mp 167.5-168°C).
Following the general procedure of Example 39 but employing the appropriate phenylmethoxy aminochromone in place of (7-phenyl-methoxy)-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one there are prepared the following products :
Cpd 40 6-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one,
Mp 290-2°C;
Cpd 41 7-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one; Cpd 42 5-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one,
Mp 295-7ºC;
Cpd 43 8-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one,
Mp 300°C;
Cpd 44 7-Methoxy-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one, Mp 224.5-225.5ºC; Cpd 45 [(8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-7-yl)oxy) acetic acid lithium salt;
Cpd 46 [[8-Methyl-2-(4-morpholinyl)-4-oxy-4H-1-benzopyran-7- yl]oxy]acetic acid methyl ester, Mp 181-2°C;
Cpd 47 7-[(4-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpho
linyl)-4H-1-benzopyran-4-one, Mp 171-2ºC;
Cpd 48 8-Methyl-7-[(4-methylphenyl)methoxy]-2-(4-morpho
linyl)-4H-1-benzopyran-4-one, Mp 167.5-8ºC;
Cpd 49 7-[(4-Chlorophenyl)methoxy]-8-methyl-2-(4-morpho
linyl)-4H-1-benzopyran-4-one, Mp 226-7ºC;
Cpd 50 7-[(4,5-Dichlorophenyl)methoxy]-8-methyl-2-(4-morpho linyl)-4H-1-benzopyran-4-one, Mp 243-4ºC;
Cpd 51 8-Methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- 1-benzopyran-4-one; Mp 174-175.5; and
Cpd 52 8-Methyl-7-[[(phenyl)carbonyl]oxy]-2-(4-morpho
linyl)-4H-1-benzopyran-4-one, Mp 223.5-25°C
Cpd 53 8-Methyl-7-(2-(4-methyl-(1-piperizinyl))ethyl)oxy-2- (4-morpholinyl)-4H-1-benzopyran-4-one, Mp 159.0¬
159.5ºC
Cpd 54 7-[[4-(1,1-Dimethylethyl)phenyl]methoxy]-8-methyl-2- (4-morpholinyl)-4H-1-benzopyran-4-one, Mp 218.5-220ºC;
Cpd 55 8-Methyl-2-(4-morpholinyl)-7-[[4-phenylmethoxy)- phenyl]methoxy]-4H-1-benzopyran-4-one, Mp 110-111°C;
Cpd 56 7-[(3-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp 153.5-155.5°C;
Cpd 57 7-[(4-Nitrophenyl)methoxy]-8-methyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one, Mp 285°C dec;
Cpd 58 7-[(2-Phenylethyl)methoxy]-8-methyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one, Mp 200.5-201.5°C dec;
Cpd 59 7-[(2-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp 202-203°C;
Cpd 60 7-[(4-Ethoxyphenyl)methoxy]-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp 186-188°C;
Cpd 61 8-(4-Ethoxy-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp 149.5-151.5°C;
Cpd 62 2-(4-Morpholinyl)-8-(4-nitro-benzyloxy)-4H-1-benzopyran-4-one, Mp 240-241°C;
Cpd 63 8-(2-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H--- benzopyran-4-one, Mp 149 - 150° C;
Cpd 64 2-(4-Morpholinyl)-8-(2-phenyl-ethoxy)-4H-1-benzopyran- 4-one, Mp 131-132°C;
Cpd 65 2-(4-Morpholinyl)-(2-oxo-2-phenyl-ethoxy)-4H-1- benzopyran-4-one, Mp 200- 201.5°C;
Cpd 66 8-(4-Benzyloxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one, Mp 143.5- 145°C;
Cpd 67 8-(4-Chloro-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp 208-209°C;
Cpg 68 8-(4-t-Butyl-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one, Mp 165.5-166.5°C;
Cpd 69 8-(3-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one, Mp 177 - 178° C;
Cpd 70 8-(3,4-Dichloro-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one, Mp 207-208°C;
Cpd 71 8-(4-Methyl-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one, Mp 177-178ºC;
Cpd 72 8-(4-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one, Mp 173.5-174.5°C;
Cpd 73 2-(4-Morpholinyl)-8-(naphthyl-2-methyloxy)-4H-1- benzopyran-4-one, Mp 200.5 -201.5°C;
Cpd 74 2-(4-Morpholinyl)-8-(naphthyl-1-methyloxy)-4H-1- benzopyran-4-one, Mp 192.5-193.5ºC;
Cpd 75 8-Methyl-2-(4-morpholinyl)-7-(naphthyl-2-methyloxy)- 4H-1-benzopyran-4-one, Mp 158.5-159.5°C;
Cpd 76 8-Methyl-2-(4-morpholinyl)-7-(naphthyl-1-methyloxy)- 4H-1-benzopyran-4-one, Mp 205.5-207°C;
Cpd 77 2-(Dimethylamino)-8-methyl-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester.
Cpd 78 2-(Dimethylamino)-4-oxo-4H-1-benzopyran-6-yl carbamic acid dimethyl ester, Mp 179.5- 80°C;
Cpd 79 2-(Dimethylamino)-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester, Mp 158-9°C;
Cpd 80 2-(Dimethylamino)-4H-1-benzopyran-4-one, Mp 122¬
23.5°C;
Cpd 81 2-(Dimethylamino)-8-methyl-7-(phenylmethoxy)-4H-1- benzopyran-4-one, Mp 165-6°C.
Cpd 102 8-Methyl-2-(4-morpholinyl)-7-(2-oxo-2-phenylethoxy)- 4H-1-benzopyran-4-one mp. 226.5-227.5
Cpd 103 6-Chloro-8-methyl-2-(4-morpholinyl)-7-(phenylmethoxy)- 4H-1-benzopyran-4-one mp. 207-209
Cpd 104 [[2-(4-Morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]oxy]- acetic acid, methyl ester mp. 192.5-193
Cpd 105 4-[[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]methyl]-benzoic acid, methyl ester mp. 226¬
228
Cpd 106 4-[[[2-(4-Morpholinyl)-4-oxo-4H-1-benzopyran-8- yl]oxy]methyl]-benzoic acid, methyl ester mp. 207¬
209
Cpd 107 8 - Me thyl - 2 - ( 4-morpholinyl ) - 7 - [ [ 3 - (trifluoromethyl)phenyl]methoxy]-4H-1-benzopyran-4-one mp. 194.5-195.5
Cpd 108 2-(4-Morpholinyl)-8-[[3-(trifluoromethyl)- phenyl]methoxy]-4H-1-benzopyran-4-one mp. 204-204.5 Cpd 109 7-(Cyclohexylmethoxy)-8-methyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one mp. 184.5-185.5
Cpd 110 8-Methyl-2-(4-morpholinyl)-7-(2-propenyloxy)-4H-1- benzopyran-4-one mp. 191-192
Cpd 111 2-(4-Morpholinyl)-7-(1-naphthalenylmethoxy)-4H-1- benzopyran-4-one mp. 195.2-195.8
Cpd 112 8-Methyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one mp. 182.5-184
Cpd 113 8-Methyl-2-(4-morpholinyl)-7-(4=pyrindinylmethoxy)-4H- 1-benzopyran-4-one mp. 253.5-255.5
Cpd 115 8-methyl-2-(4-morpholinyl)-7-(2-quinoxalinylmethoxy)- 4H-1-Benzopyran-4-one, mp. 250.5-252.5
Cpd 116 8-methyl-2-(4-morpholinyl)-7-(pyrazinlymethoxy)-4H-1- Benzopyran-4-one, mp. 236-237
Cpd 117 8-methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- 1-Benzopyran-4-one, N-oxide mp. 248-249.5 Cpd 118 8-methyl-2-(4-morpholinyl)-7-(3-pyridinylmethoxy)-4H- 1-Benzopyran-4-one, N-oxide mp. 233.5-234 Cpd 119 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one mp. 214-215
Cpd 120 3,3-Dimethyl-1-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H- 1-benzopyran-7-yl]oxy]-butan-2-one mp. 197-198 Cpd 121 1-[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-propan-2-one mp. 206.5
Cpd 122 1-[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-butan-2-one mp. 183-184
Cpd 123 8-Methyl-2-(4-morpholinyl)-7-(2-oxo-2-(2- naphthyl)ethoxy)-4H-1-benzopyran-4-one mp. 214.5¬
215.5
Cpd 125 2-(4-Morpholinyl)-7-(2-pyrindinylmethoxy)-4H-1- benzopyran-4-one mp. 274-276
Cpd 126 2-(4-Morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one mp. 193-194
Cpd 127 2-(4-Morpholinyl)-8-(2-pyrindinylmethoxy)-4H-1- benzopyran-4-one mp. 199-200
Cpd 128 2-(4-Morpholinyl)-8-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one mp. 160-161
Cpd 129 8-methyl-2-(4-morpholinyl)-7-(2-quinolinylmethoxy)-4H- 1-Benzopyran-4-one, mp. 223.5-224.5
Cpd 130 7,8-(Bis)-phenylmethoxy-2-(4-morpholinyl)-4H-1- benzopyran-4-one mp. 165.5-167
Cpd 131 7,8-(Bis)-acetyloxy-2-(4-morpholinyl)-4H-1-benzopyran- 4-one mp. 231.5-233
Cpd 132 7,8-(Bis)-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4- one mp . >300
Cpd 133 7-Hydroxy-2-(4-morpholinyl)-8-phenylmethoxy-4H-1- benzopyran-4-one mp. 198-199
Cpd 134 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4- morpholinyl)-4H-1-benzopyran-4-one mp. 178.5-179.5 Cpd 135 8 - Hydr oxy - 2 - ( 4 - morphol inyl ) - 7 - ( 3 - trifluoromethyl)phenylmethoxy-4H-1-benzopyran-4-one mp. 262-262.5
Cpd 136 7 - Hydr oxy - 2 - ( 4 -morphol inyl ) - 8 - ( 3 - trifluoromethyl)phenylmethoxy-4H-1-benzopyran-4-one mp. 236-237
Cpd 137 7-[3-(1-cyclohexyl-1H-tetrazol-5-yl)propoxyl-8-methyl- 2-(4-morpholinyl)-4H-1-Benzopyran-4-one, mp. 228¬
230
Cpd 138 8-[3-(1-cyclohexyl-1H-tetrazol-5-yl)propoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one, mp. 185-186 Cpd 139 7-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-8-methyl-2- (4-morpholinyl)-4H-1-Benzopyran-4-one, mp. 228
Cpd 140 8-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one, mp. 218
Cpd 141 2-(4-morpholinyl)-8-[(1-phenyl-1H-tetrazol-5-yl)oxy]- 4H-1-Benzopyran-4-one, mp. 214-215
Cpd 142 N-cyclohexyl-2-[[2-(4-morpholinyl)-4-oxo-4H-1- benzopyran-8-yl]oxy]-acetamide mp. 238-241 Cpd 143 N-(1,1-dimethylethyl)-2-[[2-(4-morpholinyl)-4-oxo-4H- 1-benzopyran-8-yl]oxy]-acetamide mp. 219-220
Cpd 144 2-[[2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]-N- phenyl-acetamide mp. 225-228
Cpd 145 2-[[2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]oxy]- N-(1-phenylethyl)-acetamide mp. 178-180
Cpd 146 N-cyclohexyl-2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H- 1-benzopyran-7-yl]oxy]-acetamide mp. 255-256 Cpd 147 N-[[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]acetyl]-Phenylalanine, ethyl ester mp. 173175
Cpd 148 2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-N-phenyl-acetamide mp. 242-244
Cpd 149 8-methyl-2-(4-morpholinyl)-7-[(1-phenyl-1H-tetrazol-5- yl)oxy]-4H-1-Benzopyran-4-one, mp. 209-211 Cpd 150 6-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one, mp. 215-217
Cpd 151 2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-N-(1-phenylethyl)-acetamide mp. 203-205 Cpd 152 2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-N-3-pyridinyl-acetamide mp. 243-245
Cpd 153 N-[[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]acetyl]-Phenylalanine mp. 259-262 Cpd 154 7-(2,2-dimethoxyethoxy)-8-methyl-2-(4-morpholinyl)- 4H-1-Benzopyran-4-one, mp. 168-169
Cpd 155 2-(4-Morpholinyl)-8-(2-propenyl)-4H-1-benzopyran-4-one mp. 145.5-146.5
Cpd 156 2-(4-Morpholinyl)-8-(1-propenyl)-4H-1-benzopyran-4-one mp. 163-164
Cpd 157 8-Formyl-2-(4-Morpholinyl)-4H-1-benzopyran-4-one mp. 209-209.5
Cpd 158 2-(4-morpholinyl)-8-(phenylamino)methyl-4H-1- benzopyran-4-one, mp. 226-227
Cpd 159 2-(4-morpholinyl)-8-(2E-phenyl)ethenyl-4H-1- benzopyran-4-one, mp.209 -209.5
Cpd 160 8-Hydroxymethyl-2-(4-Morpholinyl)-4H-1-benzopyran-4- one, mp. 243-243.5
Cpd 162 8-methyl-7-[(1-methyl-3-piperidinyl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one, mp. 159-161
Cpd 163 8-Methyl-2-(4-morpholinyl)-7-(2- (1-piperidinyl)ethyl)oxy-4H-1-benzopyran-4-one mp. 154-156 Cpd 164 8 -Methyl - 2 - ( 4 - morpholinyl) - 7 - ( 2- (1 - pyrrolidinyl)ethyl)oxy-4H-1-benzopyran-4-one mp.
136-138
Cpd 165 8-Methyl-2-(4-morpholinyl)-7-(2-(4-morpholinyl)ethyl)- oxy-4H-1-benzopyran-4-one mp. 170.5-172.5
Cpd 166 8-Methyl-2-(4-morpholinyl)-7-(3- (1-piperidino)propyl)oxy-4H-1-benzopyran-4-one mp. 144-145 Cpd 167 7-(2-Diethylaminoethyl)oxy-8-methyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one mp. 162-162.5
Cpd 168 7-[2-(ethylphenylamino)ethoxy]-8-methyl-2-(4-morpholinyl)-4H-1-Benzopyran-4-one, mp. 146-147
Cpd 169 7-(2-Diisopropylaminoethyl)oxy-8-methyl-2-(4- morpholinyl)-4H-1-benzopyran-4-one mp. 136.5-138.5 Cpd 170 7-Hydroxy-8-methyl-2-(l-piperidinyl)-4H-1-benzopyran- 4-one mp. 278-284
Cpd 171 8-Methyl-2-(1-piperidinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one mp. 144-158
Cpd 172 7-(2-(4-Benzyl-(1-piperizinyl))ethyl)oxy-8-methyl-2- (4-morpholinyl)-4H-1-benzopyran-4-one mp. 138-139
Example 82: Preparation of 2-(4-Morpholinyl)-4H-1-benzopyran- 4-one, Compound 2
Part A: Potassium t-butoxide (134 g, 1.2 mole) is covered with benzene (1 L) in a flame dried round bottom flask equipped with an overhead stirrer, addition funnel, thermometer, and a nitrogen inlet. This suspension is maintained at 15°C. A solution of o-hydroxyacetophenone (54.4 g, 48.1 ml, 0.4 mole) and carbon disulfide (30.4, 24 ml, 0.4 mole) in benzene (700 ml) is slowly added over 1.3 hours, applying an ice bath periodically in order to maintain the temperature 18°C The slurry which forms is stirred at ambient temperature for one day. The reaction mixture is transferred to a separatory funnel containing water (4 L) and extracted with ether (4 x 250 ml) and EtOAc (3 x 250 ml). The aqueous layer is acidified with 10% H2SO4 (1 L) and stirred at ambient temperature overnight. The resulting solid is filtered off and dried in vacuo at 50°C overnight to yield 22.07 g of 2-mercapto-4H-1-benzopyran-4-one. Mp 207-8°C.
Part B:
Tosic acid (0.4g, 2 mmol) is added to a solution of 2-mercapto- 4H-1-benzopyran-4-one (3.56 g, 20 mmol) and morpholine (2.44 g, 2.44ml, 28 mmol) in benzene (400ml). After refluxing for 4 hours, the reaction mixture is transferred to a separatory funnel containing EtOAc and water. Extracting with EtOAc (2x), washing with combined organic layers with water and brine, and filtering through sodium sulfate yields 4.56 of crude material after evaporation of the solvent. Flash chromatography over silica gel (300 g, 2.5% MeOH/CHCl3, 50 ml fractions) yields 2.07 g of 2-(4-Morpholinyl)-4H-1- benzopyran-4-one (44.8%, fractions 22-32). Mp 160-1ºC.
Example 83 Preparation of 6-Methyl-2-(4-morpholinyl)-4H-1,3- benzoxazin-4-one, Compound 83
The methyl ester of 5-methylsalicylic acid (2.73 g; 16.4 mmol) is dissolved in acetone (50 ml), cyanogen bromide (1.81g; 17.2 mmol) is added and the solution is cooled to 0°C Triethylamine (1.73 g; 18.2 mmol) is dissolved in acetone (5 ml) and added dropwise. Precipitation occurred rapidly and the solid is removed by filtration. The filtrate is concentrated in vacuo to afford 3.41 g of the intermediate cyanoether. The cyanoether is dissolved in acetonitrile (50 ,1), morpholine (1.43 g; 16.4 mmol) is added in 5 ml of acetonitrile and the reaction is stirred for two hours at room temperature. Crystals form and the reaction mixture is cooled to 0°C, and washed with cold acetonitrile to afford 1.65 g (40.8%). Mother liquors are recrystallized from acetonitrile to afford 0.54 g (13.4%); mp 197-197.9°C; IR (mull) 2955, 2923, 2858, 1674, 1619, 1576, 1466, 1453, 1433, 1424, 1333, 1325, 1315, 1112, 817 cm'1; 1H- NMR (CDCl3, δ) 7.91 (d, J=1.4 Hz, 1 H, aromatic), 7.40 (d of d's, J=8.3 Hz, 1.9 Hz, 1 H, aromatic), 7.09 (d, J-8.4 Hz, 1 H, aromatic), 3.81 (broad s, 8H, morpholine methylenes), 2.40 (s, 3 H, methyl); UV λ max (ε) 217sh(26,550), 223sh(26,350), 259(15,100), 296(4,250), 304sh(3,550); Mass spectrum, ions at m/e (relative intensity) 246(parent, 29), 218(10), 189(20), 134(base, 100), 106(18), 105(10), 78(12), 77(8), 28(19);
Anal. Calc'd. for: C13H14N2O3: C, 63.40; H, 5.73; N, 11.38.
Found: C, 63.29; H, 5.92; N, 11.31.
Following the general procedure of Example 83 , but employing the appropriate o-hydroxy salicylic methyl ester in place of the methyl ester of 5-methylsalicylie acid there are prepared the following products :
Cpd 84 8-Methyl-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one,
Mp 229-231°C;
Cpd 85 6-Bromo-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one,
Mp 207-214°C;
Cpd 86 7-Chloro-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one
Mp 207-214°C;
Cpd 87 6,8-Bis(1-methylethyl)-2-(4-morpholinyl)-4H-1,3- benzoxazin-4-one, Mp 120-120.5°C;
Cpd 88 6-Fluoro-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one,
Mp 220-231°C;
Cpd 89 6-Dimethoxymethyl-2-(4-morpholinyl)-4H-1,3-benzoxazin- 4-one; Mp101-108°C;
Cpd 90 7-Methoxy-2-(4-morpholinyl)-4H-1,3-benzoxazin- 4-one, Mp 197-200°C; and
Cpd 91 6-(Morpholin-1-yl)-pyrido(2,3-e)-1,3-oxazine-8-one
Mp 181-184°C
Following the general procedure of Example 83, but employing the appropriate o-hydroxy salicylic methyl ester in place of the methyl ester of 5-methylsalicylic acid and the appropriate heterocylic compound in place of morpholine there are prepared the following products :
Cpd 92 8-Methyl-2-(1-piperidinyl)-4H-1,3-benzoxazin-4-one,Mp 214.5-217.5°C;
Cpd 93 8-Methyl-2-(1-pyrrolidinyl)-4H-1,3-benzoxazin-4-one,
Mp 199.5-200.5°C;
Cpd 94 2-(1-pyrrolidinyl)-4H-1,3-benzoxazin-4-one, Mp 163 164°C;
Cpd 95 2- (1- (4-Thiomorpholinyl) ) -4H-1, 3-benzoxazin-4-one,
Mp 179-180°C;
Cpd 96 2-(4-Methyl-1-piperazinyl)-4H-1,3-benzoxazin-4-one; Example 98: Preparation of 2-(4-Morpholinyl)-4H-1,3-benzoxazin-4- one, Compound 98 (Method A)
Methyl salicylate (25 g, 0.164 M) and BrCN (18.08 g, 0.172 M) is added to dry acetone (500 mL) and cooled to 0ºC That mixture is then treated with TEA (17.37 g, 0.172M) in acetone (50 mL) dropwise over 20 minutes. A white precipitate separates from the solution. After stirring 1 hr the acetone is decanted and the precipitate washed with acetone. The filtrate is concentrated in vacuo and used without further purification. The above cyanoether (29.0 g, 0.164 M) is added to acetonitrile (300 mL) under an atmosphere of nitrogen. An acetonitrile solution of morpholine (14.26 g, 0.164 M) is then added dropwise over 30 minutes. The reaction becomes warm during addition. After stirring a total of 3 hrs the solvent is removed in vacuo to yield a tan solid which is washed with ether to yield 22 g (58%) of pure product. An analytical sample is prepared by recrystallization from EtOAc. MP 184.5-86.0°C (lit. MP 187-9°C);6 IR (CHCl3) 2950, 2825, 2750, 1670, 1620, 1600, 1560, 1460, 1440, 1420, 1340, 1260, 1110, 980, 850 cm-1; 1H-NMR (CDCI3) 8.25 (dd, 1H, J=1.5 and 6.0 Hz), 7.8-7.2 (m, 3H, aromatic), 3.80 (s, 8H); Mass spectrum: ions at m/e (relative intensity) 232 (47), 215 (13), 204 (20), 189 (11), 176 (14), 175 (56), 121 (35), 120 (100), 92 (46), 64 (14); UV (EtOH) λ max (ε) 210 (24,000), 218 (24,200), 240sh (11,200), 258 (14,750), 286 (4,850), 295 (3,900); Anal, calc'd. for C12H12N2O3: C, 62.06; H, 5.17; N, 12.06. Found: C, 61.70; H, 5.22; N, 11.99.
Example 99: Preparation of 2-(4-Morpholinyl)-4H-1,3-benzoxazin-4- one, Compound 98 (Method B)
Tosic acid (0.4g, 2 mmol) is added to a solution of 2-mercapto- 4H-1-benzopyran-4-one (3.56 g, 20 mmol) and piperidine (2.38 g, 2.77 ml, 28 mmol) in benzene (400ml). After refluxing for 5 hours, the reaction solution is evaporated in vacuo. The residue is transferred to a separatory funnel with methylene chloride and water. Extracting with methylene chloride, washing the organic layer twice with water, and filtering through sodium sulfate affords 2.80 g of crude material after evaporation of the solvent. Flash chromatography over silica gel (300 g, 7% MeOH/CH2Cl2) affords 0.39 g of 2-(4-Morpholinyl)-4H-1,3-benzoxazin-4-one.
Example 101 2-(4-Morpholinyl)-7-(phenylmethoxy)-4H-1-benzopyran-4- one, Compound 101
Prepared by the method outlined in Chart C
Example 173 Preparation of 4'-Acetoxy-3'-methyl-2'-hydroxypropiophenone (Relating to Chart E)
Part A
2',4'-Dihydroxy-3'methyl-propiophenone (7.21 g, 40 mmole) is suspended in 200ml dichloromethane in a 500 ml one neck round bottom flask under nitrogen. The suspension is treated with diisopropylethylamine (6.97 ml, 40 mmole) and the solution is cooled to 0°C. Acetyl chloride (3.26 ml, 46 mmole), in 80 ml dichloromethane, is added slowly dropwise to the reaction mixture (1 h) at 0 C. The mixture is warmed to room temperature and is stirred 20 min. The reaction is washed with 1 X 150 ml 5% hydrochloric acid and the organics are dried over magnesium sulfate. The mixture is concentrated in vacuo to a yellow oil which is crystallized and then recrystallized from ethanol to afford 7.2 g (81%) of the acetate as a white solid. Melting Point: 59-61 C
Part B
Preparation of 7-Acetoxy-3,8-dimethyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one (Cpd 173)
4'-Acetoxy-2'-hydroxy-3'-methyl-propiophenone (6.2 g, 27.9 mmole) is dissolved, in 60 ml diethyl ether in a 100 ml one neck round bottom flask under nitrogen. The solution is treated with boron trifluoride etherate and the reaction mixture is stirred overnight at room temperature. The precipitate is collected by filtration and is washed with 150 ml diethyl ether to afford 6.8 g (90%) of the boron difluoride complex as a yellow solid. The boron difluoride complex (1.05 g, 5.13 mmole) and 4-morpholine phosgene iminium chloride (1.25 g, 4.63 mmole) are combined in 12 ml 1,2-dichloroethanein a 25 ml one neck round bottom flask under nitrogen. The reaction mixture is warmed to 60 C for 3 h. The reaction is cooled to room temperature and the dichloroethane is removed in vacuo. The residual oil is taken up in 12ml acetonitrile in a 25 ml one neck round bottom flask. The mixture is warmed to 60°C, is diluted with 10 ml water, and is stirred for 5 min. The reaction mixture is immediately neutralized with 25 ml saturated sodium bicarbonate and the acetonitrile is removed in vacuo. The aqueous residue is extracted with 4 X 25 ml dichloromethane. The combined organics are dried over magnesium sulfate and are concentrated in vacuo to afford 750mg (51%) of Cpd 173 as an orange solid.
Melting Point: 142.5-144.5°C
Part C
Preparation of 3,8-dimethyl-7-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one (Cpd 174)
The boron difluoride complex (prepared as in Part A above, 3.0 g, 11.1 mmole) is combined with 4-morpholine phosgene iminium chloride (2.5 g, 12.2 mmole) in 29 ml 1,2-dichloroethane in a 50 ml one neck round bottom flask under nitrogen. The reaction mixture is warmed to 60°C for 3.5 h and is cooled to room temperature. The dichloroethane is removed in vacuo and the oily residue is dissoved in 30 ml acetonitrile in a 100 ml one neck round bottom flask under nitrogen. The solution is warmed to 60°C, is diluted with 25 ml water, and is stirred for 5 min. The reaction mixture is immediately quenched with 30 ml saturated sodium bicarbonate and the acetonitrile is removed in vacuo. The aqueous residue is extracted with 4 X 25 ml dichloromethane and the combined organics are dried over magnesium sulfate. The dried organics are concentrated in vacuo to a yellow solid (2.82 g) which is dissolved in 30 ml methanol in 100 ml one neck round bottom flask under nitrogen. The solution is diluted with 15 ml water and the mixture is treated with lithium hydroxide (800 mg, 19.1 mmole). The reaction mixture is stirred Ih at room temperature. The methanol is removed in vacuo and the pH of the aqueous residue is adjusted to 5 with 5% hydrochloric acid (pH meter). The precipitated phenol is collected by filtration and is dried to afford 1.2g (40%) of Cpd 174.
Melting Point: >300 C
Part D
Preparation of 7-benzyloxy-3,8-dimethyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one (Cpd 175).
3,8-Dimethyl-7-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one (355 mg, 1.29 mmole) is suspended in 9 ml dry acetonitrile in a 25 ml one neck round bottom flask under nitrogen. The suspension is treated successively with potassium carbonate (1.1 g, 8.0 mmole) and benzyl bromide (213 mg, 1.79 mmole). The reaction mixture is warmed to 60°C for 16 h and is cooled to room temperature. The volatiles are removed in vacuo and the residue is washed with 25 ml dichloromethane. The insoluable material is removed by filtration and the filtrate is concentrated to a pale oil. The oil is crystallized from diethyl ether to afford 323 mg (69%) of Cpd 175 as a white solid. Melting Point: 136-137.5°C.
Following the general procedure of Example 173, but starting with the appropriate 2'-hydroxypropiophenone, there are prepared the following products:
Cpd 176 3,8-Dimethyl-2-(4-morpholinyl)-7-(naphthyl-1- methyloxy)-4H-1-benzopyran-4-one mp. 204-206
Cpd 177 3,8-Dimethyl-7-(4-methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one mp. 141-142
Cpd 178 3,8-Dimethyl-2-(4-morpholinyl)-7-(2-phenyl-ethyloxy)- 4H-1-benzopyran-4-one mp. 160-161.5
Cpd 179 3,8-Dimethyl-7-(4-chlorobenzyloxy)-2-(4-morpholinyl)- 4H-1-benzopyran-4-one mp. 166-167.5
Cpd 180 3,8-Dimethyl-2-(4-morpholinyl)-7-(3-trifluoromethyl- benzyloxy)-4H-1-benzopyran-4-one mp. 158.5-160
Cpd 181 7- (Carbomethoxy-methoxyl)-3,8-dimethyl-2-(4- morpholinyl)-4H-1-benzopyran-4-one mp. 174-175 Cpd 182 8-Hydroxy-3-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one mp. 239-240
Cpd 183 8-Benzyloxy-3-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one mp. 134-135
Cpd 184 3-methyl-2-(4-morpholinyl)-8-(m-trifluoromethylbenzyloxy)-4H-1-benzopyran-4-one mp. 160.5-161 Example 185 Preparation of C-7 alkyl, alkenyl and alkynylaryl substituents. (relating to Chart F)
Part A
Preparation of 2'-Hydroxy-3'-methyl-4'-trifluormethanesulfonyloxy-acetophenone.
2',4'-Dihydroxy-3'methyl-acetophenone (11 g, 60.2 mmole) is suspended in 300 ml dichloromethane in a 1000 ml one neck round bottom flask under nitrogen. The suspension is treated successively with pyridine (4.4 ml, 54 mmole) and N,N, dimethylamino-pyridine (730 mg, 6 mmole) and the solution is cooled to 0ºC Triflic anhydride (11 ml, 66.2 mmole), in 1 X 100 ml dichloromethane, is added slowly dropwise to the reaction mixture (30 min) . The reaction is stirred for 1 h at room temperature for 1 h and the mixture is washed with 2 X 200 ml 5% hydrochloric acid. The organics are dried over magnesium sulfate and are concentrated in vacuo to a yellow oil. The oil is distilled via kugelrhor under high vacuum (165 C) to provide 16.4 (91%) of triflate as a white solid.
Melting Point: 60-64°C
Part B
Preparation of 8-methyl-2-(4-morpholinyl)-7-trifluormethanesulfonyloxy-4H-1-benzopyran-4-one.
2'-Hydroxy-3'-methyl-4'-triflouromethanesulfonyloxy-acetophenone (1.5 g, 5.03 mmole) is dissolved in 10 ml diethyl ether in a 25 ml one neck round bottom flask under nitrogen. The solution is treated with boron trifluoride etherate (0.9 ml, 7.5 mmole) and the reaction mixture is stirred for 6 h at room temperature. Approximately 1/2 the ether is removed in vacuo and the precipitate is collected by filtration. The pale solid is washed with cold diethyl ether to afford 1.1 g (63%) of difluoroboronate. Boron difluoride complex (1.1 g, 3.2 mmole) is combined with 4-morpholinophosgeniminium chloride (0.72 g, 3.5 mmole) in 12 ml 1,2-dichloroethane in a 50 ml one neck round bottom flask under nitrogen. The reaction mixture is warmed to 65ºC for 3 h and is cooled to room temperature. The precipitate is removed by filtration and is washed with diethyl ether to provide 1.35 g. The solid is supended in 12 ml acetonitrile in a 25 ml one neck round bottom flask under nitrogen. The suspension is stirred with 1.2 ml water for 48 h. The colorless solution is diluted with 10 ml saturated sodium bicarbonate and the acetonitrile is removed in vacuo. The aqueous residue is extracted with 4 X 25 ml dichloromethane. The combined organics are dried over magnesium sulfate and are concentrated in vacuo to a red solid. The solid is recrystallized from ethyl acetate to afford 566 mg (45%) of chromonetriflate as an off white solid.
Melting Point: 151-155°C
Part C
Preparation of 8-methyl-7-(2-phenyl)ethynyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one (Cpd 185). 8-Methyl-7-(trifluoromethanesulfonyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one (190 mg, 0.48 mmole) is suspended in 6 ml 1:1 benzene/triethylamine in a 15 ml screw cap pressure tube. The suspension is treated successively with phenyl acetylene (100 ul, 0.91 mmole), bis (triphenylphosphine) palladium dichloride (14 mg, 0.02 mmole), and cuprous iodide (2 mg, 0.01 mmole). The reaction mixture is warmed to 100-110°C overnight. The reaction mixture is cooled to room temperature and is again treated successively with phenyl acetylene (100 ul, 0.91 mmole), bis (triphenylphosphine) palladium dichloride (14 mg, 0.02 mole), and cuprous iodide (2 mg, 0.01 mmole). The reaction is heated to 110°C for 4 h and is cooled to room temperature. The volatiles are removed in vacuo to a black residue. The residue is chromatographed over 12 g silica gel (230400 mesh) eluting with 1% methanol/dichloromethane and collecting 3 ml fraction s for 48 fractions. Thereafter elution is carried out with 2% methanol/dichloromethane and 5 ml fractions are collected. Fractions 55-72 are combined and concentrated to provide 153 mg of a dark brown solid. The solid is recrystallized from ethyl acetate to afford 94 mg (56%) of Cpd 185 as a pale grey solid.
Melting Point: 228.5-229.5°C
Example 186 Preparation of 8-methyl-2-(4-morpholinyl)-7-(2-phenyl)ethyl-4H-1-benzopyran-4-one (Cpd 186).
8-Methyl-2-(4-morpholinyl)-7-(2-phenyl-ethynyl)-4H-1-benzopyran-4-one (90 mg, 0.261 mmole) is dissolved in 90 ml 8:1 methanol/acetone in a Parr shaker bottle. The solution is treated with 18 mg 10% palladium on carbon and the reaction mixture is hydrogenated at 40 PSI for 2 h. The catalyst is removed by filtration through a 1" bed of celite and the filter cake is washed well with methanol. The filtrate is concentrated in vacuo to a yellow oil which crystallized from hexane to give 70 mg (77%) of Cpd 186 as a tan solid. Melting Point: 162-163°C
Following the general procedures of Example 185 , but starting with the appropriate 2'-hydroxyacetophenone, there are prepared the following products :
Cpd 187 2-(4-Morpholinyl)-8-(2-phenyl)ethynyl-4H-1-benzopyran- 4-one mp. 196-197
Cpd 188 2-(4-Morpholinyl)-8-(2-phenyl)ethyl-4H-1-benzopyran-4- one .p. 110-112 Cpd 189 2 - ( 4 - Morpho l inyl ) - 8 - ( 2 - ( 3 - tr i f luo r omethyl - )phenyl)ethynyl-4H-1-benzopyran-4-one mp . 157.5¬
158.5
Cpd 190 2- (4-Morpholinyl) - 8 - (2- (3- trifluoromethyl)phenyl) - ethyl-4H-1-benzopyran-4-one mp . 13O-131
Cpd 192 8-Methyl-2- (4-morpholinyl) -7- (2- (1-naphthyl) )ethyl-4H- 1-benzopyran-4-one mp. 188.5-189.5
Cpd 193 8-Methyl-2-(4-morpholinyl)-7-phenyl-4H-1-benzopyran-4- one mp. 194.5-195
Example 194 (Relating to Chart G)
Part A
Preparation of 4'-acetoxy-3'-iodo-2'-hydroxy-propiophenone
2',4'-dihydroxy-3'-iodoacetophenone (55.6 g, 0.2 mol) is suspended in 600 ml of methylene chloride. Triethylamine (27.8 ml, 0.2 mol) is added and the cooled mixture (0°C) is treated dropwise with acetyl chloride (16.35 ml, 0.23 mol). The mixture is stirred at 0°C for 1 h and at ambient temperature for 2 h. The mixture is washed with 5% hydrochloric acid, dried owver magnesium sulfate and evaporated. The solid is recrystallized from ethanol to provide 48.39 g of the product.
Part B
Preparation of 7-acetyloxy-8-iodo-2-(4-morpholinyl)-4H-1-benzopyran-4-one (Cpd 194)
4'-Acetoxy-3'-iodo-2'-hydroxy-propiophenone (48.4 g, 0.15 mol) is suspended in 750 ml of ether and treated with boron trifluoride etherate (27.9 ml, 0.22 mol). The mixture is stirred overnight at ambient temperature, filtered and the solid is washed well with ether to afford 47.0 g of the boron difluoride complex. The complex is combined with 4-morpholine dichloromethyleniminium chloride in 400 ml of ethylene dichloride and heated at 70°C for 5 h and at 50°C for 16 h. The reaction is cooled to 0°C and the solid is filtered and washed well with ether (45 g). The solid is suspended in 400 ml of acetonitrile, 40 ml of water is added and the mixture is stirred overnight at room temperature, heated at 50°C for 2 h and finally heated at 60°C for 30 min. The solvent is evaporated and the material is taken up in methylene chloride/ saturated sodium bicarbonate. The aqueous layer is extracted twice with methylene chloride and the combined organics are dried over magnesium sulfate. Evapora tion of the solvent and recrystallization from methanol gave 20.8 g (39%) of the chromone. The mother liquors contained 5.8 g of crude product from which a second recrystallization yielded 0.7 g. mp. 201.5-202.5
Part C
Preparation of 8-ethyl-7-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one
7-Acetyloxy-8-iodo-2-(4-morpholinyl)-4H-1-benzopyran-4-one (2.07 g, 5.0 mmol) is combined with lithium chloride (0.64 g, 15 mmol) tetraethyltin (1.04 ml, 5.25 mmol) and (bis)triphenylphosphine palladium dichloride (70 mg, 0.10 mmol) in 20 ml of dimethylformamide. The mixture is heated a 100°C for 40 min., poured into half saturated sodium chloride and extracted twice with methylene chloride. The organics are washed twice with half saturated sodium chloride, dried over magnesium sulfate and evaporated. The material is taken up in 20 ml of methanol and 10 ml of water and treated with 0.63 g (15 mmol) of lithium hydroxide. The mixture is stirred at room temperature for 30 min. The solvent is evaporated, the mixture is diluted with water and extracted twice with ethyl acetate. The aqueous layer is acidified to pH 6.1 qirh 5% hydrochloric acid and the solid is filtered, washed with ether and dried to afford 0.98 gt (71%) of the product.
Part D
Preparation of 8-ethyl-2-(4-morpholinyl)-7-(3-pyrindiny1-methoxy)-4H-1-benzopyran-4-one (Cpd 195)
8-Ethyl-7-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one (0.176 g, 0.64 mmol) and sodium hydride (0.105 g, 60%, 2.6 mmol) are combine in 4 ml of dimethylformamide and heated to 60°C for 20 min. 3-Picoyl chloride hydrochloride (0.321 g, 1.76 mmol) is added and the mixture is heated at 60°C for 1 h. The cooled mixture is poured into 2N sodium hydroxide and ice. The solid is filtered, washed well with water and ether and recrystallzed form ethyl acetate to provide 0.156 g of the product, mp.178-179
Following the general procedure of Example 194, but starting with the 2'-hydroxyacetophonone, there are prepared the following products :
Cpd 196 8-Ethyl-2-(4-morpholinyl)-7-phenylmethoxy-4H-1- benzopyran-4-one mp. 153-154.5 Cpd 197 8-Iodo-2-(4-morpholinyl)-7-phenylmethoxy-4H-1- benzopyran-4-one mp. 155-157
Cpd 198 8-Ethyl-2-(4-morpholinyl)-7-(2-(1-piperidinyl)ethyl)oxy-4H-1-benzopyran-4-one mp. 151-152
Cpd 199 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one mp. 214-215
Cpd 200 8-Iodo-7-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4- one mp. 224-225
Example 201 (Relating to Chart H)
Part A
Preparation of 7-hydroxy-8-methyl-2-(1-piperidinyl)-4H-1-benzopyran-4-one (Cpd 201).
Palladium black (225 mg) is added to a solution of the benzyl ether Cpd 31 (1.00 g, 2.86 mmol) in EtOAc (80 ml). After shaking in a Parr hydrogenation apparatus under 50 lbs pressure of hydrogen for 2 days, the catalyst is filtered off through a cintered glass funnel rinsing with EtOAc and MeOH. Evaporation of the solvent afforded 0.99 g of crude material. Flash chromatography (60 g silica gel, 10% MeOH/CH2Cl2) afforded 0.83 g of the phenol. Recrystallization from MeOH/EtOAc at 4°C afforded 0.65 g (88%) of white crystalline title product, mp 278-284°C
Part B
Preparation of 7-(3-pyridinylmethoxy)-2-(1-piperidinyl)-8-methyl-4H-1-benzopyran-4-one, Cpd 202.
A suspension of phenol Cpd 170 (130 mg, 0.5 mmol), 3-picolinyl chloride-HCl (161 mg, 1.0 mmol), and potassium carbonate (277 mg, 2.0 mmol) in dimethylformamide (5 ml) is stirred at 90°C After 7 days, the reaction mixture is evaporated down and then CHCI3 added. The solids are filtered off and the filtrate evaporated. Flash chromatography of the residue (15 g silica gel, 2% MeOH/CH2Cl2, 6 ml fractions) afforded 18 mg (10%, fractions 37-52) of Cpd 202. mp 14458°C
Example 203 Preparation of 7-phenylmethoxy-2-methylthiomethyl-8- methyl-4H-1-benzopyran-4-one, Cpd 203 (Relating to Chart I)
Part A: Sodium hydride (50% oil dispersion washed 3x in hexane, 23.2 g, 0.48 mol) is stirred in THF (195 ml) under nitrogen in a flame dried 2 1 three-necked round bottom flask equipped with an addition funnel and a condensor. A solution of the 2-hydroxyaceto phenone (25 g, 97.6 mmol) and ethyl α-thiomethyl- acetate (130.4 g, 123 ml, 0.9 mol) in THF (164 ml) is slowly dropped into the sodium hydride slurry. After about half of the reagent solution had been added the reaction is heated with a heating gun until the reaction had begun to reflux on its own. The remainder of the reagent solution is slowly added with stirring. After 10 min at ambient temperature and 1 h 40 min at reflux, the solution is evaporated in vacuo. The solution is transferred to a separatory funnel with methylene chloride/2N HCl and shaken for about 10 min. Extraction with methylene chloride (2x) and drying over magnesium sulfate affords the crude β-diketone which is not further purified.
A biphasic solution of the β-dikeone and 6N HCl (250 ml) is stirred at ambient temperature overnight. Extraction with methylene chloride and drying over magnesium sulfate afforded 127.13g of crude material after evaporation of the solvent. Flash chromatography (700 g silica gel, 30-50% EtOAc/hexane) afforded 122 g of a mixture of the starting acetophenone, the thiomethylacetate, and some β-diketone and 4.94 g Cpd 203 (15%). An analytical sample is recrystallized from ether/hexane to afford white crystalline title product. mp 110114°C
Part B
Preparation of 7-phenylmethoxy-2-iodomethyl-8-methyl-4H-1-benzopyran-4-one
A solution of Cpd 203 (4.0 g, 12.3 mmol) in methyl iodide (12.5 ml) and CH2Cl2 (8 ml) is stirred under reflux. After 3 days, the solution is cooled to 0°C and the yellow precipitate filtered off. The filtrate is evaporated down and the residue flash chromatographed (100 g silica gel, 40% EtOAc/hexane) to afford 1.48 g of 7-phenylmethoxy-2-iodomethyl-8-methyl-4H-1-benzopyran-4-one (30%). An analytical sample is prepared by recrystallization from CH2Cl2/EtOAc/hexane to afford white crystalline title product. mp 144-7°C;
Part C
Preparation of 8-Methyl-2-(4-morpholinylmethyl)-7-(phenylmethoxy)-4H-1-benzopyran-4-one (Cpd 204)
Morpholine (0.21 g, 2.5 mmol) is added to a stirring solution of 7-phenylmethoxy-2-iodomethyl-8-methyl-4H-1-benzopyran-4-one (1.0 g, 2.5 mmol) and triethylamine (0.25 ml, 2.5 mmol) in CHCI3 (12 ml). After stirring at ambient temperature for 2.5 h, the solvent is evaporated in vacuo. The residue is flash chromatographed (100 g silica gel, 50-100% Et0Ac/CH2Cl2, 45 ml fractions) to afford 0.72 g (79%) of the product. Recrystallization from ether afforded a white solid title product. MP 130-3°C
Part D
Preparation of 7-hydroxy-2-(4-morpholinylmethyl)-8-methyl-4H-1-benzopyran-4-one, Cpd 205
Palladium black (140 mg) is added to a solution of the benzyl ether Cpd 204 (0.65 g, 1.78 mmol) in EtOAc (50 ml). After shaking in a Parr hydrogenation apparatus under 50 lbs pressure of hydrogen for
23 h, the catalyst is filtered off through a cintered glass funnel rinsing with EtOAc and MeOH. Evaporation of the solvent afforded
0.49 g of crude material. Flash chromatography (100 g silica gel, 4% MeOH/CH2Cl2, 50 ml fractions) afforded 35 mg (5%, fractions 6-7) of the starting material and 0.33 g (68%, fractions 11-16) of the phenol. An analytical sample is prepared by recrystallization from
EtOAc/ether/hexane at 4°C to afford white crystalline title product.
MP 144-6°C;
Part E
Preparation of 7-[(1-cyclohexyl-1H-tetrazol-5-yl)methyoxy]-8- methyl-2-(4-morpholinylmethy)-4H-1-benzopyran-4-one, Cpd 206
A suspension of Cpd 205 (100 mg, 0.36 mmol), 5-(4- chloromethyl)-1-cyclohexyltetrazole [see e.g. Chem. Pharm. Bull. 31, 1151 (1983)] (146 mg, 0.73 mmol), and potassium carbonate (201 mg, 1.45 mmol) in acetonitrile (3 ml) is stirred at 60ºC After 17 h, the reaction mixture is evaporated down and then CHCI3 added. The solids are filtered off and the filtrate evaporated. Flash chromatography of the residue (25 g silica gel, 3% MeOH/CH2Cl2, 15 ml fractions) afforded 134 mg (85%, fractions 5-6) of white crystalline title product. MP 193-5°C;
Part F
Preparation of 8-Methyl-2-(4-morpholinylmethyl)-7-(3- pyridinylmethoxy)-4H-1-benzopyran-4-one, Cpd 207
A suspension of Cpd 205 (50 mg, 0.18 mmol), 3-picolinyl chloride-HCl (58 mg, 0.36 mmol), and potassium carbonate (100 mg, 0.72 mmol) in acetonitrile (2 ml) is stirred at 60°C. After 2 days, the reaction mixture is evaporated down and then CHCI3 added. The solids are filtered off and the filtrate evaporated. Flash chromatography of the residue (20 g silica gel, 3% MeOH/CH2Cl2, 10 ml fractions) afforded 45 mg (68%, fractions 17-25) of white crystalline title product which is recrystallized from ether, mp 105-8°C

Claims (1)

  1. 1. A compound of Formula I
    wherein X is CZ where Z is H, C1-C5 alkyl, amino (-NH2) or a halogen atom;
    Y is selected from the group consisting of
    -(CH2)nNR9R10 wherein R9 and R10, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that R9 and R10 are not both hydrogen; (b) C1-C12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl); (d)- (CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], (e) -(CH2)npyridinyl or (f) wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of
    (aa) 4-morpholine optionally substituted
    with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (cc) 3-amino-1-pyrrolidine,
    (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
    (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3
    C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl),
    (ff) 1-piperazine, 4-methyl-1-piperazine,
    4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH2OH, -CO2H, -CO2CH3 or -CO2CH2CH3, and
    (gg) thiazolidine, thiazolidine-4-carboxylic
    acid, pipecolinic acid, p-piperazinacetophenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetrahydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole;
    and R5, R6, R7 and R8, being the same or different, are selected from the group consisting of hydrogen, C1-C8 alkyl,
    -(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)nnaphthyl, -(CH2)npyridinyl,
    -(CH2)qNR9R10, -CH-CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -CH2-CH=CH2, -CH-CH-CH3, -O-CH2-CH=CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O(CH2)p(N-methylpiperdin-3-yl), -O-(CH2)pNR9R10, -O-CH2CH(OCH3)2, -O-(CH2)pOR15,
    -(CH2)nC(O)-(CH2)nR9, -(CH2)nC(O)O-(CH2)pR9, -(CH)nC(O)O- (CH2)pNR9R10, - (CH2)nC(O) (CH2)nNR9R10, NO2, -O-(CH2)nC(O)- (CH2)pR9, -O-(CH2)nC(O)O-(CH2)pR9, -O-(CH2)nC(O) - (CH2)nNR9R10, -NR9R10, -N(R9)(CH2)nC(O)-(CH2)nR10, -N(R9) -(CH2)nC(O)O- (CH2)nR10, N(R9)(CH2)nC(O)-(CH2)nNR9R10, -O-(C(2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1C4alkyl)], -O-(CH2)npyridine, -O(CH2)nC(O)-(CH2)npyridine.
    -O-(CH2)nC(O)O-(CH2)npyridine. -O(CH2)nC(O)-N(R9) (CH2)npyridine, -O-(CH2)nquinoxalinyl, -O-(CH2)nquinolinyl -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O-(CH2)nC(O)-(CH2)nnaphthyl,
    -O-(CH2)nC(O)O-(CH2)nnaphthyl, -O-(CH2)nC(O)NR9- (CH2)nnaphthyl, halo (fluoro, chloro, bromo, iodo), OH, -(CH2)q-OH, (CH2)qOC(O)R9, -(CH2)qOC(O) -NR9R10, -(1-cyclohexyl-1H-tetrazo1-5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)],-[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(1-phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy,
    -C1-C4 alkoxyl, a group of Formula II wherein R' is methyl or carboxy, R'' is hydrogen and R''' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], C1C5 alkyl, -(CH2)nCO2H, -CH2SH, -CH2SCH3, imidazolinylmethylene, indolinylmethylene, CH3CH(OH), CH2OH, H2N(CH2)4- (optionally in protected form) or H2NC(NH)NH(CH2)3 (optionally in protected form); with the overall proviso that when Y is other than -(CH2)nmorpholinyl, at least one member of R5, R6, R7 or R8 is other than hydrogen, C1-C8 alkyl, NO2 , OH, C1-C4 alkoxy, a halogen atom, phenyl, benzyl, 4-morpholinylmethyl, NH2, or dimethyamino; with the further proviso that when Y is 4-morpholinyl, the compound is other than:
    6,7-dimethoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one,
    7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one,
    N-cyclohexyl-2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7-yl]oxy]-acetamide,
    2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7-yl]oxy]-N-phenyl-acetamide,
    6-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one, 2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7- yl]oxy]-N-(1-phenylethyl)-acetamide;
    with the further provisio that when Y is dimethylamino, the compound is other than:
    2-(Dimethylamino)-8-methyl-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester,
    (Dimethylamino)-4-oxo-4H-1-benzopyran-6-yl carbamic acid dimethyl ester,
    2-(Dimethylamino)-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester;
    R15 is selected from C1-C5 alkyl, -(CH2)nphenyl [phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)npyridin-1-yl or
    - (CH2)ppiperidin-1-yl;
    n is 0-5;
    p is 2-5;
    q is 1-5;
    and pharmaceutically acceptable salts and hydrates thereof. 2. A compound according to Claim 1 wherein Y is selected from the group consiting of -(CH2)nNR9R10 wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of:
    (aa) 4-morpholine optionally substituted
    with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (cc) 3-amino-1-pyrrolidine,
    (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
    (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3
    C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-1-piperazine,
    4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH2OH,
    -CO2H, -CO2CH3 or -CO2CH2CH3.
    3. A compound according to Claim 1 wherein Z is H or C1-C5 alkyl. 4. A compound according to Claim 3 wherein Y is selected from the group consisting of -(CH2)nNR9R10 wherein n is 0 or 1, and R9 and R10, taken together with N, form 4-morpholine.
    5. A compound according to Claim 4 wherein Z is H.
    6. A compound according to Claim 5 wherein n is 0.
    7. A compound according to Claim 2 wherein at least one member selected from R5, R6, R7 or R8 is selected from:
    the group consisting of -(CH2)pphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)],
    -(CH2)nnaphthyl, -(CH2)npyridinyl, -(CH2)qNR9R10, -CH=CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1C4alkyl)], -CH2-CH-CH2, -CH-CH-CH3, -O-CH2-CH-CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl or -CO2(C1C4alkyl)], -O(CH2)p(N-methylpiperdin-3-yl), -O-(CH2)pNR9R10, -O-CH2CH(OCH3)2, -O-(CH2)pOR15, -(CH2)nC(O)-(CH2)nR9 , -(CH2)n- C(O)O-(CH2)pR9, -(CH)nC(O)O-(CH2)pNR9R10, -(CH2)nC(O) (CH2)n- NR9R10, -O-(CH2)nC(O)-(CH2)pR9, -O-(CH2)nC(O)O-(CH2)pR9,
    -O-(CH2)nC(O)-(CH2)nNR9R10, -NR9R10, -N(R9) (CH2)nC(O)- (CH2)nR10, -N(R9)-(CH2)nC(O)O-(CH2)nR10. N(R9) (CH2)nC(O)- (CH2)nNR9R10, -O-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O-(CH2)npyridine, -O(CH2)nC(O)-(CH2)npyridine, -O-(CH2)nC(O)O-(CH2)npyridine, -O(CH2)nC(O)-N(R9) (CH2)npyridine, -O-(CH2)nquinoxalinyl,
    -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O-(CH2)nC(O)- (CH2)nnaphthyl, -O-(CH2)nC(O)O-(CH2)nnaphthyl,
    -O-(CH2)nC(O)NR9-(CH2)nnaphthyl, -(CH2)q-OH, (CH2)qOC(O)R9, -(CH2)qOC(O) -NR9R10, -(1-cyclohexyl-1H-tetrazol-5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy,
    -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)],
    -[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(1- phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, or -C1-C4 alkoxyl.
    8. A compound according to Claim 2, 3,. 4 or 6 wherein R5, R6, R7 and R8 are selected from the following groups:
    (i) R5, R6, R7 and R8 are each hydrogen; or
    (ii) R5, R6, and R8 are each hydrogen, and R7 is selected from:
    -O-(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -C≡C-phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), or -(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1C4 alkoxy, halo or trifluoromethyl); or
    (iii) R5 and R6 are hydrogen, R8 is hydrogen, halo or C1-C5 alkyl, and R7 is selected from: -O-(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl),
    -O-(CH2)npyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -O-(CH2)nnaphthyl, -(CH2)nphenyl
    (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -(CH2)ppyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -(CH2)p(1-piperidinyl), -(CH2)p(1-pyrrolidinyl) or -[(1-cyclohexyl-1H-tetrazol-5- yl)C1-C4 alkoxy; or
    (iv) R5, R7 and R8 are each hydrogen, and R6 is
    -NH-C(O)-O-CH2phenyl.
    9. A compound according to Claim 1 selected from the group consisting of:
    Cpd 1 6-Chloro-2-(4-morpholinyl)-4H-1-benzo
    pyran-4-one;
    Cpd 2 2-(4-morpholinyl)-4H-benzopyran-4-one;
    Cpd 3 8-Methyl-2-(4-morpholinyl)-(7-phenylmethoxy)-4H- benzopyran-4-one;
    Cpd 4 7-Chloro-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 5 8-Chloro-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 6 6-Bromo-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 7 6-Fluoro-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 8 6-Methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 9 7-Methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 10 8-Methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 11 6-Methoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 12 7-Methoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 13 6-(Phenylmethoxy)-2-(4-morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 14 8-(Phenylmethoxy)-2-(4-morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 15 [2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-6-yl]-1,1- dimethylethyl carbamic acid ester;
    Cpd 16 6-(3-pyridinecarboxamide)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 17 2-(4-Morpholinyl)-6-nitro-4H-1-benzopyran-4-one;
    Cpd 19 6-([[Phenylmethoxy]carbonyl]amino)-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 20 8-Methoxy-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 21 3-Amino-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 22 3-Chloro-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 23 3-Bromo-2-(4-morpholinyl)-4H-1-benzopyran-4-one; Cpd 24 8-Methyl-2-(4-morpholinyl)-7-(phenylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 25 2-(4-Morpholinyl)-5-(phenylmethoxy)-4H-1-benzopyran-4- one;
    Cpd 26 7,8-Dimethoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 27 2-(4-Methyl-2-piperazinyl)-4H-1-benzopyran-4-one;
    Cpd 28 8-Methyl-7-(phenylmethoxy)-2-[4-(2-pyridinyl)-1- piperazinyl]-4H-benzopyran-4-one;
    Cpd 29 8-Methyl-7-(phenylmethoxy)-2-(1-piperazinyl)-4H- benzopyran-4-one;
    Cpd 30 8-Methyl-7-(phenylmethoxy)-2-(1-pyrrolidinyl)-4H- benzopyran-4-one;
    Cpd 31 8-Methyl-7-(phenylmethoxy)-2-(1-piperidinyl)-4H- benzopyran-4-one;
    Cpd 32 8-Methyl-2-(4-methyl-1-piperazinyl)-7-(phenylmethoxy)- 4H-benzopyran-4-one;
    Cpd 33 8-Methyl-7-(phenylmethoxy)-2-(2,6-dimethyl-4- morpholinyl)-4H-benzopyran-4-one;
    Cpd 34 2-[4-(Hydroxyethyl)-1-piperazinyl]-8-methyl-7-(phenyl- methoxy)-4H-benzopyran-4-one monohydrochloride;
    Cpd 35 2-[4-(Diphenylmethyl)-1-piperazinyl]-8-methyl-7- (phenylmethoxy)-4H-benzopyran-4-one;
    Cpd 36 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-1-piperidinyl)- 4H-benzopyran-4-one;
    Cpd 37 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-1-piperazinyl)- 4H-benzopyran-4-one;
    Cpd 38 2-(4-Hydroxy-1-piperdinyl)-8-methyl-7-(phenylmethoxy)- 4H-benzopyran-4-one;
    Cpd 39 7-Hydroxy-S-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one;
    Cpd 40 6-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 41 7-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 42 5-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 43 8-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one; Cpd 44 7-Methoxy-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one;
    Cpd 45 [(8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-7-yl)oxy] acetic acid lithium salt; Cpd 46 [[8-Methyl-2-(4-morpholinyl)-4-oxy-4H-1-benzopyran-7- yl]oxy]acetic acid methyl ester;
    Cpd 47 7-[(4-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpho
    linyl)-4H-1-benzopyran-4-one;
    Cpd 48 8-Methyl-7-[(4-methylphenyl)methoxy]-2-(4-morpho
    linyl)-4H-1-benzopyran-4-one;
    Cpd 49 7-[(4-Chlorophenyl)methoxy]-8-methyl-2-(4-morpho
    linyl)-4H-1-benzopyran-4-one;
    Cpd 50 7-[(4,5-Dichlorophenyl)methoxy]-8-methyl-2-(4-morpho linyl)-4H-1-benzopyran-4-one;
    Cpd 51 8-Methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 52 8-Methyl-7-[[(phenyl)carbonyl]oxy]-2-(4-morpho
    linyl)-4H-1-benzopyran-4-one;
    Cpd 53 7-Methoxy-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one;
    Cpd 54 7-[[4-(1,1-Dimethylethyl)phenyl]methoxy]-8-methyl-2- (4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 55 8-Methyl-2-(4-morpholinyl)-7-[[4-phenylmethoxy)- phenyl]methoxy]-4H-1-benzopyran-4-one;
    Cpd 56 7-[(3-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 57 7-[(4-Nitrophenyl)methoxy]-8-methyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 58 7-[(2-Phenylethyl)methoxy]-8-methyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 59 7-[(2-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 60 7-[(4-Ethoxyphenyl)methoxy]-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 61 8-(4-Ethoxy-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 62 2-(4-Morpholinyl)-8-(4-nitro-benzyloxy)-4H-1-benzopyran-4-one;
    Cpd 63 8-(2-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 64 2-(4-Morpholinyl)-8-(2-phenyl-ethoxy)-4H-1-benzopyran- 4-one; Cpd 65 2-(4-Morpholinyl)-(2-oxo-2-phenyl-ethoxy)-4H-1- benzopyran-4-one;
    Cpd 66 8-(4-Benzyloxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 67 8-(4-Chloro-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpg 68 8-(4-t-Butyl-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 69 8-(3-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 70 8-(3,4-Dichloro-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 71 8-(4-Methyl-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 72 8-(4-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 73 2-(4-Morpholinyl)-8-(naphthyl-2-methyloxy)-4H-1- benzopyran-4-one;
    Cpd 74 2-(4-Morpholinyl)-8-(naphthyl-1-methyloxy)-4H-1- benzopyran-4-one;
    Cpd 75 8-Methyl-2-(4-morpholinyl)-7-(naphthyl-2-methyloxy)- 4H-1-benzopyran-4-one;
    Cpd 76 8-Methyl-2-(4-morpholinyl)-7-(naphthyl-1-methyloxy)- 4H-1-benzopyran-4-one;
    Cpd 80 2-(Dimethylamino)-4H-1-benzopyran-4-one; and
    Cpd 81 2-(Dimethylamino)-8-methyl-7-(phenylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 100 [8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7- yl]4-morpholinyl carboxylic acid ester;
    Cpd 101 2-(4-morpholinyl)-7-(phenylmethoxy)-4H-1-benzopyran-4- one;
    Cpd 102 8-Methyl-2-(4-morpholinyl)-7-(2-oxo-2-phenylethoxy)- 4H-1-benzopyran-4-one;
    Cpd 103 6-Chloro-8-methyl-2-(4-morpholinyl)-7-(phenylmethoxy)- 4H-1-benzopyran-4-one;
    Cpd 104 [[2-(4-Morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]oxy]- acetic acid methyl ester;
    Cpd 105 4-[[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]methyl]-benzoic acid methyl ester;
    Cpd 106 4-[[[2-(4-Morpholinyl)-4-oxo-4H-1-benzopyran-8- yl]oxy]methyl]-benzoic acid methyl ester; Cpd 107 8 - Me thyl - 2 - ( 4 - mo rphol inyl ) - 7 - [ [ 3 - (trifluoromethyl)phenyl]methoxy]-4H-1-benzopyran-4- one;
    Cpd 108 2-(4-Morpholinyl)-8- [ [3- (trifluoromethyl)- phenyl]methoxy]-4H-1-benzopyran-4-one;
    Cpd 109 7-(Cyclohexylmethoxy)-8-methyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 110 8-Methyl-2-(4-morpholinyl)-7-(2-propenyloxy)-4H-1- benzopyran-4-one;
    Cpd 111 2-(4-Morpholinyl)-7-(l-naphthalenylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 112 8-Methyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 113 8-Methyl-2-(4-morpholinyl)-7-(4-pyrindinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 115 8-methyl-2-(4-morpholinyl)-7-(2-quinoxalinylmethoxy)- 4H-1-benzopyran-4-one;
    Cpd 116 8-methyl-2-(4-morpholinyl)-7-(pyrazinlymethoxy)-4H-1- benzopyran-4-one;
    Cpd 117 8-methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- 1-benzopyran-4-one N-oxide;
    Cpd 118 8-methyl-2-(4-morpholinyl)-7-(3-pyridinylmethoxy)-4H- 1-benzopyran-4-one N-oxide;
    Cpd 119 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 120 3,3-Dimethyl-1-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H- 1-benzopyran-7-yl]oxy]-butan-2-one;
    Cpd 121 1-[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-propan-2-one;
    Cpd 122 1-[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-butan-2-one;
    Cpd 123 8-Methyl-2-(4-morpholiny1) -7-(2-oxo-2- (2- naphthyl)ethoxy)-4H-1-benzopyran-4-one;
    Cpd 125 2-(4-Morpholinyl)-7-(2-pyrindinylmethoxy)-4H-1- bbnzopyran-4-one; Cpd 126 2-(4-Morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 127 2-(4-Morpholinyl)-8-(2-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 128 2-(4-Morpholinyl)-8-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 129 8-methyl-2-(4-morpholinyl)-7-(2-quinolinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 130 7,8-(Bis)-phenylmethoxy-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 131 7,8-(Bis)-acetyloxy-2-(4-morpholinyl)-4H-1-benzopyran- 4-one;
    Cpd 132 7,8-(Bis)-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 133 7-Hydroxy-2-(4-morpholinyl)-8-phenylmethoxy-4H-1- benzopyran-4-one;
    Cpd 135 8 - Hydroxy - 2 - ( 4 -morpholinyl ) - 7 - ( 3 - trifluoromethyl)phenylmethoxy-4H-1-benzopyran-4-one; Cpd 136 7 - Hydroxy - 2 - (4 -morpholinyl ) - 8 - ( 3 - trifluoromethyl)phenylmethoxy-4H-1-benzopyran-4-one;
    Cpd 137 7-[3-(l-cyclohexyl-1H-tetrazol-5-yl)propoxyl-8-methyl2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 138 8-[3-(l-cyclohexyl-1H-tetrazol-5-yl)propoxy]-2-(4-morpholinyl)-4H«l-benzopyran-4-one;
    Cpd 139 7-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-8-methyl-2- (4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 140 8-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 141 2-(4-morpholinyl)-8-[(1-phenyl-1H-tetrazol-5-yl)oxy]- 4H-1-benzopyran-4-one;
    Cpd 142 N-cyclohexyl-2-[[2-(4-morpholinyl)-4-oxo-4H-1- benzopyran-8-yl]oxy]-acetamide;
    Cpd 143 N-(1,1-dimethylethyl)-2-[[2-(4-morpholinyl)-4-oxo-4H- 1-benzopyran-8-yl]oxy]-acetamide;
    Cpd 144 2-[[2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]-N- phenyl-acetamide;
    Cpd 145 2-[[2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]oxy]- N-(1-phenylethyl)-acetamide; Cpd 147 N-[[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]acetyl]-phenyalanine, ethyl ester;
    Cpd 149 8-methyl-2-(4-morpholinyl)-7-[(1-phenyl-1H-tetrazol-5- yl)oxy]-4H-1-Benzopyran-4-one;
    Cpd 152 2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-N-3-pyridinyl-acetamide;
    Cpd 153 N-[[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]acetyl]-Phenylalanine;
    Cpd 154 7-(2,2-dimethoxyethoxy)-8-methyl-2-(4-morpholinyl)-4H- 1-Benzopyran-4-one;
    Cpd 155 2-(4-Morpholinyl)-8-(2-propenyl)-4H-1-benzopyran-4- one;
    Cpd 156 2-(4-Morpholinyl)-8-(1-propenyl)-4H-1-benzopyran-4- one;
    Cpd 157 8-Formyl-2-(4-Morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 158 2-(4-morpholinyl)-8-(phenylamino)methyl-4H-1- benzopyran-4-one;
    Cpd 159 2-(4-morpholinyl)-8-(2E-phenyl)ethenyl-4H-1- benzopyran-4-one;
    Cpd 160 8-Hydroxymethyl-2-(4-Morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 162 8-methyl-7-[(1-methyl-3-piperidinyl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one;
    Cpd 163 8-Methyl-2-(4-morpholinyl)-7-(2-(1-piperidinyl)ethyl)oxy-4H-1-benzopyran-4-one;
    Cpd 164 8 -Methyl - 2 - (4-morpholinyl) -7- (2- (1- pyrrolidinyl)ethyl)oxy-4H-1-benzopyran-4-one;
    Cpd 165 8-Methyl-2-(4-morpholinyl)-7-(2-(4-morpholinyl)ethyl)- oxy-4H-1-benzopyran-4-one;
    Cpd 166 8-Methyl-2-(4-morpholinyl)-7-(3-(1-piperidino)propyl)oxy-4H-1-benzopyran-4-one;
    Cpd 167 7-(2-Diethylaminoethyl)oxy-8-methyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 168 7-[2-(ethylphenylamino)ethoxy]-8-methyl-2-(4-morpholinyl)-4H-1-Benzopyran-4-one;
    Cpd 169 7-(2-Diisopropylaminoethyl)oxy-8-methyl-2-(4- morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 170 7-Hydroxy-8-methyl-2-(1-piperidinyl)-4H-1-benzopyran- 4-one;
    Cpd 171 8-Methyl-2-(1-piperidinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 172 7-(2-(4-Benzyl-(1-piperizinyl))ethyl)oxy-8-methyl-2- (4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 173 7-Acetoxy-3,8-dimethyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 174 3,8-dimethyl-7-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 175 7-benzyloxy-3,8-dimethyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 176 3,8-Dimethyl-2-(4-morpholinyl)-7-(naphthyl-1- methyloxy)-4H-1-benzopyran-4-one;
    Cpd 177 3,8-Dimethyl-7-(4-methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 178 3,8-Dimethyl-2-(4-morpholinyl)-7-(2-phenyl-ethyloxy)- 4H-1-benzopyran-4-one;
    Cpd 179 3,8-Dimethyl-7-(4-chlorobenzyloxy)-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 180 3,8-Dimethyl-2-(4-morpholinyl)-7-(3-trifluoromethylbenzyloxy)-4H-1-benzopyran-4-one;
    Cpd 181 7-(Carbomethoxy-methoxyl)-3,8-dimethyl-2-(4- morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 182 8-Hydroxy-3-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one,
    Cpd 183 8-Benzyloxy-3-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 184 3-methyl-2-(4-morpholinyl)-8-(m-trifluoromethylbenzyloxy)-4H-1-benzopyran-4-one,
    Cpd 185 8-methyl-7-(2-phenyl)ethynyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 186 8-methyl-2-(4-morpholinyl)-7-(2-phenyl)ethyl-4H-1- benzopyran-4-one;
    Cpd 187 2-(4-Morpholinyl)-8-(2-phenyl)ethynyl-4H-1-benzopyran- 4-one;
    Cpd 188 2-(4-Morpholinyl)-8-(2-phenyl)ethyl-4H-1-benzopyran-4- one;
    Cpd 189 2-(4-Morpholinyl)-8- (2-(3-trifluoromethyl- )phenyl)ethynyl-4H-1-benzopyran-4-one;
    Cpd 190 2-(4-Morpholinyl)-8-(2-(3-trifluoromethyl)phenyl)- ethyl-4H-1-benzopyran-4-one;
    Cpd 192 8-Methyl-2-(4-morpholinyl)-7-(2-(l-naphthyl))ethyl-4H- 1-benzopyran-4-one;
    Cpd 193 8-Methyl-2-(4-morpholinyl)-7-phenyl-4H-1-benzopyran-4- one;
    Cpd 194 7-acetyloxy-8-iodo-2-(4-morpholinyl)-4H-1-benzopyran- 4-one;
    Cpd 195 8-ethyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 196 8-Ethyl-2-(4-morpholinyl)-7-phenylmethoxy-4H-1- benzopyran-4-one;
    Cpd 197 8-Iodo-2-(4-morpholinyl)-7-phenylmethoxy-4H-1- benzopyran-4-one;
    Cpd 198 8-Ethyl-2- (4-morpholinyl)-7-(2-(1-piperidinyl)ethyl)oxy-4H-1-benzopyran-4-one;
    Cpd 199 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 200 8-Iodo-7-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 202 7-(3-pyridinylmethoxy)-2-(1-piperidinyl)-8-methyl-4H- 1-benzopyran-4-one;
    Cpd 204 8-Methyl-2-(4-morpholinylmethyl)-7-(phenylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 205 7-hydroxy-2-(4-morpholinylmethyl)-8-methyl-4H-1- benzopyran-4-one;
    Cpd 206 7-[(1-cyclohexyl-1H-tetrazol-5-yl)methyoxy]-8-methyl- 2-(4-morpholinylmethy)-4H-1-benzopyran-4-one;
    Cpd 207 8 -Methyl - 2 - (4-morpholinylmethyl) -7- (3- pyridinylmethoxy)-4H-1-benzopyran-4-one or a pharmaceutically acceptable salt or hydrate thereof.
    10. A compound according to Claim 1 selected from the group consisting of:
    Cpd 2 2-(4-morpholinyl)-4H-benzopyran-4-one;
    Cpd 3 8-Methyl-2-(4-morpholinyl)-(7-phenylmethoxy)-4H- benzopyran-4-one; Cpd 19 6-([[Phenylmethoxy]carbonyl]amino)-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 51 8-Methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 72 8-(4-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 76 8-Methyl-2-(4-morpholinyl)-7-(naphthyl-1-methyloxy)- 4H-1-benzopyran-4-one;
    Cpd 112 8-Methyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 139 7-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-8-methyl-2- (4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 163 8-Methyl-2-(4-morpholinyl)-7-(2-(1-piperidinyl)ethyl)oxy-4H-1-benzopyran-4-one;
    Cpd 164 8 -Methyl- 2 - (4-morpholinyl) -7- (2- (1- pyrrolidinyl)ethyl)oxy-4H-1-benzopyran-4-one;
    Cpd 171 8-Methyl-2-(1-piperidinyl)-7-(3-pyrindinylmethoxy)-4H- 1-behzopyran-4-one;
    or a pharmaceutically acceptable salt or hydrate thereof.
    11. Use of a compound selected from the group consisting of a compound of Formula I
    wherein X is N, or CZ where Z is H, C1-C5 alkyl, amino (-NH2) or a halogen atom;
    when X is CZ, Y is selected from the group consisting of
    -(CH2)nNR9R10 wherein R9 and R10, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that R9 and R10 are not both hydrogen; (b) C1-C12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl); (d)
    -(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or carboC1-C4 alkoxy), (e) -(CH2)npyridinyl or (f) wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of (aa) 4-morpholine optionally substituted
    with one or two members selected from
    the group consisting of C1-C4 alkyl,
    C1-C4 alkoxy, halo or trifluoromethyl
    (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (cc) 3-amino-1-pyrrolidine,
    (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
    (ee) 1-piperldine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3
    C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-1-piperazine,
    4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH2OH, -CO2H, -CO2CH3 or -CO2CH2CH3, and
    (gg) thiazolidine, thiazolidine-4-carboxylic
    acid, pipecolinic acid, p-piperazinacetophenone, 1-homopiperazine, 1* methylhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetrahydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole; and R5, R6, R7 and R8, being the same or different, are selected from the group consisting of hydrogen, C1-C8 alkyl,
    -(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)nnaphthyl, -(CH2)npyridinyl,
    -(CH2)qNR9R10, -CH-CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -CH2-CH-CH2, -CH-CH-CH3,-O-CH2-CH-CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O(CH2)p(N-methylpiperdin-3-yl), -O-(CH2)pNR9R10, -O-CH2CH(OCH3)2, -O-(CH2)pOR15,
    -(CH2)nC(O)-(CH2)nR9, -(CH2)nC(O)O-(CH2)pR9, -(CH)nC(O)O- (CH2)pNR9R10, -(CH2)nC(O)(CH2)nNR9R10, N02, -O-(CH2)nC(O)- (CH2)pR9, -O-(CH2)nC(O)O-(CH2)pR9, -O-(CH2)nC(O) -(CH2)nNR9R10,
    -NR9R10, -N(R9)(CH2)nC(O)-(CH2)nR10, -N(R9)- (CH2)nC(O)O- (CH2)nR10, N(R9) (CH2)nC(O) - (CH2)nNR9R10. -O-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1C4alkyl)], -O-(CH2)npyridine, -O(CH2)nC(O)-(CH2)npyridine, -O-(CH2)nC(O)O-(CH2)npyridine, -O(CH2)nC(O)-N(R9) (CH2)npyridine, -O-(CH2)nquinoxalinyl, -O-(CH2)nquinolinyl -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O-(CH2)nC(O)-(CH2)nnaphthyl,
    -O-(CH2)nC(O)O-(CH2)nnaphthyl, -O-(CH2)nC(O)NR9-(CH2)nnaphthyl, halo (fluoro, chloro, bromo, iodo), OH, -(CH2)q-OH, (CH2)qOC(O)R9, -(CH2)qOC(O) -NR9R10, -(1-cyclohexyl-1H-tetrazol- 5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy,
    -[1-(1-phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy,
    -C1-C4 alkoxyl, a group of Formula II wherein R' is methyl or carboxy, R'' is hydrogen and R''' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], C1C5 alkyl, -(CH2)nCO2H, -CH2SH, -CH2SCH3, imidazolinylmethylene, indolinylmethylene, CH3CH(OH), CH2OH, H2N(CH2)4- (optionally in protected form) or H2NC(NH)NH(CH2)3 (optionally in protected form); with the overall proviso that when Y is other than -(CH2)nmorpholinyl, at least one member of R5, R6, R7 or R8 is other than hydrogen, C1-C8 alkyl, NO2, OH, C1-C4 alkoxy, a halogen atom, phenyl, benzyl, 4-morpholinylmethyl, NH2, or dimethyamino; with the further proviso that when Y is 4- morpholinyl, the compound is other than:
    6,7-dimethoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one, 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4- morpholinyl)-4H-1-benzopyran-4-one,
    N-cyclohexyl-2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1- benzopyran-7-yl]oxy]-acetamide,
    2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7- yl]oxy]-N-phenyl-acetamide,
    6-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one,
    2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7- yl]oxy]-N-(1-phenylethyl)-acetamide;
    with the further provisio that when Y is dimethylamino, the compound is other than:
    2-(Dimethylamino)-8-methyl-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester,
    (Dimethylamino)-4-oxo-4H-1-benzopyran-6-yl carbamic acid dimethyl ester,
    2-(Dimethylamino)-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester;
    when X is N, Y is selected from the group consisting of
    -NR9R10 wherein R9 and R10, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that R9 and R10 are not both hydrogen;
    (b) C1-C12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl); (d) -(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or carboC1-C4 alkoxy), (e) -(CH2)npyridinyl or (f) wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of
    (aa) 4-morpholine optionally substituted
    with one or two members selected from
    the group consisting of C1-C4 alkyl,
    C1-C4 alkoxy, halo or trifluoromethyl
    (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (cc) 3-amino-1-pyrrolidine,
    (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
    (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl),
    (ff) 1-piperazine, 4-methyl-1-piperazine,
    4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH2OH, -CO2H, -CO2CH3 or -CO2CH2CH3, and
    (gg) thiazolidine, thiazolidine-4-carboxylic
    acid, pipecolinic acid, p-piperazinacetophenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetrahydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole;
    and R5, R6, R7 and R8, being the same or different, are selected from the group consisting of hydrogen, C1-C8 alkyl, -(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)nnaphthyl, -(CH2)npyridinyl,
    -(CH2)qNR9R10. -CH-CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -CH2-CH-CH2, -CH-CH-CH3, -O-CH2-CH-CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O(CH2)p(N-methylpiperdin- 3-yl), -O-(CH2)pNR9R10, -O-CH2CH(OCH3)2, -O-(CH2)pOR15,
    -(CH2)nC(O)-(CH2)nR9, - (CH2)nC(O)O-(CH2)pR9, -(CH)nC(O)O- (CH2)pNR9R10, - (CH2)nC(O) (CH2)nNR9R10. N02 , -O-(CH2)nC(O)- (CH2)pR9, -O-(CH2)nC(O)O-(CH2)pR9, -O-(CH2)nC(O) - (CH2)nNR9R10, -NR9R10, -N(R9)(CH2)nC(O)-(CH2)nR10, -N(R9) - (CH2)nC(O)O- (CH2)nR10. N(R9)(CH2)nC(O)-(CH2)nNR9R10, -O-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1C4alkyl)], -O-(CH2)npyridine, -O(CH2)nC(O) - (CH2)npyridine, -O-(CH2)nC(O)O-(CH2)npyridine, -O(CH2)nC(O) -N(R9) (CH2)npyridine, -O-(CH2)nquinoxalinyl, -O-(CH2)nquinolinyl, -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O-(CH2)nC(O)- (CH2)nnaphthyl,
    -O-(CH2)nC(O)O-(CH2)nnaphthyl, -O-(CH2)nC(O)NR9-(CH2)nnaphthyl, halo (fluoro, chloro, bromo, iodo), OH, -(CH2)q-OH, (CH2)qOC(O)R9, -(CH2)qOC(O)-NR9R10, -(1-cyclohexyl-1H-tetrazol- 5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, - [1-(1- phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, or -C1-C4 alkoxyl;
    R15 is selected from C1-C5 alkyl, -(CH2)nphenyl [phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)npyridin-1-yl or
    - (CH2)ppiperidin-1-yl]
    n is 0-5;
    p is 2-5
    q is 1-5,
    and pharmaceutically acceptable salts or hydrates thereof; to prepare a medicament for preventing or treating atherosclerosis.
    12. A method according to Claim 11 where Y is selected from the group consiting of - (CH2)nNR9R10 wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of:
    (aa) 4-morpholine optionally substituted
    with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (cc) 3-amino-1-pyrrolidine,
    (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
    (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3
    C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-1-piperazine,
    4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH2OH, -CO2H, -CO2CH3 or -CO2CH2CH3.
    13. A method according to Claim 12 wherein X is CZ where Z is H or methyl.
    14. A method according to Claim 12 wherein X is N.
    15. A method according to Claim 13 or 14 wherein R5, R6, R7 and R8 are selected from the following groups:
    (i) R5, R6, R7 and R8 each hydrogen;
    (ii) R5, R6, and R8 are each hydrogen, and R7 is selected from:
    -O-(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -C≡C-phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), or -(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1C4 alkoxy, halo or trifluoromethyl);
    (iii) R5 and R6 are hydrogen, R8 is hydrogen, halo or C1-C5 alkyl, and R7 is selected from: -O-(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl),
    -O-(CH2)npyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -O-(CH2)nnaphthyl, -(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl),
    -(CH2)ppyridinyl (wherein pyridinyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), -(CH2)p(1-pyrrolidinyl) or -[(1- cyclohexyl-1H-tetrazol-5-yl)C1-C4 alkoxy; or
    (iv) R5, R7 and R8 are each hydrogen, and R6 is
    -NH-C(O)-O-CH2phenyl.
    16. The method according to Claim 11 where the compound is selected from the group consisting of:
    Cpd 1 6-Chloro-2-(4-morpholinyl)-4H-1-benzo
    pyran-4-one;
    Cpd 2 2-(4-morpholinyl)-4H-benzopyran-4-one;
    Cpd 3 8-Methyl-2-(4-morpholinyl)-(7-phenylmethoxy)-4H- benzopyran-4-one;
    Cpd 4 7-Chloro-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 5 8-Chloro-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 6 6-Bromo-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 7 6-Fluoro-2-(4-morpholinyl)-4H-1-benzopyran-4-one; Cpd 8 6-Methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 9 7-Methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 10 8-Methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 11 6-Methoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 12 7-Methoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 13 6-(Phenylmethoxy)-2-(4-morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 14 8-(Phenylmethoxy)-2-(4-morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 15 [2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-6-yl]-1,1- dimethylethyl carbamic acid ester;
    Cpd 16 6-(3-pyridinecarboxamide)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 17 2-(4-Morpholinyl)-6-nitro-4H-1-benzopyran-4-one;
    Cpd 19 6-([[Phenylmethoxy]carbonyl]amino)-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 20 8-Methoxy-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 21 3-Amino-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 22 3-Chloro-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 23 3-Bromo-2- (4-morpholinyl) -4H-1-benzopyran-4-one ;
    Cpd 24 8 -Methyl - 2- (4-morpholinyl) - 7 - (phenylmethoxy) -4H-1- benzopyran-4-one ;
    Cpd 25 2- (4-Morpholinyl) -5- (phenylmethoxy) -4H-1-benzopyran-4- one ;
    Cpd 26 7 , 8-Dimethoxy-2- (4-morpholinyl) -4H-1-benzopyran-4-one ;
    Cpd 27 2-(4-Methyl-2-piperazinyl)-4H-1-benzopyran-4-one;
    Cpd 28 8-Methyl-7-(phenylmethoxy)-2-[4-(2-pyridinyl)-1- piperazinyl]-4H-benzopyran-4-one;
    Cpd 29 8-Methyl-7-(phenylmethoxy)-2-(1-piperazinyl)-4H- benzopyran-4-one;
    Cpd 30 8-Methyl-7-(phenylmethoxy)-2-(1-pyrrolidinyl)-4H- benzopyran-4-one;
    Cpd 31 8-Methyl-7-(phenylmethoxy)-2-(1-piperidinyl)-4H- benzopyran-4-one;
    Cpd 32 8-Methyl-2-(4-methyl-1-piperazinyl)-7-(phenylmethoxy)- 4H-benzopyran-4-one;
    Cpd 33 8-Methyl-7-(phenylmethoxy)-2-(2,6-dimethyl-4- morpholinyl)-4H-benzopyran-4-one; Cpd 34 2-[4-(Hydroxyethyl)-1-piperazinyl]-8-methyl-7-(phenylmethoxy)-4H-benzopyran-4-one monohydrochloride;
    Cpd 35 2-[4-(Diphenylmethyl)-1-piperazinyl]-8-methyl-7- (phenylmethoxy)-4H-benzopyran-4-one;
    Cpd 36 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-1-piperidinyl)- 4H-benzopyran-4-one;
    Cpd 37 8-Methyl-7-(phenylmethoxy)-2-(4-phenyl-1-piperazinyl)- 4H-benzopyran-4-one;
    Cpd 38 2-(4-Hydroxy-1-piperdinyl)-8-methyl-7-(phenylmethoxy)- 4H-benzopyran-4-one;
    Cpd 39 7-Hydroxy-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one;
    Cpd 40 6-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one; Cpd 41 7-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one; Cpd 42 5-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one; Cpd 43 8-Hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one; Cpd 44 7-Methoxy-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one;
    Cpd 45 [(8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-7-yl)oxy] acetic acid lithium salt;
    Cpd 46 [[8-Methyl-2-(4-morpholinyl)-4-oxy-4H-1-benzopyran-7- yl]oxy]acetic acid methyl ester;
    Cpd 47 7-[(4-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpho
    linyl)-4H-1-benzopyran-4-one;
    Cpd 48 8-Methyl-7-[(4-methylphenyl)methoxy]-2-(4-morpho
    linyl)-4H-1-benzopyran-4-one;
    Cpd 49 7-[(4-Chlorophenyl)methoxy]-8-methyl-2-(4-morpho
    linyl)-4H-1-benzopyran-4-one;
    Cpd 50 7-[(4,5-Dichlorophenyl)methoxy]-8-methyl-2-(4-morpho linyl)-4H-1-benzopyran-4-one;
    Cpd 51 8-Methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 52 8-Methyl-7-[[(phenyl)carbonyl]oxy]-2-(4-morpho
    linyl)-4H-1-benzopyran-4-one;
    Cpd 53 7-Methoxy-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one ;
    Cpd 54 7 - [ [ 4- (1 , 1-Dimethylethyl)phenyl]methoxy] -8-methyl-2- (4-morpholinyl) -4H-1-benzopyran-4-one ; Cpd 55 8-Methyl-2-(4-morpholinyl)-7-[[4-phenylmethoxy)- phenyl]methoxy]-4H-1-benzopyran-4-one;
    Cpd 56 7-[(3-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 57 7-[(4-Nitrophenyl)methoxy]-8-methyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 58 7-[(2-Phenylethyl)methoxy]-8-methyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 59 7-[(2-Methoxyphenyl)methoxy]-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 60 7-[(4-Ethoxyphenyl)methoxy]-8-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 61 8-(4-Ethoxy-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 62 2-(4-Morpholinyl)-8-(4-nitro-benzyloxy)-4H-1-benzopyran-4-one;
    Cpd 63 8-(2-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 64 2-(4-Morpholinyl)-8-(2-phenyl-ethoxy)-4H-1-benzopyran- 4-one;
    Cpd 65 2-(4-Morpholinyl)-(2-oxo-2-phenyl-ethoxy)-4H-1- benzopyran-4-one;
    Cpd 66 8-(4-Benzyloxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 67 8-(4-Chloro-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpg 68 8-(4-t-Butyl-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 69 8-(3-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 70 8-(3,4-Dichloro-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 71 8-(4-Methyl-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 72 8-(4-Methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 73 2-(4-Morpholinyl)-8-(naphthyl-2-methyloxy)-4H-1- benzopyran-4-one; Cpd 74 2-(4-Morpholinyl)-8-(naphthyl-1-methyloxy)-4H-1- benzopyran-4-one;
    Cpd 75 8-Methyl-2-(4-morpholinyl)-7-(naphthyl-2-methyloxy)- 4H-1-benzopyran-4-one;
    Cpd 76 8-Methyl-2-(4-morpholiny1)-7-(naphthyl-1-methyloxy)- 4H-1-benzopyran-4-one;
    Cpd 80 2-(Dimethylamino)-4H-1-benzopyran-4-one; and
    Cpd 81 2-(Dimethylamino)-8-methyl-7-(phenylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 83 6-Methyl-2-(4-morpholinyl)-4H-1,3- benzoxazin-4-one;
    Cpd 84 8-Methyl-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one;
    Cpd 85 6-Bromo-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one;
    Cpd 86 7-Chloro-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one;
    Cpd 87 6,8-Bis(1-methylethyl)-2-(4-morpholinyl)-4H-1,3- benzoxazin-4-one;
    Cpd 88 6-Fluoro-2-(4-morpholinyl)-4H-1,3-benzoxazin-4-one;
    Cpd 89 6-Dimethoxymethyl-2-(4-morpholinyl)-4H-1,3-benzoxazin- 4-one;
    Cpd 90 7-Methoxy-2-(4-morpholinyl)-4H-1,3-benzoxazin4-one;
    Cpd 91 6-(Morpholin-1-yl)-pyrido(2,3-e)-1,3-oxazine-8-one;
    Cpd 92 8-Methyl-2-(1-piperidinyl)-4H-1,3-benzoxazin-4-one;
    Cpd 93 8-Methyl-2-(1-pyrrolidinyl)-4H-1,3-benzoxazin-4-one;
    Cpd 94 2-(1-pyrrolidinyl)-4H-1,3-benzoxazin-4-one;
    Cpd 95 2-(1-(4-Thiomorpholinyl))-4H-1,3-benzoxazin-4-one;
    Cpd 96 2-(4-Methyl-1-piperazinyl)-4H-1,3-benzoxazin-4-one;
    Cpd 98 2-(4-Morpholinyl)-4H-1,3-benzoxazin-4-one;
    Cpd 100 [8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7- yl]4-morpholinyl carboxylic acid ester;
    Cpd 101 2-(4-morpholinyl)-7-(phenylmethoxy)-4H-1-benzopyran-4- one;
    Cpd 102 8-Methyl-2-(4-morpholinyl)-7-(2-oxo-2-phenylethoxy)- 4H-1-benzopyran-4-one;
    Cpd 103 6-Chloro-8-methyl-2-(4-morpholinyl)-7-(phenylmethoxy)- 4H-1-benzopyran-4-one;
    Cpd 104 [[2-(4-Morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]oxy]- acetic acid methyl ester; Cpd 105 4-[[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]methyl]-benzoic acid methyl ester; Cpd 106 4-[[[2-(4-Morpholinyl)-4-oxo-4H-1-benzopyran-8- yl]oxy]methyl]-benzoic acid methyl ester;
    Cpd 107 8 -Me thyl - 2 - (4 -morpholinyl) - 7 - [ [ 3 - (trifluoromethyl)phenyl]methoxy]-4H-1-benzopyran-4- one;
    Cpd 108 2-(4-Morpholinyl)-8-[[3-(trifluoromethyl)- phenyl]methoxy]-4H-1-benzopyran-4-one;
    Cpd 109 7-(Cyclohexylmethoxy)-8-methyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 110 8-Methyl-2-(4-morpholinyl)-7-(2-propenyloxy)-4H-1- benzopyran-4-one;
    Cpd 111 2-(4-Morpholinyl)-7-(1-naphthalenylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 112 8-Methyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 113 8-Methyl-2-(4-morpholinyl)-7-(4-pyrindinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 115 8-methyl-2-(4-morpholinyl)-7-(2-quinoxalinylmethoxy)- 4H-1-benzopyran-4-one;
    Cpd 116 8-methyl-2-(4-morpholinyl)-7-(pyrazinlymethoxy)-4H-1- benzopyran-4-one;
    Cpd 117 8-methyl-2-(4-morpholinyl)-7-(2-pyridinylmethoxy)-4H- 1-benzopyran-4-one N-oxide;
    Cpd 118 8-methyl-2-(4-morpholinyl)-7-(3-pyridinylmethoxy)-4H- 1-benzopyran-4-one N-oxide;
    Cpd 119 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 120 3,3-Dimethyl-1-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H- 1-benzopyran-7-y1]oxy]-butan-2-one;
    Cpd 121 1-[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-propan-2-one;
    Cpd 122 1-[[8-Methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-butan-2-one;
    Cpd 123 8-Methyl-2-(4-morpholinyl)-7-(2-oxo-2-(2- naphthyl)ethoxy)-4H-1-benzopyran-4-one;
    Cpd 125 2-(4-Morpholinyl)-7-(2-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 126 2-(4-Morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 127 2-(4-Morpholinyl)-8-(2-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 128 2-(4-Morpholinyl)-8-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 129 8-methyl-2-(4-morpholinyl)-7-(2-quinolinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 130 7,8-(Bis)-phenylmethoxy-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 131 7,8-(Bis)-acetyloxy-2-(4-morpholinyl)-4H-1-benzopyran- 4-one;
    Cpd 132 7,8-(Bis)-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 133 7-Hydroxy-2-(4-morpholinyl)-8-phenylmethoxy-4H-1- benzopyran-4-one;
    Cpd 135 8 - Hydroxy - 2 - ( 4 - morpholinyl ) - 7 - ( 3 - trifluoromethyl)phenylmethoxy-4H-1-benzopyran-4-one; Cpd 136 7 - Hydroxy - 2 - (4 - lorpholinyl) - 8 - ( 3 - trifluoromethyl)phenylmethoxy-4H-1-benzopyran-4-one; Cpd 137 7-[3-(1-cyclohexyl-1H-tetrazol-5-yl)propoxyl-8-methyl- 2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 138 8-[3-(1-cyclohexyl-1H-tetrazol-5-yl)propoxy]-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 139 7-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-8-methyl-2- (4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 140 8-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 141 2-(4-morpholinyl)-8-[(1-phenyl-1H-tetrazol-5-yl)oxy]- 4H-1-benzopyran-4-one;
    Cpd 142 N-cyclohexyl-2-[[2-(4-morpholinyl)-4-oxo-4H-1- benzopyran-8-yl]oxy]-acetamide;
    Cpd 143 N-(1,1-dimethylethyl)-2-[[2-(4-morpholinyl)-4-oxo-4H- 1-benzopyran-8-yl]oxy]-acetamide;
    Cpd 144 2-[[2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]-N- phenyl-acetamide;
    Cpd 145 2-[[2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]oxy]- N-(1-phenylethyl)-acetamide;
    Cpd : 147 N-[[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]acetyl]-phenyalanine, ethyl ester;
    Cpd 149 8-methyl-2-(4-morpholinyl)-7-[(1-phenyl-1H-tetrazol-5- yl)oxy]-4H-1-Benzopyran-4-one;
    Cpd 152 2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]-N-3-pyridinyl-acetamide;
    Cpd 153 N-[[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran- 7-yl]oxy]acetyl]-Phenylalanine;
    Cpd 154 7-(2,2-dimethoxyethoxy)-8-methyl-2-(4-morpholinyl)-4H- 1-Benzopyran-4-one;
    Cpd 155 2-(4-Morpholinyl)-8-(2-propenyl)-4H-1-benzopyran-4- one;
    Cpd 156 2-(4-Morpholinyl)-8-(1-propenyl)-4H-1-benzopyran-4- one;
    Cpd 157 8-Formyl-2-(4-Morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 158 2-(4-morpholinyl)-8-(phenylamino)methy1-4H-1- benzopyran-4-one;
    Cpd 159 2-(4-morpholinyl)-8-(2E-phenyl)ethenyl-4H-1- benzopyran-4-one;
    Cpd 160 8-Hydroxymethyl-2-(4-Morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 162 8-methyl-7-[(l-methyl-3-piperidinyl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one;
    Cpd 163 8-Methyl-2-(4-morpholinyl)-7-(2-(1-piperidinyl)ethyl)oxy-4H-1-benzopyran-4-one;
    Cpd 164 8 -Methyl- 2 - (4-morpholinyl) - 7- (2- (1- pyrrolidinyl)ethyl)oxy-4H-1-benzopyran-4-one;
    Cpd 165 8-Methyl-2-(4-morpholinyl)-7-(2-(4-morpholinyl)ethyl)- oxy-4H-1-benzopyran-4-one;
    Cpd 166 8-Methyl-2-(4-morpholinyl)-7-(3-(1-piperidino)propyl)oxy-4H-1-benzopyran-4-one;
    Cpd 167 7-(2-Diethylaminoethyl)oxy-8-methyl-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 168 7-[2-(ethylphenylamino)ethoxy]-8-methyl-2-(4-morpholinyl)-4H-1-Benzopyran-4-one;
    Cpd 169 7-(2-Diisopropylaminoethyl)oxy-8-methyl-2-(4- morpholinyl)-4H-1-benzopyran-4-one; Cpd 170 7-Hydroxy-8-methyl-2-(l-piperidinyl)-4H-1-benzopyran- 4-one;
    Cpd 171 8-Methyl-2-(1-piperidinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 172 7-(2-(4-Benzyl-(1-piperizinyl))ethyl)oxy-8-methyl-2- (4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 173 7-Acetoxy-3,8-dimethyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 174 3,8-dimethyl-7-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 175 7-benzyloxy-3,8-dimethyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 176 3,8-Dimethyl-2-(4-morpholinyl)-7-(naphthyl-1- methyloxy)-4H-1-benzopyran-4-one;
    Cpd 177 3,8-Dimethyl-7-(4-methoxy-benzyloxy)-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 178 3,8-Dimethyl-2-(4-morpholinyl)-7-(2-phenyl-ethyloxy)- 4H-1-benzopyran-4-one;
    Cpd 179 3,8-Dimethyl-7-(4-chlorobenzyloxy)-2-(4-morpholinyl)- 4H-1-benzopyran-4-one;
    Cpd 180 3,8-Dimethyl-2-(4-morpholinyl)-7-(3-trifluoromethylbenzyloxy)-4H-1-benzopyran-4-one;
    Cpd 181 7-(Carbomethoxy-methoxyl)-3,8-dimethyl-2-(4- morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 182 8-Hydroxy-3-methyl-2-(4-morpholinyl)-4H-1-benzopyran- 4-one,
    Cpd 183 8-Benzyloxy-3-methyl-2-(4-morpholinyl)-4H-1-benzopyran-4-one;
    Cpd 184 3-methyl-2-(4-morpholinyl)-8-(m-trifluoromethylbenzyloxy)-4H-1-benzopyran-4-one,
    Cpd 185 8-methyl-7-(2-phenyl)ethynyl-2-(4-morpholinyl)-4H-1- benzopyran-4-one;
    Cpd 186 8-methyl-2-(4-morpholinyl)-7-(2-phenyl)ethyl-4H-1- benzopyran-4-one;
    Cpd 187 2-(4-Morpholinyl)-8-(2-phenyl)ethynyl-4H-1-benzopyran- 4-one;
    Cpd 188 2-(4-Morpholinyl)-8-(2-phenyl)ethyl-4H-1-benzopyran-4- one; Cpd 189 2-(4-Morpholinyl)-8-(2-(3-trifluoromethyl- )phenyl)ethynyl-4H-1-benzopyran-4-one;
    Cpd 190 2-(4-Morpholinyl)-8-(2-(3-trifluoromethyl)phenyl)- ethyl-4H-1-benzopyran-4-one;
    Cpd 192 8-Methyl-2-(4-morpholinyl)-7-(2-(1-naphthyl))ethyl-4H- 1-benzopyran-4-one;
    Cpd 193 8-Methyl-2-(4-morpholinyl)-7-phenyl-4H-1-benzopyran-4- one;
    Cpd 194 7-acetyloxy-8-iodo-2-(4-morpholinyl)-4H-1-benzopyran- 4-one;
    Cpd 195 8-ethyl-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 196 8-Ethyl-2-(4-morpholinyl)-7-phenylmethoxy-4H-1- benzopyran-4-one;
    Cpd 197 8-Iodo-2-(4-morpholinyl)-7-phenylmethoxy-4H-1- benzopyran-4-one;
    Cpd 198 8-Ethyl-2- (4-morpholinyl)-7-(2-(1-piperidinyl)ethyl)oxy-4H-1-benzopyran-4-one;
    Cpd 199 8-Iodo-2-(4-morpholinyl)-7-(3-pyrindinylmethoxy)-4H-1- benzopyran-4-one;
    Cpd 200 8-Iodo-7-hydroxy-2-(4-morpholinyl)-4H-1-benzopyran-4- one;
    Cpd 202 7-(3-pyridinylmethyleneoxy)-2-(1-piperidinyl)-8- methyl-4H-1-benzopyran-4-one;
    Cpd 204 8-Methyl-2-(4-morpholinylmethyl)-7-(phenylmethoxy)-4H- 1-benzopyran-4-one;
    Cpd 205 7-hydroxy-2-(4-morpholinylmethyl)-8-methyl-4H-1- benzopyran-4-one;
    Cpd 206 7-[(1-cyclohexyl-1H-tetrazol-5-yl)methyoxy]-8-methyl- 2-(4-morpholinylmethy)-4H-1-benzopyran-4-one;
    Cpd 207 8-Methyl-2-(4-morpholinylmethyl)-7-(3- pyridinylmethoxy)-4H-1-benzopyran-4-one;
    or a pharmaceutically acceptable salt thereof. 17. A pharmaceutical composition comprising a compound selected from the group consisting of compounds of Formula I
    wherein X is N, or CZ where Z is H, C1-C5 alkyl, amino (-NH2) or a halogen atom;
    when X is CZ, Y is selected from the group consisting of
    -(CH2)nNR9R10 wherein R9 and R10, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that R9 and R10 are not both hydrogen; (b) C1_C12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl); (d)- (CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], (e) -(CH2)npyridinyl or (f) wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of
    (aa) 4-morpholine optionally substituted
    with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (cc) 3-amino-1-pyrrolidine,
    (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
    (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3
    C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-1-piperazine,
    4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH2OH,
    -CO2H, -CO2CH3 or -CO2CH2CH3, and
    (gg) thiazolidine, thiazolidine-4-carboxylic
    acid, pipecolinic acid, p-piperazinacetophenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetrahydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole;
    and R5, R6, R7 and R8, being the same or different, are selected from the group consisting of hydrogen, C1-C8 alkyl,
    -(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)nnaphthyl, -(CH2)npyridinyl,
    -(CH2)qNR9R10, -CH=CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -CH2-CH=CH2, -CH=CH-CH3, -O-CH2-CH=CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O(CH2)p(N-methylpiperdin-3-yl), -O-(CH2)pNR9R10, -O-CH2CH(OCH3)2, -O-(CH2)pOR15,
    -(CH2)nC(O)-(CH2)nR9, -(CH2)nC(O)O-(CH2)pR9. -(CH)nC(O)O- (CH2)pNR9R10, -(CH2)nC(O)(CH2)nNR9R10, NO2, -O-(CH2)nC(O)- (CH2)pR9. -O-(CH2)nC(O)O-(CH2)pR9, -O-(CH2)nC(O)-(CH2)nNR9R10, -NR9R10, -N(R9) (CH2)nC(O) - (CH2)nR10, -N(R9) -(CH2)nC(O)O- (CH2)nR10, N(R9)(CH2)nC(O)-(CH2)nNR9R10, -O-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1- C4alkyl)], -O-(CH2)npyridine, -O(CH2)nC(O)-(CH2)npyridine, -O-(CH2)nC(O)O-(CH2)npyridine. -O(CH2)nC(O)-N(R9) (CH2)npyridine, -O-(CH2)nquinoxalinyl, -O-(CH2)nquinolinyl, -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O-(CH2)nC(O) - (CH2)nnaphthyl,
    -O-(CH2)nC(O)O-(CH2)nnaphthyl, -O-(CH2)nC(O)NR9-(CH2)nnaphthyl, halo (fluoro, chloro, bromo, iodo), OH, -(CH2)q-OH, (CH2)qOC(O)R9, - (CH2)qOC(O) -NR9R10, -(1-cyclohexyl-1H-tetrazol-5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(1-phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -C1-C4 alkoxyl, a group of Formula II wherein R' is methyl or carboxy, R'' is hydrogen and R''' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], C1-C5 alkyl,-(CH2)nCO2H, -CH2SH, -CH2SCH3, imidazolinylmethylene, indolinylmethylene, CH3CH(OH), CH2OH, H2N(CH2)4- (optionally in protected form) or H2NC(NH)NH(CH2)3 (optionally in protected form); with the overall proviso that when Y is other than -(CH2)nmorpholinyl, at least one member of R5, R6, R7 or R8 is other than hydrogen, C1-C8 alkyl, NO2, OH, C1-C4 alkoxy, a halogen atom, phenyl, benzyl, 4-morpholinylmethyl, NH2, or dimethyamino; with the further proviso that when Y is morpholinyl, the compound is other than:
    6,7-dimethoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one, 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one,
    N-cyclohexyl-2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7-yl]oxy]-acetamide,
    2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7-yl]oxy]-N-phenyl-acetamide,
    6-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one,
    2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7-yl]oxy]-N-(1-phenylethyl)-acetamide; with the further provisio that when Y is dimethylamino, the compound is other than:
    2-(Dimethylamino)-8-methyl-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester,
    (Dimethylamino)-4-oxo-4H-1-benzopyran-6-yl carbamic acid dimethyl ester,
    2-(Dimethylamino)-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester;
    when X is N, Y is selected from the group consisting of
    -NR9R10 wherein R9 and R10, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that R9 and R10 are not both hydrogen;
    (b) C1-C12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl); (d) -(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or carboC1-C4 alkoxy), (e) -(CH2)npyridinyl or (f) wherein R9 and R10. taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of
    (aa) 4-morpholine optionally substituted
    with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (cc) 3-amino-1-pyrrolidine,
    (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
    (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-1-piperazine,
    4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH2OH,- CO2H, -CO2CH3 or -CO2CH2CH3, and
    (gg) thiazolidine, thiazolidine-4-carboxylic
    acid, pipecolinic acid, p-piperazinacetophenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-1,2-3,6tetrahydropyridine, proline, tetrahydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole;
    and R5, R6, R7 and R8, being the same or different, are selected from the group consisting of hydrogen, C1-C8 alkyl,
    -(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)nnaphthyl, -(CH2)npyridinyl,
    -(CH2)qNR9R10. -CH=CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -CH2-CH=CH2, -CH=CH-CH3, -O-CH2-CH=CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O(CH2)p(N-methylpiperdin-3-yl), -O-(CH2)pNR9R10, -O-CH2CH(OCH3)2, -O-(CH2)pOR15,
    -(CH2)nC(O)-(CH2)nR9. -(CH2)nC(O)O-(CH2)pR9, -(CH)nC(O)O-(CH2)pNR9R10, -(CH2)nC(O)(CH2)nNR9R10, NO2 , -O-(CH2)nC(O)-(CH2)pR9, -O-(CH2)nC(O)O-(CH2)pR9, -O-(CH2)nC(O) -(CH2)nNR9R10, -NR9R10, -N(R9)(CH2)nC(O)-(CH2)nR10, -N(R9)-(CH2)nC(O)O-(CH2)nR10, N(R9)(CH2)nC(O)-(CH2)nNR9R10. -O-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O-(CH2)npyridine, -O(CH2)nC(O)-(CH2)npyridine, -O-(CH2)nC(O)O-(CH2)npyridine, -O(CH2)nC(O) -N(R9) (CH2)npyridine, -O-(CH2)nquinoxalinyl, -O-(CH2)nquinolinyl, -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O- (CH2)nC(O) - (CH2)nnaphthyl,
    -O-(CH2)nC(O)O-(CH2)nnaphthyl, -O-(CH2)nC(O)NR9-(CH2)nnaphthyl, halo (fluoro, chloro, bromo, iodo), OH, -(CH2)q-OH, (CH2)qOC(O)R9, -(CH2)qOC(O) -NR9R10, -(1-cyclohexyl-1H-tetrazol- 5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy,
    -[1-(1-phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, or -C1-C4 alkoxyl;
    R15 is selected from C1-C5. alkyl, -(CH2)nphenyl [phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)npyridin-1-yl or
    -(CH2)ppiperidin-1-yl];
    n is 0-5;
    p is 2-5;
    q is 1-5;
    and pharmaceutically acceptable salts and hydrates thereof, in association with a pharmaceutcal carrier.
    21. A process for the preparation of a compound of Formula I
    wherein X is CZ where Z is H, C1-C5 alkyl, amino (-NH2) or a halogen atom;
    Y is selected from the group consisting of
    -(CH2)nNR9R10 wherein R9 and R10, being the same or different, are selected from the group consisting of (a) hydrogen, with the provisio that R9 and R10 are not both hydrogen; (b) C1-C12 alkyl; (c) phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl); (d)-(CH2)nphenyl (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or carboC1-C4 alkoxy), (e) -(CH2)npyridinyl or (f) wherein R9 and R10, taken together with N, form a saturated or unsaturated heterocyclic amine ring selected from the group consisting of
    (aa) 4-morpholine optionally substituted
    with one or two members selected from
    the group consisting of C1-C4 alkyl,
    C1-C4 alkoxy, halo or trifluoromethyl
    (bb) 4-thiomorpholine optionally substituted with one or two members selected from the group consisting of C1C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl
    (cc) 3-amino-1-pyrrolidine,
    (dd) 1-pyrrolidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, OH, -CH2OH, or trifluoromethyl
    (ee) 1-piperidine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -(CH2)qOH, -CO2H, -CO2CH3 -CO2CH2CH3 or phenyl (wherein phenyl is optionally substituted with one, 2 or 3
    C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl), (ff) 1-piperazine, 4-methyl-1-piperazine,
    4-phenyl-1-piperazine (wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo or trifluoromethyl) or 4-pyridinyl-1- piperazine optionally substituted with one or two members selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halo, trifluoromethyl, -CH2OH,- CO2H, -CO2CH3 or -CO2CH2CH3, and
    (gg) thiazolidine, thiazolidine-4-carboxylic
    acid, pipecolinic acid, p-piperazinaceto- phenone, 1-homopiperazine, 1- methylhomopiperazine, 4-phenyl-1,2-3,6- tetrahydropyridine, proline, tetrahydrofurylamine, 1-(3-hydroxy)pyrrolidine, nipecotamide, 1,2,3,4-tetrahydroisoquinoline or imidazole;
    and R5, R6, R7 and R8, being the same or different, are selected from the group consisting of hydrogen, C1-C8 alkyl,
    -(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)nnaphthyl, -(CH2)npyridinyl,
    -(CH2)qNR9R10, -CH=CH-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -CH2-CH=CH2, -CH=CH-CH3, -O-CH2-CH=CH2, -C≡C-phenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -O(CH2)p(N-methylpiperdin-3-yl), -O-(CH2)pNR9R10, -O-CH2CH(OCH3)2, -O- (CH2)pOR15,
    -(CH2)nC(O)-(CH2)nR9, -(CH2)nC(O)O-(CH2)pR9, - (CH)nC(O)O- (CH2)pNR9R10, -(CH2)nC(O) (CH2)nNR9R10, NO2, -O-(CH2)nC(O)- (CH2)pR9, -O-(CH2)nC(O)O-(CH2)pR9, -O-(CH2)nC(O)-(CH2)nNRgR10,
    -NR9R10, -N(R9)(CH2)nC(O)-(CH2)nR10, -N(R9)-(CH2)nC(O)O- (CH2)nR10, N(R9)(CH2)nC(O)-(CH2)nNR9R10, -O-(CH2)nphenyl [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1C4alkyl)], -O-(CH2)npyridine, -O(CH2)nC(O)-(CH2)npyridine, -O-(CH2)nC(O)O-(CH2)npyridine, -O(CH2)nC(O)-N(R9) (CH2)npyridine, -O-(CH2)nquinoxalinyl, -O-(CH2)nquinolinyl, -O-(CH2)npyrazinyl, -O-(CH2)nnaphthyl, -O-(CH2)nC(O)-(CH2)nnaphthyl,
    -O-(CH2)nC(O)O-(CH2)nnaphthyl, -O-(CH2)nC(O)NR9-(CH2)nnaphthyl, halo (fluoro, chloro, bromo, iodo), OH, -(CH2)q-OH, (CH2)qOC(O)R9, -(CH2)qOC(O) -NR9R10, -(1-cyclohexyl-1H-tetrazol- 5-yl)C1-C4 alkoxy, -[1-(C1-C5alkyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(phenyl)-1H-tetrazol-5-yl]C1-C4 alkoxy [wherein phenyl is optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)],
    -[1-(pyridinyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -[1-(1- phenylethyl)-1H-tetrazol-5-yl]C1-C4 alkoxy, -C1-C4 alkoxyl, or a group of Formula II (see Formula Sheet) wherein R' is methyl or carboxy, R'' is hydrogen and R''' is selected from benzyl [optionally substituted with one, two or three groups selected from hydroxy, halogen or phenoxy (optionally substituted with one, two or three groups selected from hydroxy or halogen)], C1C5 alkyl, -(CH2)nCO2H, -CH2SH, -CH2SCH3, imidazolinylmethylene, indolinylmethylene, CH3CH(OH), CH2OH, H2N(CH2)4-(optionally in protected form) or H2NC(NH)NH(CH2)3 (optionally in protected form); with the overall proviso that when Y is other than - (CH2)nmorpholinyl, at least one member of R5, R6, R7 or R8 is other than hydrogen, C1-C8 alkyl, NO2. OH, C1-C4 alkoxy, a halogen atom, phenyl, benzyl, 4-morpholinylmethyl, NH2, or dimethyamino; with the further proviso that when Y is 4- morpholinyl, the compound is other than:
    6,7-dimethoxy-2-(4-morpholinyl)-4H-1-benzopyran-4-one, 7,8-(Bis)-(3-trifluoromethyl)phenylmethoxy-2-(4- morpholinyl)-4H-1-benzopyran-4-one,
    N-cyclohexyl-2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1- benzopyran-7-yl]oxy]-acetamide,
    2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7- yl]oxy]-N-phenyl-acetamide,
    6-[(1-cyclohexyl-1H-tetrazol-5-yl)methoxy]-2-(4-morpholinyl)-4H-1-Benzopyran-4-one,
    2-[[8-methyl-2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-7- yl]oxy]-N-(1-phenylethyl)-acetamide;
    with the further provisio that when Y is dimethylamino, the compound is other than:
    2-(Dimethylamino)-8-methyl-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester,
    (Dimethylamino)-4-oxo-4H-1-benzopyran-6-yl carbamic acid dimethyl ester,
    2-(Dimethylamino)-4-oxo-4H-1-benzopyran-7-yl carbamic acid dimethyl ester;
    R15 is selected from C1-C5 alkyl, -(CH2)nphenyl [phenyl optionally substituted with one, 2 or 3 C1-C4 alkyl, C1-C4 alkoxy, halo, OH, trifluoromethyl or -CO2(C1-C4alkyl)], -(CH2)npyridin-1-yl or
    -(CH2)ppiperidin-1-yl];
    n is 0-5;
    p is 2-5; q is 1-5 ;
    which comprises reacting a salicylic acid ester of Formula A
    with an ynamine of Formula B
AU48071/90A 1988-12-21 1989-12-15 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones Ceased AU634994B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28779688A 1988-12-21 1988-12-21
US287796 1988-12-21

Publications (2)

Publication Number Publication Date
AU4807190A true AU4807190A (en) 1990-07-10
AU634994B2 AU634994B2 (en) 1993-03-11

Family

ID=23104392

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48071/90A Ceased AU634994B2 (en) 1988-12-21 1989-12-15 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Country Status (8)

Country Link
EP (1) EP0459983A1 (en)
JP (1) JPH04502322A (en)
AU (1) AU634994B2 (en)
DK (1) DK118791A (en)
FI (1) FI912995A0 (en)
HU (2) HUT58310A (en)
RU (1) RU2118321C1 (en)
WO (1) WO1990006921A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0525123T3 (en) * 1990-06-20 1998-05-04 Upjohn Co Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazin-4-ones
CA2064796A1 (en) * 1990-06-29 1991-12-30 Joel Morris Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
IL112764A0 (en) * 1994-03-18 1995-05-26 Ferrer Int New chromene derivatives
CA2182932A1 (en) * 1995-08-10 1997-02-11 Koju Watanabe Chromone derivative, process for preparing same and pharmaceutical composition
DE19850131A1 (en) 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon and chromanone derivatives
AU3704400A (en) * 1999-03-04 2000-09-21 E.I. Du Pont De Nemours And Company Fused bicyclic oxazinone and thiazinone fungicides
NZ520300A (en) 2000-01-24 2004-05-28 Kinacia Pty Ltd Morpholino-substituted pyridopyrimidine, quinolone and benzopyranone derivatives that inhibit the enzyme phosphoinositide (PI) 3-kinase
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
CN100381437C (en) * 2002-04-17 2008-04-16 赛特凯恩蒂克公司 Compounds, compositions and methods
JP2005533119A (en) 2002-07-17 2005-11-04 サイトキネティクス・インコーポレーテッド Compounds, compositions and methods
JP4646626B2 (en) 2002-08-16 2011-03-09 アストラゼネカ アクチボラグ Inhibition of phosphoinositide 3-kinase β
CN101260104A (en) * 2002-08-16 2008-09-10 阿斯利康(瑞典)有限公司 Inhibition of phosphoinositide 3-kinase beta
CN100518740C (en) * 2003-06-06 2009-07-29 阿里克斯股份公司 Use of heterocyclic compounds as SCCE inhibitors
CA2525383C (en) * 2003-06-06 2012-03-06 Arexis Ab Use of heterocyclic compounds as scce inhibitors
GB2420781B (en) 2003-08-13 2008-07-09 Kudos Pharm Ltd Aminopyrones and their use as ATM inhibitors
CN1889958A (en) * 2003-12-09 2007-01-03 美国政府健康及人类服务部 Methods for suppressing an immune response or a treating a proliferative disorder
BRPI0515498A (en) 2004-09-20 2008-07-29 Kudos Pharm Ltd dna-pk inhibitors
WO2006085067A1 (en) 2005-02-09 2006-08-17 Kudos Pharmaceuticals Limited Atm inhibitors
AR054438A1 (en) 2005-04-15 2007-06-27 Kudos Pharm Ltd DNA INHIBITORS -PK
US20100234363A1 (en) * 2007-09-19 2010-09-16 Institute Of Medicinal Molecular Design, Inc. Heterocyclic derivative having inhibitory activity on type-i 11 data-hydroxysteroid dehydrogenase
WO2010037127A1 (en) 2008-09-29 2010-04-01 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
US8399460B2 (en) * 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
UY34013A (en) 2011-04-13 2012-11-30 Astrazeneca Ab ? CHROMENONE COMPOUNDS WITH ANTI-TUMORAL ACTIVITY ?.
RU2468018C1 (en) * 2011-10-06 2012-11-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Российский университет дружбы народов" (РУДН) Method of producing 4-oxo-4h-chromene derivatives containing vinyl and enamine groups
ES2648154T3 (en) * 2012-01-26 2017-12-28 Daiichi Sankyo Company, Limited Chromone derivative that has an osteogenesis promoter effect
WO2014030688A1 (en) * 2012-08-24 2014-02-27 第一三共株式会社 Chromone derivative having linear side chain
KR102222346B1 (en) 2013-03-04 2021-03-02 아스트라제네카 아베 Combination treatment
CN108947952B (en) * 2017-05-24 2021-09-21 中国医学科学院药物研究所 2-substituted amino-5-trifluoromethyl-8-nitrobenz (thio) pyran-4-ketone compound and preparation method and application thereof
CN108929329B (en) * 2017-05-24 2020-12-11 中国医学科学院药物研究所 2-azacyclo-5-trifluoromethyl-8-nitrobenz (thio) pyran-4-ones
AR121719A1 (en) 2020-04-03 2022-06-29 Petra Pharma Corp ALLESTERIC INHIBITORS OF CHROMENONE OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASES
CA3217937A1 (en) 2021-05-03 2022-11-10 Erin Danielle ANDERSON Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
TWI829179B (en) 2021-05-27 2024-01-11 美商佩特拉製藥公司 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
TW202329930A (en) 2021-09-30 2023-08-01 美商佩特拉製藥公司 Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2205913A1 (en) * 1972-02-08 1973-08-16 Thiemann Chem Pharm Fab 2-AMINO-3-HYDROXY-CHROMONE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE2555290A1 (en) * 1975-12-09 1977-06-16 Boehringer Mannheim Gmbh NEW BENZOPYRONE DERIVATIVES AND METHOD FOR THEIR PRODUCTION
US4412071A (en) * 1982-05-17 1983-10-25 The Upjohn Company Antiatherosclerotic compositions
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
IL89840A (en) * 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them

Also Published As

Publication number Publication date
FI912995A0 (en) 1991-06-19
EP0459983A1 (en) 1991-12-11
HU900394D0 (en) 1991-09-30
RU2118321C1 (en) 1998-08-27
WO1990006921A1 (en) 1990-06-28
DK118791D0 (en) 1991-06-19
HU211339A9 (en) 1995-11-28
AU634994B2 (en) 1993-03-11
DK118791A (en) 1991-06-19
HUT58310A (en) 1992-02-28
JPH04502322A (en) 1992-04-23

Similar Documents

Publication Publication Date Title
AU634994B2 (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5703075A (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
WO1991019707A2 (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CA2556653C (en) Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
EP0585913B1 (en) Condensed heterocyclic compounds, their production and use
AU2002362385B2 (en) DNA-PK inhibitors
US5252735A (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
AU630822B2 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones
JPH069585A (en) Sulfonamideendoserine antagonist
WO2007045876A1 (en) Chromenones and their use as modulators of metabotropic glutamate receptors
US4593092A (en) Class of spiro-linked pyrrolidine-2,5-diones
IE913186A1 (en) 1,3-benzoxazine derivatives, their production and use
Chantegrel et al. Synthesis of [1] benzopyrano [3, 4-d] isoxazol-4-ones from 2-substituted chromone-3-carboxylic esters. A reinvestigation of the reaction of 3-acyl-4-hydroxycoumarins with hydroxylamine. Synthesis of 4-(2-hydroxybenzoyl) isoxazol-5-ones
CA2580221A1 (en) Novel cyclic and acyclic propenones for treating cns disorders
US5302613A (en) Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US4230850A (en) 3-Substituted-4-aminoalkoxy-5,6-condensed ring-2-pyranones
JP3724818B2 (en) Fused heterocyclic compounds, production methods and agents thereof
JP3187837B2 (en) Compound
LV11029B (en) Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity
CA2006306A1 (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
Graef et al. Synthesis of 6-phenyl substituted 2-formylnicotinates
US4591587A (en) Cyclopropyl pyridine compounds useful as calcium channel blockers
Awad et al. STUDIES ON THE VILSMEIER-HAACK REACTION. PART IV. SYNTHESIS AND REACTION OF SOME 3-METHY Ll-PHENYL-4-(ACETY L; IMINOACETYL AND THIOACETYL)-2-PYRAZOLIN-5-THIONE
JPH09500878A (en) Benzoxazinone and benzothiazinone with therapeutic activity
US4590276A (en) Process for the preparation of cyclopropyl pyridine compounds useful as calcium channel blockers